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1. The CaMKII Family 
Calcium/Calmodulin-dependent protein kinase II (CaMKII), a second messenger-
mediated kinase, is one of the most abundant proteins in the brain, as it accounts for up to 
2% of total protein, depending on the brain region1, 2. It was first discovered as the 
Synapsin I kinase, indicating that the protein was located presynaptically and involved in 
neurotransmitter release3, 4. However, subsequent studies showed that this kinase was also 
present at the postsynaptic site5, 6 where it is enriched in the postsynaptic density (PSD)7-9.  
The CaMKII family consists of four different isozymes, α, β, γ and δ, each encoded by a 
separate gene. The first CaMKII isozymes discovered were α- and βCaMKII4, 10, which 
form holoenzymes consisting of 12 subunits1. Later the two other isozymes were described 
(γ and δ), which are much less prominent in the brain11, 12. Even though the different 
isozymes are encoded by different genes, they are highly homologous in their domain 
organization (as reviewed by13). They all contain a catalytic, an autoregulatory and an 
association domain (fig 1). The autoregulatory domain, containing several 
autophosphorylation sites, is highly conserved in all isozymes. The differences between 
the proteins are found in the association domain, where variable insertions reside or 
splicing can occur. All isozymes also have different subtypes (e.g. β’ and βΜ, or αΒ) due to 
alternative splicing in the association domain.  
Figure 1. Domain organization of CaMKII. All CaMKII isoforms contain a catalytic, a regulatory and an 
association domain. Calmodulin (CaM) binds the regulatory domain, where also the autophosphorylation sites (T286 
and TT305/6) are located. The variable region consists of several variable domains (the small blue ovals around the 
association domain), which determine the differences between the isozymes. Adjusted from Colbran, Biochem J, 2004 
 
Are all these different isozymes functionally redundant, or have they evolved to fulfill 
specific roles?  Small organisms like invertebrates (e.g. Drosophila melanogaster (fruit fly), C. 
elegans (nematode), Suberites domuncula (sponge)) only have a single Camk2 gene (as 
reviewed by14). However, from the single Camk2 gene in Drosophila at least five different 
isoforms are expressed, of which one during development15 and four isoforms in the late 
embryonic state, all generated by alternative splicing16. The more evolved species (e.g. 
Xenopus laevis (frog), Mus musculus (mouse), Homo sapiens (human)) have 2 or more 
different Camk2 genes. It is very likely that the different isozymes found in vertebrates are 
also evolved from one single ancestral Camk2 gene. Indeed, when an evolutionary tree of 
the nucleotide sequence of the different isoforms throughout species is made14, it shows 
that there is one ancestral Camk2 gene (fig 2). Via multiple duplications, four Camk2 genes 
evolved in mammals, with Camk2d being the first gene to diverge. As described above, the 
four different genes show a high degree of homology, but differ in the variable region, 
which is located in the association domain. When aligning the mouse protein sequences of 
the variable regions of the different genes, highest homology is seen between β- and 
γCaMKII, indicating that these two isozymes are closely related to each other (fig 3). 
αCaMKII is the most specialized isozyme, being expressed solely in the central nervous 
system12, 14, 17.  
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Figure 2. Phylogenic tree of the nucleotide sequences of Camk2. Looking at the phylogenic tree, there is one 
single ancestral Camk2 gene, and Camk2d is the first gene to diverge. Abbreviations: γ = Camk2g; β = Camk2b; α = 
Camk2a; δ = Camk2d. Adapted from Tombes et al., Gene, 2003 
 
The phylogenic data described above indicates that indeed the different Camk2 genes 
are all derived from one ancestral gene. But have they evolved further to fulfill different 
functions, or are they functionally redundant and just evolved through evolution without 
acquiring functional specializations? This question can be answered at different levels.  
First, one can look at the expression patterns of the different proteins. γCaMKII and 
δCaMKII are expressed throughout the rat/mouse body11, 12, 18. βCaMKII however, is 
primarily expressed in the central nervous system19, but has an isoform, βΜCaMKII, which 
is expressed in skeletal muscle18. αCaMKII is solely expressed in the central nervous 
system12, 17. These differences in expression pattern make sense, if indeed CaMK2d was the 
first gene to diverge and is expressed throughout the organism. αCaMKII, with its specific 
localization and not being present in invertebrates, is very likely then to fulfill another 
function than the other CaMKII isozymes. The other isozymes however, are also expressed 
in the brain, but with different regional preferences and protein expression levels. The 
δCaMKII and γCaMKII are much less abundant in the brain compared to αCaMKII and 
βCaMKII12. Both δCaMKII and γCaMKII are expressed throughout the brain, however not 
everywhere with the same expression levels. δCaMKII shows higher expression levels in 
the cerebellum compared to the cerebrum and brainstem12 and is together with βCaMKII 
the only isozyme found in the deep cerebellar nuclei18, 20. γCaMKII shows lower expression 
levels in the cerebellum compared to the cerebrum and brainstem11. Both δCaMKII and 
γCaMKII predominate in the medulla oblongata18. αCaMKII and βCaMKII are the major 
brain specific isozymes. αCaMKII is the major forebrain isozyme, (α:β ratio of 3:11, 21, 22), 
and βCaMKII is the main cerebellar isozyme (α:β ratio of 1:423). In the olfactory bulb all 
four isozymes are shown to be equally abundant18. Thus there are regional differences, but 
there is also some overlap. 
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Figure 3. CaMKII variable region alignment. Alignment of the variable region and association domain of 
CaMKII mouse protein sequence using MUSCLE (MUltiple Sequence Comparison by Log-Expectation). When 
comparing the different sequences, βCaMKII and γCaMKII show highest homology. 
 
 Second, are there differences in the temporal expression patterns? Two isozymes are 
expressed during embryonic development, which are δCaMKII and γCaMKII18. Expression 
of these isozymes starts around E10 – E11 in the peripheral and the entire central nervous 
system, indicating that these two isozymes could play a role in the development of the 
nervous system. However, their expression levels increase postnatally18. βCaMKII is the 
next isozyme to be expressed. Expression starts in the late phase of embryonic 
development (E12.5) at low levels, which increase to a maximum at P3-518. The αCaMKII 
isozyme however, is only expressed postnatally (starting at P5, increasing to a maximum 
in the adult brain24), in post-mitotic cells18. These findings indicate different roles for the 
different isozymes in the brain during development and post-developmentally.  
What are these functional differences? This introduction will only focus on the function 
of the CaMKIIs in the brain, since that is the region where all four isozymes are expressed. 
γCaMKII and δCaMKII are less abundantly present in the brain, compared to αCaMKII 
and βCaMKII, and not much is known about their function, however there are a few 
interesting findings to mention. δCaMKII has been shown to play a role in neurite 
outgrowth in vitro, by stabilizing the actin cytoskeleton in cellular extensions25, 26. δCaMKII 
is also present in the nucleus and can, upon activation, promote BDNF gene expression27. 
The αBCaMKII isoform and the γACaMKII isoform both contain a nuclear localization 
signal (NLS)11, 28, indicating they also play a role in the nucleus. However, the exact 
function of δCaMKII and γCaMKII and all their isoforms, remain elusive.  
Extensive research has been done on the function of neuronal αCaMKII, and to a lesser 
extent on neuronal βCaMKII. αCaMKII mainly functions as a memory molecule in 
excitatory neurons in forebrain, by inducing long-lasting changes in the postsynaptic 
density upon transient calcium influx (as reviewed by29 and30). βCaMKII contains an actin-
binding domain, with which it binds to the actin cytoskeleton. Upon activation βCaMKII is 
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released from actin, thus it is able to regulate the cellular localization of αCaMKII31. 
Furthermore, in vitro studies have shown that βCaMKII can induce neurite outgrowth32, 33, 
plays a role in dendritic morphology34, can bundle F-actin and phosphorylate actin35. The 
role of βCaMKII in vivo is unknown and an important topic of this thesis. 
The details on the functional aspects of α- and βCaMKII, and the differences between 
them, will be described in the rest of this introduction. But looking at these general 
differences between the CaMKII isozymes, one can conclude that they are not redundant 
at all, but have indeed evolved to fulfill specific functions in higher organisms. Also the 
fact that deletion of, or mutations in one of the isozymes (e.g. Camk2a (see review36)) in an 
organism cannot be compensated for by one of the other isozymes, indicates that the 
different isozymes have evolved to fulfill different functions in the organism. 
 
2. General regulation of CaMKII 
All CaMKII isozymes share the same domain organization (as reviewed by13). They all 
contain a catalytic domain, an autoregulatory domain, a variable region and an association 
domain. Different CaMKII isozymes can either form homo-oligomers or hetero-oligomers, 
each consisting of 11–13 subunits37, 38. Crystallography studies showed that the subunits 
form a doughnut-like structure of two layers each containing 5-7 units, which are 
connected at the association domain (fig 4)39. The subunit composition of an oligomer 
determines its properties, like cellular localization and the affinity for Ca2+/CaM, as will 
be discussed later. The autoregulatory domain is the domain that can regulate the 
activation state of CaMKII, and has been most extensively studied in αCaMKII (as 
reviewed by40). The N-terminal part of the autoregulatory domain binds to the catalytic 
domain, thereby blocking the ATP-binding site, thus inactivating the enzyme41. The C-
terminal part of the autoregulatory domain is the part where the activated Ca2+/CaM 
complex can bind42.  
Upon increases in Ca2+ levels in the cell, the following steps will occur (fig 5): a) Ca2+ 
binds to calmodulin, and this complex binds to the C-terminal part of the autoregulatory 
domain of CaMKII. b) Binding of this complex to the autoregulatory domain induces a 
conformational change. It releases the catalytic domain from the autoregulatory domain, 
thereby relieving the auto-inhibition. c) The conformational change now allows the 
catalytic domain to phosphorylate its neighboring subunit at Threonine 286 (T286 
αCaMKII; T287 βCaMKII) in the autoregulatory domain. This phosphorylation increases 
the affinity of CaMKII for the Ca2+/CaM complex more than a 1000-fold (a mechanism 
called “CaM trapping”43, 44). When eventually the concentration of Ca2+ in the cell is low 
for a longer period, the complex will dissociate from CaMKII. However, due to the T286 
phosphorylation, the kinase will remain at 20-60% of its full activity45 (dependent on the 
substrate), which is referred to as the autonomous active (or calcium-independent) state. It 
is this property that makes CaMKII a molecular memory switch. d) Upon release of the 
Ca2+/CaM complex, the inhibitory phosphorylation sites of CaMKII (Threonine 305 and 
Threonine 306 (TT305/6 of αCaMKII; TT306/7 of βCaMKII) are exposed and can therefore 
be phosphorylated by the catalytic domain of the neighboring subunits. In this state 
CaMKII is still active (although less than with Ca2+/CaM still bound), i.e. it can still fulfill 
its kinase function, since T286 phosphorylation keeps the catalytic domain released from 
the autoregulatory domain, but can no longer bind the Ca2+/CaM complex due to 
phosphorylation of the TT305/6 residues. This therefore prevents maximum activation of 
the oligomer, hence the name inhibitory phosphorylation sites. e) CaMKII in the TT305/6 
autophosphorylation status cannot be activated anymore upon new influx of calcium. 
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After dephosphorylation CaMKII returns to its resting-state (i.e. binding of the catalytic 
domain to the regulatory domain, blocking the T286 phosphorylation site). And the whole 
cycle can start again.  
 
Figure 4: domain organization 
(a) and structure of an 
αCaMKII homo-oligomer (b). 
The N-terminal part of the 
autoregulatory domain binds the 
catalytic domain, blocking the 
phosphorylation sites and the ATP-
binding site.  
 
 
It has been shown that 
CaMKII can be directly 
dephosphorylated by 
Protein Phosphatase 1 
(PP1)46,  and Protein 
Phosphatase 2A (PP2A), and indirectly by Protein Phosphatase 2B (PP2B or calcineurin) 
(as reviewed by47). Inhibition of PP1 activity has been shown to result in increased levels 
of T286 phosphorylation, therefore PP1 is suggested to “gate” the CaMKII 
autophosphorylation at T28648, 49. PP1 activity is regulated by inhibitor-1 and DARRP-3249.  
PP2B increases PP1 activity by dephosphorylating inhibitor-1 or DARRP-3250. PP2B is the 
only phosphatase that is activated via the Ca2+/CaM complex, and due to its higher 
affinity for Ca2+/CaM, PP2B is activated at lower Ca2+/CaM concentrations than 
CaMKII51. PP2A and CaMKII interact directly, since CaMKII activation can reduce PP2A 
activity52, and vice versa53. Also TT305/6 residues are dephosphorylated by PP1 and PP2A 
in vitro45. If this also occurs in vivo still remains elusive.  
 
 
Figure 5 Schematic overview of activation and autophosphorylation of one CaMKII subunit. (a) 
Ca2+/CaM (yellow) binds to the CaM binding domain, resulting in release of the catalytic domain from the 
autoregulatory domain (b). (c) The T286 residue is now available to be phosphorylated by one of the neighboring 
CaMKII subunits, resulting in autonomous active CaMKII (d) When the calcium levels in the synapse are reduced 
again, Ca2+/CaM is being released from the CaM binding site, thereby exposing the TT305/6 phosphorylation sites to be 
phosphorylated, again by neighboring CaMKII subunits (e). After TT305/6 phosphorylation, CaMKII can become 
dephosphorylated and the whole process can start again from (a). 
 
Using biochemical studies more phosphorylation sites have been discovered on 
αCaMKII in vitro54-56. Whether these sites are also phosphorylated in vivo is still unknown 
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for most of these sites, but recently evidence has been found that Threonine 253 (one of the 
recently discovered phosphorylation sites) is phosphorylated in vivo too57. The function of 
this phosphorylation site is not totally clear yet. Previously it has already been shown that 
phosphorylation or dephosphorylation of this site does not influence the (autonomous) 
kinase activity of αCaMKII and that phosphorylation at this site is Ca2+-independent in in 
vitro studies55, 56. Recent studies show that phosphorylation at T253, like T286, also occurs 
during neuronal stimulation, however at a slower rate than T286 phosphorylation, and 
that this phosphorylation enhances the binding of αCaMKII to the PSD57. Phosphorylation 
of T253 appears to be independent of T286-phosphorylation, since a T286A or T286D 
mutation did not affect the levels of phosphorylated T25357. However, the exact 
physiological function of this phosphorylation site still needs to be discovered.   
Although there are several phosphorylation sites of which the exact function is not 
known yet, the mechanism described in fig. 5 is the widely accepted mechanism 
underlying the regulation of CaMKII.  
 
3.  Function of αCaMKII 
αCaMKII is the most extensively studied CaMKII isozyme, and presumably even one 
of the most studied kinases of the brain. Already since the late ‘80s scientists are trying to 
discover the exact functions of this protein, and the mechanisms by which it exerts these 
functions. Most of the studies have focused on the hippocampus, but lately also the role of 
αCaMKII in the Purkinje cells of the cerebellum has been unraveled. 
 
3.1.  The role of αCaMKII in postsynaptic hippocampal plasticity 
αCaMKII is the most abundant protein in the postsynaptic density (PSD)8, which is the 
active site of the postsynapse, and therefore is thought to play a crucial role in learning 
and memory.  Indeed, pharmacological and genetic manipulations revealed that αCaMKII 
is necessary for hippocampal and cortical plasticity (LTP) and for learning and memory 
(as reviewed by36). But how is it involved in all these processes? 
 
3.1.1.  Translocation of αCaMKII to the post-synaptic density (PSD) 
At the postsynaptic site there are three pools of CaMKII oligomers: an actin-bound 
pool, a soluble cytoplasmic pool and a PSD-bound pool. In basal state only a small fraction 
of the total CaMKII is located in the PSD, but this changes as soon as calcium enters the 
post-synaptic cell and binds calmodulin to form Ca2+/CaM complexes58. The Ca2+/CaM 
complex binds CaMKII, thereby inducing release of CaMKII oligomers from actin, T286-
autophosphorylation of the subunits and translocation to the PSD59, where αCaMKII can 
bind to the NR2B subunit of the NMDA receptor60, 61. Activation of the NMDA receptor is 
necessary for CaMKII autophosphorylation and activation59, 62. Moreover, T286-
autophosphorylation is not necessary for the translocation of CaMKII to the PSD. Just the 
binding of Ca2+/CaM is sufficient to achieve CaMKII translocation to the PSD and binding 
to the NR2B subunit. This has been shown in vitro using the Camk2aT286A mutant, which 
cannot be phosphorylated at the T286 site, in which αCaMKII is still translocated to the 
PSD and can bind the NR2B-C subunit of the NMDA receptor, upon Ca2+/CaM 
stimulation59, 63. However, Camk2aT286A dissociates much faster from the PSD, that is as 
soon as the Ca2+ levels decrease. Binding of αCaMKII to the NR2B subunit increases the 
affinity of αCaMKII for CaM, which is similar to the “CaM trapping” by 
autophosphorylation at T286. It increases the autonomous activity of αCaMKII and 
additionally stabilizes the activity level, by making it less sensitive to ATP fluctuations in 
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the synapse63, 64. Furthermore, it suppresses the inhibitory phosphorylation at TT305/6. 
This means that αCaMKII activity can only be decreased by dissociation of αCaMKII from 
the NMDA receptor. Taken together, there are two different ways to generate increased 
autonomous activation of αCaMKII: 1) through autophosphorylation of the T286 site and 
2) through interaction with the NMDA receptor. Therefore, decreasing autonomous 
activity can be achieved either by phosphatase activity or dissociation from the NMDA 
receptor. Binding of αCaMKII to the NMDA receptor also has an advantage for the 
NMDA receptor, since it traps the CaM, thereby reducing the inhibitory effect of CaM on 
the NMDA receptor65.  
 
3.1.2.  AMPA receptor trafficking 
What happens in the post-synaptic site of the synapse when αCaMKII is activated and 
LTP is induced? One of the major targets (next to the NMDA receptor) of αCaMKII is 
another ionotropic receptor present in the synapse: the AMPA receptor. Upon binding of 
glutamate, this receptor opens, resulting in Na2+-influx. AMPA receptor channel 
conductance can be enhanced by phosphorylation of the GluR1 subunit66, 67, which is 
shown to be important for synaptic plasticity68 and certain forms of spatial memory69. 
Apart from the increased channel conductance of AMPA receptors, it is known that the 
total number of AMPA receptors present at the postsynaptic membrane largely 
determines the weight of the postsynaptic response to presynaptic glutamate release. 
Changes in the number of post-synaptic AMPA receptors has been shown to be of crucial 
importance for LTP70, 71.  
Phosphorylation of the GluR1 subunit of the AMPA receptor at Serine 831 (S831) has 
in some in vitro studies been attributed to activated αCaMKII66, 72, 73, including in 
hippocampal cultures after glutamate stimulation74. However, more recently a study was 
published, in which it was found that not αCaMKII but PKC is responsible for the 
phosphorylation of GluR1 in hippocampal cultures and in neuronal lysates75. The role of 
αCaMKII in phosphorylation of the AMPA receptor is therefore not yet clearly 
determined, and more research is needed to clarify this further.  
αCaMKII is known to play a crucial role in the trafficking of AMPA receptors and 
internalization in the postsynaptic membrane76. It has been shown that NMDA receptor 
activation induces a rapid translocation of AMPA receptors to the active site of the 
synapse, which is thought to be critical for expression of LTP77. This translocation of 
AMPA receptors does not require phosphorylation at S83176. How does αCaMKII exerts 
its role in AMPA trafficking? It has been shown that αCaMKII can activate the Ras – 
MAPK pathway by inhibiting SynGAP (a Ras-GTPase activating protein)78 and that this 
pathway can mediate AMPA receptor trafficking during LTP induction79. Furthermore 
αCaMKII is shown to phosphorylate PSD-95 and stargazin75, two crucial proteins involved 
in AMPA receptor trafficking.  
PSD-95 is a scaffold protein, which is located in the PSD, close to the postsynaptic 
membrane, and is therefore thought to play a role in the localization and clustering of 
receptors at the postsynaptic membrane (as reviewed by80). PSD-95 has been shown to 
directly bind NR2B, and it can form complexes with the GluR1 subunit of the AMPA 
receptor via interactions with stargazin, an AMPA receptor-associated protein81. By 
interacting with stargazin, PSD-95 translocates AMPA receptors to the synapse82.  
The effect of phosphorylation of PSD-95 by αCaMKII is not yet fully unraveled, 
however it has been shown that phosphorylation of the Drosophila homologue of PSD-95 
(Dgl) by αCaMKII results in more extra-synaptic localization of Dgl83. In addition, it is 
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known that phosphorylation of the NR2B subunit of the NMDA receptor by protein 
kinase CK2, induced by αCaMKII, results in dissociation of PSD-95 from the NR2B 
subunit84. Furthermore it has been shown that αCaMKII competes with PSD-95 to bind to 
the NR2B subunit in the synapse85. With these findings one could hypothesize that PSD-95 
regulates the localization and surface expression of the NMDA receptor in synapses at the 
rest state, but when the synapse is stimulated and Ca+2 enters, αCaMKII could induce 
changes in the synapse, resulting in dissociation of PSD-95 from the NR2B subunit, 
thereby making PSD-95 available to form complexes with stargazin and translocate AMPA 
receptors to the activated synapse. However, more research is needed to support this 
hypothesis.  
Stargazin can be phosphorylated by αCaMKII and PKC, since the application of either 
CaMKII inhibitors or PKC inhibitors blocks the phosphorylation of stargazin86. This 
phosphorylation of stargazin is required for LTP, whereas dephosphorylation of stargazin, 
by PP1 and PP2B, mediates LTD. When phosphorylated, stargazin promotes the 
trafficking of AMPA receptors to the synapse. On top of that, stargazin is even shown to 
be necessary for the delivery of AMPA receptors to the membrane surface, since the 
Stargazer mice, which lack stargazin82, do not show any functional AMPA receptors in the 
synapse at all. After transfecting the mutant neurons with stargazin, hence re-expressing 
the protein, the AMPA receptors are translocated and delivered to the membrane surface.  
 
3.1.3.  Other αCaMKII substrates 
Another binding partner for αCaMKII, which is also enriched in the PSD, is CASK. 
CASK is a member of the membrane associated guanylate kinases (MAGUKs), a class of 
proteins known to interact with the cytoskeleton, and to play a role in signaling pathways. 
The Drosophila homologue of CASK, camguk, binds to αCaMKII in the PSD resulting in an 
autonomously active αCaMKII. This induces conformational changes in αCaMKII 
favoring autophosphorylation at the T305/6 sites87. Eventually, this will result in direct 
autophosphorylation at these sites as soon as the calcium levels drop and CaM dissociates 
from αCaMKII87. αCaMKII subsequently dissociates from camguk, generating a pool of 
CaMKII insensitive to changes in calcium levels, until they have been dephosphorylated 
by phosphatases. This CaMKII/camguk (or CASK) interaction is hypothesized to be a 
mechanism involved in dowregulating the calcium-sensitive pool of CaMKII and thereby 
differentiating between active and inactive synapses87. 
As described above, αCaMKII can activate Ras by inhibiting SynGAP, and via this Ras 
– MAPK pathway, αCaMKII can mediate AMPA trafficking. But this activation of Ras 
could serve another purpose as well. Recently, it has been shown that αCaMKII is 
activated in single dendritic spines during LTP induction88. The activated αCaMKII does 
not spread to neighboring spines, most likely due to rapid activity decay after LTP 
induction and relatively slow spine-dendrite diffusion coupling88. Ras has also been 
shown to be activated in single spines, but spreads to neighboring spines upon 
activation89. Additionally, it has been shown that single spine activation, reduces the 
threshold for LTP of neighboring spines90. Therefore, it is hypothesized that the activation 
of Ras, through inhibition of SynGAP by αCaMKII, could regulate the threshold levels for 
neighboring spines, and thereby creating plasticity units on a dendritic branch88, 90. 
Apart from the PSD-associated targets of αCaMKII described above, many more 
targets have already been discovered, as has been described by91-93 (see table 1 adapted 
from93). However, the exact effect of αCaMKII on all these substrates and their role in the 
induction or maintenance of LTP still remains unknown. Therefore, more research is 
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needed to fully understand the role of αCaMKII at the postsynaptic site, in the induction 
or maintenance of LTP. 
 
Table 1 
Substrates of CaMKII 
Receptors and 
Channel 
proteins 
Scaffold 
proteins 
Cytoskeletal and 
associated proteins 
Motor 
proteins 
Enzymes 
 
Neuro- 
transmitter release Others 
NR2B 
PSD-95-
associated 
protein 
Neurofilaments H, 
M and L Myosin II B CaMKII Synapsin I TOAD64 
GluR1 PSD95 α-internexin Myosin V Dynamin 1 Synaptotagmin TNFraf3 
VDAC1 SAP97 α-tubulin C protein Cyclic nucleotide phosphodiesterase Synaptophysin 
Insulin 
receptor 
kinase 
IP3 receptor SAP90 β-tubulin Caldesmon SynGAP  NeuroD94 
N-type Ca2+ 
channel Homer 1b Clipin C  Calcineurin  LRP4
95 
GABAAR Densin-180 α-actinin  Phospholipase A2   
GABA-
modulin Liprinα1
96 MAP2  Calpain   
KV4.297  
Microtubule-
associated protein 
Tau 
 Nitric oxide synthase   
Modified from Fink and Meyer, Curr Opinion Neurobiol, 2002. The proteins that contain a reference number were 
discovered later and added to the table by the author of this thesis. Abbreviations: VDAC1, voltage dependent anion 
Channel 1; IP3, inositol triphosphate; TNFraf3, tumor necrosis factor receptor-associated factor 3; TOAD64, turned on 
after division 64kD; LRP4, LDL receptor-related protein 4. 
 
3.1.4.  αCaMKII and LTD 
Whether αCaMKII at the postsynaptic site also plays a role in LTD is not clear. There 
is one study published where they showed that LTD was deficient in the Camk2a–/– mice98, 
but subsequent studies showed it was mainly the lack of presynaptic αCaMKII that was 
responsible for the LTD deficit99. Phosphatases play an important role in LTD100, with 
activation of PP1 via calcineurin (PP2B) at low [Ca2+] being required for LTD induction50. 
It is known that PP1 dephosphorylates αCaMKII at low Ca2+/CaM concentrations46, but 
whether this occurs during LTD has never been shown. This indicates that the balance 
between phosphatase and kinase activity can be regulated by the [Ca2+] concentration in 
the synapse, which then determines the direction of plasticity at the synapse (as proposed 
by Lisman51). When the [Ca2+] in the synapse is high, more kinases (e.g. CaMKII) will 
become activated than phosphatases, resulting in AMPA receptor expression at the 
membrane surface, hence LTP will be induced. Low [Ca2+] on the other hand, will result in 
more phosphatase activity compared to kinase activity, prompting AMPA receptor 
internalization and thereby inducing LTD. 
Interestingly, αCaMKII has been found to influence excitability by regulating GABAA-
mediated inhibition under LTD inducing conditions. Activated αCaMKII induces a 
transient increase in GABAA receptor Cl– current, which can be blocked by a CaMKII 
inhibitor101. This is probably achieved by phosphorylation of the GABAA receptor by 
αCaMKII since this is indeed shown to change the properties of the GABAA receptor102. 
Additionally, NMDA receptor activation, with a stimulus known to induce LTD, results in 
increased surface expression of GABAA receptors, which is also dependent on αCaMKII 
activation103. The same stimulus also results in internalization of AMPA receptors103. 
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These findings suggest that αCaMKII could indirectly play a role in the induction of LTD, 
by regulating GABAA receptor properties and surface expression. The exact subcellular 
location of these processes is still not well known, but it is most likely that in the synapse 
the phosphatases regulate AMPA internalization, and in the dendritic shaft αCaMKII is 
transiently activated and regulates the GABAA receptor. However, this remains to be 
examined.     
 
3.2.  The role of αCaMKII in presynaptic hippocampal plasticity   
CaMKII has first been discovered as the Synapsin I kinase1, indicating that it is likely 
to play a role presynaptically. Indeed, in vitro studies have shown that presynaptic 
CaMKII is necessary for synaptic plasticity104. But what is the presynaptic role of CaMKII? 
It is known that αCaMKII is associated with presynaptic vesicles by binding to Synapsin 
I105, 106. Synapsin I is a vesicle-associated protein, that regulates the size of the reserve pool 
and of the readily releasable pool of vesicles at the presynapse107. Synapsin I in its non-
phosphorylated state tethers vesicles to the actin cytoskeleton (i.e. the reserve pool)106. 
When the presynaptic terminal is activated, Synapsin I becomes phosphorylated, which 
results in dissociation of the vesicles from the actin cytoskeleton and translocation to the 
readily releasable pool108-110. Hence, more vesicles with neurotransmitter can be released 
(as shown by111). Synapsin I contains multiple phosphorylation sites, two of which are 
phosphorylated by αCaMKII112. Phosphorylation of Synapsin I by αCaMKII results in 
conformational changes in Synapsin I, reducing the binding affinity of Synapsin I for 
vesicles106 and the binding affinity of Synapsin I for actin113. By showing that this 
phosphorylation of Synapsin I by αCaMKII also occurs during LTP induction114, and by 
showing that αCaMKII co-localizes with synaptic vesicles after depolarization in high 
K+115, it can be suggested that interactions between αCaMKII and Synapsin play a role in 
plasticity.  
Indeed, αCaMKII appears to be important in presynaptic plasticity in vivo, since 
Camk2a–/– mice showed decreased paired-pulse facilitation (PPF), a measure of presynaptic 
function116, but showed enhanced post tetanic potentiation (PTP), indicating that αCaMKII 
actually has an inhibiting effect on vesicle release117. However, this latter result is 
somewhat in conflict with the findings that CaMKII activation can regulate vesicle 
transport from the reserve pool to the readily releasable pool via Synapsin I 
phosphorylation, as described above, and with the fact that injecting activated CaMKII 
into synaptosomes, enhances neurotransmitter release118. But Synapsin I contains more 
phosphorylation sites, and can also be phosphorylated by MAPK, PKA and cdk1 which 
prompt the same function: releasing vesicles from the actin cytoskeleton119, 120. Apart from 
that, injecting activated αCaMKII into synaptosomes reveals the functions αCaMKII could 
fulfill, but this does not necessarily have to be its physiological function in a living 
organism. Taken into account that αCaMKII is one of the most abundant proteins in the 
hippocampus is, it could very well be that αCaMKII does not only play an enzymatic role 
in the presynapse, but also exerts non-enzymatic functions. This hypothesis is confirmed 
in chapter II. 
 
3.3.  The role of αCaMKII in the cerebellum 
The cerebellum is essential for motor control and fine-tuning of motor commands, and 
consists of the highly organized cerebellar cortex and the cerebellar nuclei (as reviewed 
by121). The Purkinje cells form the sole output of the cerebellar cortex, and are known to 
integrate the excitatory inputs originating from the mossy fiber and the climbing fiber 
 20 
systems (as reviewed by122). The mossy fibers originate in the precerebellar nuclei and 
innervate the granule cells, which in turn give rise to the parallel fibers that innervate the 
dendritic spines of the Purkinje cells. The climbing fibers arise from the inferior olive. In 
the adult brain, each Purkinje cell dendritic tree is contacted by approximately 150.000 
parallel fibers, whereas it receives input of just one single climbing fiber. Apart from the 
excitatory innervation, the Purkinje cells also receive inhibitory input from basket cells 
and stellate cells. All these excitatory and inhibitory synaptic inputs are integrated with 
the intrinsic pacemaking activity of Purkinje cells and are projected to the cerebellar 
nuclei.  
The parallel fiber-Purkinje cell synapse is the most extensively studied synapse in the 
cerebellum. Similar to the hippocampus, the direction of plasticity at this synapse is 
shown to be dependent on the level of Ca2+ at the postsynapse123. However, the effect of 
the calcium concentration on the direction of plasticity at this synapse is opposite to the 
hippocampus. Repetitive parallel fiber stimulation leads to a moderate increase in Ca2+-
levels in Purkinje cells, which results in the expression of LTP123. Parallel fiber stimulation 
with additional repetitive stimulation of the climbing fiber results in high Ca2+ levels in the 
Purkinje cell, which induces LTD of the Parallel fiber input123. The molecular mechanisms 
underlying the induction of LTD have been extensively studied (as reviewed by124), 
showing that the mGluR1/PKC pathway plays a key role in the induction of LTD125, 126. 
Surprisingly, despite the fact that cerebellar αCaMKII is expressed in Purkinje cells127, that 
the Ca2+ levels critically determine the direction of plasticity128 and that αCaMKII plays an 
important role in hippocampal plasticity, the role of αCaMKII in parallel fiber-Purkinje 
cell plasticity was never properly assessed. This is surprising, especially since it has been 
shown that CaMKII inhibitors can potentiate glutamate response at the Purkinje cell 
synapse129, indicating that CaMKII is also likely to play a role in cerebellar plasticity. The 
first full study on the direct involvement of αCaMKII in cerebellar plasticity and learning 
showed that CaMKII indeed plays an essential role in cerebellar LTD130; Camk2a–/– mice do 
not show LTD when measured at a young age and, surprisingly, even show LTP when 
LTD is induced at an older age. Additionally, the application of a CaMKII inhibitor during 
a LTD induction protocol also results in the expression of LTP. No differences were found 
in LTP at any age. Plasticity at the parallel fiber-Purkinje cell synapse, is proposed to be 
necessary for cerebellar motor learning (as reviewed by131). One of the most commonly 
used tasks to test this hypothesis in mice is to measure adaptation of compensatory eye 
movements during visuo-vestibular training. The baseline performance in this motor task 
was normal in Camk2a–/– mice, but the mutants showed impaired learning in a gain-
increase training paradigm, indicating that αCaMKII indeed plays a role in cerebellar 
motor learning130.  
These data show that αCaMKII is essential for LTD and not for LTP in the parallel 
fiber-Purkinje cell synapse, thus that αCaMKII is essential during conditions where the 
calcium level in the cell is high. In the hippocampus αCaMKII is also activated when the 
calcium levels are high, resulting in LTP (as described previously). Thus, the final 
response induced by αCaMKII activity in Purkinje cells compared to hippocampal 
pyramidal cells is completely opposite, which is quite surprising, since both types of 
neurons require the insertion or internalization of AMPA receptors for the induction of 
LTP or LTD respectively. In pyramidal cells, high calcium levels result in AMPA receptor 
insertion in the synaptic membrane (as reviewed by132), whereas in Purkinje cells, high 
calcium levels result in AMPA receptor internalization133. Both require αCaMKII, therefore 
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it would be very interesting to unravel the exact mechanisms underlying αCaMKII-
dependent plasticity in both cell types.  
 
4.    Function of βCaMKII 
βCaMKII is the second CaMKII isoform that is highly expressed in the brain. In 
contrast to αCaMKII, it is expressed throughout the mammalian brain. There are a number 
of important differences between αCaMKII and βCaMKII that need to be mentioned here.  
First, the ratio between αCaMKII and βCaMKII subunits in hetero-oligomers differ 
between forebrain and cerebellum, with α/β ratios of 3:1 versus 1:422, 23 respectively. This 
difference in subunit ratio is mainly caused by the lack of αCaMKII subunits in cerebellar 
granule cells127, 130. The physiological relevance of the difference in subunit composition 
between cerebellum and forebrain is still unknown, but it is likely to be of great 
importance since αCaMKII and βCaMKII are not only differentially expressed in a spatial 
manner (i.e. with respect to cell-type), but also in a temporal manner: βCaMKII expression 
starts at E12.5 and reaches its maximum level at P3, whereas αCaMKII expression starts at 
P5 and reaches maximum levels in mature mice18, 134. Furthermore, the expression of the 
subunits is also regulated by neuronal activity: increased activity results in high α/β 
ratio’s and vice versa135. 
Figure 6: Domain organization 
of βCaMKII and structure of an 
α-/βCaMKII heteromer. (a) 
Unlike αCaMKII, βCaMKII has a F-
actin binding domain, containing two 
extra phosphorylation sites, of which 
the function is unknown. (b) Two 
βCaMKII subunits are enough to 
tether the α-/βCaMKII heteromer to 
actin. 
 
 
Second, βCaMKII has a 
higher affinity for 
Ca2+/CaM22. Half-maximal 
autophosphorylation levels are achieved at 130 nM calmodulin for αCaMKII and at 15 nM 
calmodulin for βCaMKII. Accordingly, the sensitivity range of the heteromeric 
holoenzyme is dependent on the ratio of α to β subunits22, 136.  
Third, βCaMKII has an extra domain in the variable region137, 138 (fig 6). This domain 
allows βCaMKII to bind to F-actin in an activity-controlled manner31, 59. It has been shown 
that only two βCaMKII subunits per holoenzyme are sufficient to change the localization 
of the entire holoenzyme31. Mainly due to these different actin-binding properties 
αCaMKII and βCaMKII have opposing effects on synaptic strength135, and on the degree 
of dendritic arborization34. Additional evidence that the actin binding domain in the 
variable region in βCaMKII probably plays a critical role in synaptic function, comes from 
the observation that exons in this domain are controlled at the transcriptional level by 
alternative splicing13, 35. Indeed, the presence of just one single exon in the variable region 
determines the interaction with F-actin35 (fig 7).  
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Figure 7: Splice variants of βCaMKII. Only βCaMKII and β’CaMKII can bind to F-actin, indicating that 
alternative splicing of exon V1 regulates the F-actin binding properties of βCaMKII. V1-4 indicate exons in the 
variable domain. Adjusted from O’leary et al., Mol. Biol Cell, 2006. 
 
βeCaMKII is an isoform that is highly expressed during embryonic development, but 
the expression declines after birth and is absent from P428. This specific isoform does not 
have the F-actin binding domain, which makes it highly similar to αCaMKII. As αCaMKII 
is not expressed during embryonic development, it seems likely that βeCaMKII functions 
as a replacement of αCaMKII. 
At the posttranslational level the actin binding domain is likely to be regulated by 
phosphorylation at Thr382137. However, the precise function of this phosphorylation site is 
currently unknown. 
 
4.1.   The role of βCaMKII in hippocampal plasticity 
In contrast to αCaMKII, there were no Camk2b mouse mutants generated until 
recently, therefore little is known on the function of βCaMKII in the hippocampus in vivo. 
However, many studies have been published on the role of βCaMKII in hippocampal 
neurons in vitro. This section will give a short overview of what is known about βCaMKII 
in vitro.  
Overexpression of βCaMKII or reduction of βCaMKII levels has been shown to have 
several effects on hippocampal neurons. First, it is shown that in developing hippocampal 
neurons, overexpression of βCaMKII enhances dendritic arborization and increases the 
number of synapses, whereas knock-down of Camk2b by siRNA results in exactly the 
opposite phenotype32, 34, indicating that βCaMKII plays an important role during 
development. Second, it is hypothesized that βCaMKII plays a role in synaptic 
homeostasis. As βCaMKII has a higher affinity for CaM compared to αCaMKII22, it is able 
to detect low levels of calcium influx. When the calcium influx increases, the levels of 
βCaMKII in the spine decrease135, thereby changing the sensitivity of the α-/βCaMKII 
holoenzyme for calcium. Additionally, the decrease in βCaMKII levels also reduces the 
number of synapses on a dendrite34, thereby preventing overactivation of the neuron. 
However, these latter findings are not supported in other studies, in which it is shown that 
LTP induction results in increased CaMKII activity together with synaptogenesis139.  
Manipulating Camk2b affects mostly the localization and function of αCaMKII and the 
bundling and organization of actin. βCaMKII has been suggested to play a structural role, 
since it tethers the holoenzyme to the actin cytoskeleton, thereby regulating the subcellular 
localization of αCaMKII31, 140. Indeed, it has been shown that when there is no βCaMKII 
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present, αCaMKII is uniformly expressed throughout the neuron31, 141. Upon calcium 
influx (e.g. by glutamate stimulation), Ca2+/CaM binds to βCaMKII and βCaMKII 
dissociates from actin, thereby releasing the heteromeric holoenzyme from the actin 
cytoskeleton and allowing it to translocate to the PSD59.  
Binding of βCaMKII to actin has implications for actin polymerization and for the 
structure of the actin cytoskeleton. βCaMKII has been shown to bind and bundle the F-
actin filaments35, but it also binds the G-actin monomers, thereby inhibiting actin 
polymerization142. Hence, βCaMKII is not only able to stabilize actin, but also to regulate 
the density of the F-actin bundles.  
Until recently only one study was published on the role of βCaMKII in vivo, in which it 
was shown that overexpression of βCaMKII in the dentate gyrus of the hippocampus, 
results in decreased LTP in the perforant path, and impaired consolidation of long-term 
memory in the contextual fear-conditioning task143. However, the exact mechanisms 
underlying these phenotypes were not deciphered.  
In chapter IV of this thesis we assessed the role of βCaMKII in the hippocampus, using 
a Camk2b–/– mouse. 
  
5.  Overview of Camk2a and Camk2b mutants  
Using mutant mice as a tool to study the role of specific proteins in the mechanisms 
underlying learning and memory has become a complete subfield within neuroscience. To 
study the exact roles of αCaMKII and βCaMKII approximately 15 different mutants have 
been generated over time, starting with the Camk2a–/–144, 145. Table 2 and 3 give an overview 
of the mouse mutants currently available to study the role of αCaMKII and/or βCaMKII, 
with their molecular, morphological, plasticity and behavioral phenotypes in 
hippocampus/cortex an cerebellum respectively (adjusted from36).  
 
Table 2.  
Overview of Camk2 mutants and their hippocampal or cortical phenotypes 
Mutant# 
 
Purpose Molecular and morphological 
characterization## 
Plasticity## Behavioral Phenotype 
Camk2a-null (-
/-)144-146 
 
Elimination of 
αCaMKII protein 
* Expression level of  βCaMKII is 
unaltered144-146 but targeting of 
βCaMKII  to PSD is increased146  
* Ca2+ (in)dependent activity 
60% reduced in forebrain. 
* HC-LTP reduced144, 146, 147 
* NC-LTP reduced in adult 
animals148-150  
* NC-LTP normal in young 
animals148, 149 
* Decreased LTD98 
* Decreased PPF144  
* Normal I/O146 
* Normal PTP98 
* HC VGCC-dependent LTP at 
200Hz decreased (Borgesius et 
al., unpublished) 
* Hippocampus dependent 
learning severely impaired but 
learning in some animals is 
observed after extended 
training145, 146, 150 
* increased seizure susceptibility151 
(background dependent?146) 
Camk2a-null 
(+/-)144, 146 
Reduction of 
αCaMKII protein 
* αCaMKII 50% reduced,  
βCaMKII levels normal 
* Ca2+ (in)dependent activity 
30% reduced in forebrain 152 
* Immature dentate gyrus153 
* HC-LTP normal 146, 154, 155 
* NC-LTP reduced155  
* Decreased PPF154 
* Increased augmentation154 
* Normal learning146 or reduced 
hippocampus dependent 
learning154 (background and 
protocol dependent) 
* Severely impaired remote 
memory156 
* Decreased fear and increased 
aggressive behavior157 
Camk2a-Floxed  
+ CA3-cre117 
Elimination of 
αCaMKII protein 
in CA3 area 
αCaMKII is absent from CA3 
area after 4 months of age 
* Increased frequency 
facilitation 
* normal PPF and basal Pr 
* Not tested 
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Camk2aT286A 158 Blocks T286 
phosphorylation 
(no autonomous 
activity)  
* Normal expression level of 
α/βCaMKII. Ca2+ independent 
activity reduced by 60%  
* Increased phosphorylation of 
βCaMKII in dentate-gyrus after 
LTP induction159 
* HC-LTP and NC-LTP 
impaired158, 160-162 
* Normal I/O158 
* Normal NMDA receptor-
dependent LTP at the MMP159 
* Impaired Schaffer 
commissural-CA1 LTP159 
* Increased excitability of  CA1 
pyramidal neurons163 
* Severely impaired learning in 
watermaze158, 164 
* Unstable place cells165 
Tg-Camk2aT286D 
166 
Mimics 
constitutive T286 
phosphorylation  
Ca2+ independent activity 2 fold 
increased 
* Favors LTD166 
* Normal NC-LTP167 
* Normal PPF166 
* Impaired learning in Barnes 
maze168 
* Impaired olfactory based spatial 
learning169 
* Normal cued and contextual 
conditioning168 
* Unstable place cells170 
Tg-Camk2aT286D 
171 
(Tet inducible) 
Mimics 
constitutive T286 
phosphorylation 
in an inducible 
fashion 
Ca2+ independent activity 6 fold 
increased at max. induction  
* Favors LTP at low expression 
level172 
* Favors LTD at high 
expression level171, 172 
* NC-LTP and LTD normal167 
* Impaired learning in Barnes 
maze171 
* Impaired learning in 
watermaze172 
* Impaired cued and contextual 
conditioning171, 172 
Tg-Camk2aT286D 
EC 173 (Tet 
inducible) 
Mimics 
constitutive T286 
phosphorylation 
in the medial 
enthorinal cortex 
in an inducible 
fashion 
Not tested Not tested * Impaired learning in watermaze 
* Impaired recognition memory in 
a visual paired comparison task 
* Normal cued and contextual fear 
memory 
* Normal anxiety-related 
responses and locomotion in open 
field and light/dark transition test 
* Disruption of previously 
established memory in watermaze  
Camk2aTT305/6VA 
146 
Blocks T305/T306 
(inhibitory) 
phosphorylation  
Increased levels of CaMKII in 
PSD 
* Favors LTP 
* Normal LTD and I/O 
* Reduced metaplasticity in 
the lateral perforant path174 
* Impaired watermaze learning 
(initial learning OK) 
* Impaired reversal learning 
* Impaired context discrimination 
* Old mice get seizures 
Camk2aT305D 146 Mimics 
constitutive T305 
(inhibitory) 
phosphorylation  
* Severely reduced levels of 
α/βCaMKII in PSD 
* Reduced NR2A subunits in the 
synapse and cytoplasm of the 
spine175 
* Favors LTD 
* No LTP 
* Normal LTD and I/O 
* Severely impaired in watermaze 
and cued conditioning. (Can not 
learn after overtraining) 
Camk2aΔ3’UTR 176 Impairs dendritic 
targeting of 
mRNA 
Reduced amount of PSD 
associated CaMKII 
* Normal (early) LTP 
* Reduced late-phase LTP 
* Impaired learning in watermaze 
* Normal  STM but impaired LTM 
after cued and contextual 
conditioning  
Tg-Camk2aF89G 
177 
Inducible system 
allowing rapid (8 
min) reversible 
decrease of 
αCaMKII 
transgene activity 
Ca2+ (in)dependent activity 2-3 
fold increased without inhibitor 
* Normal I/O and PPF 
* Enhanced LTD at 3Hz 
* Enhanced LTP at > 10Hz 
* Enhanced LTP at 100Hz 
when CaMKII is 
overexpressed during the first 
10 min after tetanization178 
* Impaired memory consolidation 
of contextual and cued 
conditioning when CaMKII 
activity is changed at the first 
week after training. 
* impaired memory retrieval of 
object recognition and fear 
memory when CaMKII is 
overexpressed at the time of recall, 
restricted to the memory being 
retrieved179 
*impaired STM when CaMKII is 
overexpressed within the first 10 
min after training178 
Camk2aK42R 152 Blocks kinase 
activity 
* 20% decrease in levels of 
αCaMKII in forebrain 
* 40% decrease in levels of 
phospho-T286 in forebrain 
* Ca2+ (in)dependent activity 60-
70% decreased 
* Faster activity-dependent 
postsynaptic translocation 
* Normal I/O, PPF and PTP 
* Reduced NMDA receptor-
dependent LTP at 100Hz 
* Severely impaired one-trial 
inhibitory avoidance learning  
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Tg-Camk2bF90G 
143 
Inducible system 
allowing rapid 
reversible 
decrease of 
βCaMKII 
transgene activity 
in dentate gyrus 
Ca2+ (in)dependent activity 2-3 
fold increased without inhibitor  
* Normal I/O and PPF 
* Normal LTP at the Schaffer 
collateral pathway 
* Reduced LTP at the 
perforant path 
* Impaired LTM consolidation of 
contextual conditioning when 
βCaMKII is overexpressed the 
initial day after training 
Camk2b-null (-
/-) (Borgesius 
et al., 
unpublished) 
Elimination of the 
βCaMKII protein 
* Normal αCaMKII expression 
* Normal T286 phosphorylation 
in total HC lysates 
* No gross morphological 
pathogenesis 
* Normal I/O, increased PPF 
* Decreased LTP at 100Hz and 
10Hz 
* Normal LTD at 1Hz 
* Normal VGCC-dependent 
LTP at 200Hz 
* impaired learning in fear 
conditioning  
* impaired motor performance and 
coordination180 
Camk2bA303R 
(Borgesius et 
al., 
unpublished) 
Blocks the 
Calmodulin 
binding site 
* Normal α/βCaMKII 
expression 
* Normal T286 phosphorylation, 
absent T287 phosphorylation in 
total HC lysates 
* No gross morphological 
pathogenesis 
* Normal I/O and PPF 
* Normal LTP at 100Hz and 
10Hz 
* Normal LTD at 1Hz 
 
* normal fear conditioning 
learning 
* impaired motor performance and 
coordination 
Ube3Am-/p+181, 182 Encodes E6-AP 
ubiquitin ligase. 
Mouse model for 
Angelman 
syndrome.  
* Increased T286-P and T305-P183  
* Decreased αCaMKII in PSD183 
* Decreased PP1/PP2a activity183 
* Impaired LTP181 
* Normal I/O181 
* Impaired spatial learning181, 182 
* Impaired motor coordination181, 
182 
* Inducible seizures181, 182 
# References given in this column refer to primary papers describing the generation and analysis of the mutant.   
## Molecular characterization and plasticity refers to hippocampus unless otherwise specified 
Abbreviations: NC= neocortex; I/O= input/output (a parameter used to assess synaptic transmission); 
HC=hippocampus, MMP= Medial perforant path; LTM= long-term memory (24 hours); STM= short-term memory (1 
hour); PSD= postsynaptic density; PPF = paired pulse facilitation; PTP=post-tetanic potentiation; Pr = probability of 
release; STM= short-term memory (30 minutes); Tg= transgenic; VGCC= voltage-gated calcium channel. 
 
Table 3.  
Overview of Camk2 mutants and their cerebellar phenotypes 
Mutant# 
 
Purpose Molecular and morphological 
characterization## 
Plasticity## Behavioral Phenotype 
Camk2a-null (-
/-)130 
 
Elimination of 
αCaMKII protein 
* Normal Purkinje cell 
morphology and maturation 
* Delayed climbing fiber 
elimination 
* No up-regulation of βCaMKII  
* Normal PPF 
* Normal basal synaptic 
transmission 
* Impaired LTD at young age 
* LTP after LTD induction at 
adult age 
* Normal LTP at all ages 
 * Impaired cerebellar learning in 
visuo-vestibular training 
* Normal saccade performance 
Camk2b-null (-
/-)180 
Elimination of the 
βCaMKII protein 
* Normal Purkinje cell 
morphology and maturation 
* Normal climbing fiber 
elimination 
* No up-regulation of αCaMKII 
* Ca2+ (in)dependent activity 
50% decreased 
* Normal PPF and PPD 
* Normal basal properties of 
Purkinje cells 
* Normal synaptic 
transmission at the climbing 
fiber-Purkinje cell synapse 
* Reversed bidirectional 
plasticity at the parallel fiber-
Purkinje cell synapse 
* Severe ataxia  
* Impaired motor performance 
and coordination on rotarod and 
balance beam 
* Normal motivation to move in 
open field and phenotyper 
# References given in this column refer to primary papers describing the cerebellar analysis of the mutants 
## Molecular characterization and plasticity refers to cerebellum 
Abbreviations: PPF = paired pulse facilitation; PPD= paired pulse depression (specific for the climbing fiber-Purkinje 
cell synapse)  
 
6.    CaMKII and Disease 
Given its important role in plasticity it is not surprising that CaMKII is found to be, 
one way or another, involved in neurological and psychiatric disorders. These include 
Alzheimer’s disease, epilepsy, schizophrenia and Angelman syndrome. This section will 
discuss what is known so far about the role of CaMKII in these diseases.  
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6.1.  CaMKII and Alzheimer’s disease 
Alzheimer’s disease is the most common form of dementia and one of the most costly 
diseases in western society. It is a neurodegenerative disease characterized by senile 
plaques, neurofibrillary tangles, neurotransmitter deficiencies and neuronal loss, which 
result in memory loss in patients. Unfortunately, the exact pathogenesis underlying 
Alzheimer’s disease is still not completely clarified. There are two biochemical processes 
that characterize the disease: 1) abnormal elevation of Aβ peptide and 2) abnormal 
hyperphosphorylation of the tau protein. Eventually these processes lead to synaptic loss 
and cell death (as discussed by184). Studies in rats have shown that elevation of the Aβ 
levels cause impairment of LTP185. Additionally, it has been shown that increased levels of 
Aβ result in decreased expression of AMPA receptors at the synapse186. CaMKII is one of 
the key proteins involved in AMPA receptor translocation, and recently it has been shown 
that increasing levels of Aβ does not change the activity of CaMKII, but selectively 
changes the subcellular localization of CaMKII187. The amount of CaMKII located at 
synapses was decreased, whereas no difference in total amount of CaMKII was found. 
Moreover, this study showed that this mislocalization of CaMKII was the main cause for 
reduced expression of AMPA receptors at the membrane187, indicating that CaMKII is 
likely to play a role in the memory loss seen in Alzheimer patients. These molecular 
processes are thought to occur already before neurodegeneration starts. At this time point, 
no changes are observed in NMDA receptor properties. However at later stages, as seen in 
brains of deceased Alzheimer patients, there is a reduction in NMDA receptor subunits188, 
189, together with a reduction of CaMKII autophosphorylation at T286, in both frontal 
cortex and hippocampus188, indicating that also the NMDA receptor is involved, but how 
exactly is still unknown. Thus, mislocalization of CaMKII could underlie the early 
memory loss seen in patients with Alzheimer’s disease, by reducing the number of AMPA 
receptors at the membrane, and at a later stage by losing its enzymatic properties. The 
exact mechanisms by which the increased levels of Aβ cause a different distribution of 
CaMKII, or how CaMKII loses its enzymatic properties still remain elusive and require 
more research.   
CaMKII has also been shown to phosphorylate tau protein190, however, whether this 
also contributes to the disease remains elusive. 
 
6.2.  CaMKII and epilepsy 
Epilepsy is a chronic neurological disease, characterized by spontaneous recurrent 
seizures, which result from excessive or synchronous discharges of a population of 
neurons191. The process responsible for the transformation of a population of normal 
neurons into neurons that show this neurophysiological abnormal behavior is called 
epileptogenesis. The molecular and cellular mechanisms underlying epileptogenesis are 
still not fully understood, but in the last few years more and more evidence became 
available showing that CaMKII is involved in this process. The first evidence for the 
involvement of CaMKII in seizures came from kindling experiments. Kindling is a model 
for epilepsy, in which repeated stimulation of certain brain regions results in a progressive 
build-up of seizure activity and could eventually result in spontaneous epileptic 
seizures192. It has been shown that kindling results in reduction of αCaMKII activity and 
expression levels (as reviewed by193). Subsequent studies showed that direct induction of 
seizures in neuronal cultures, also result in decreased autophosphorylation of both 
αCaMKII and βCaMKII194. This down-regulation of CaMKII activity and expression level, 
is shown to be the result of changes in intracellular calcium levels, induced by prolonged 
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NMDA receptor activity195. Additionally, it has also been shown vice versa, that 
downregulation of αCaMKII, as in the Camk2a–/– null mutant, results in increased neuronal 
excitability and seizures151, and that the percentage of αCaMKII downregulation correlates 
with the increase in neuronal excitability196. However, not only reducing the amount of 
CaMKII, but also manipulating its activity level is already enough to induce seizures, as 
Camk2aTT305/6VA homozygous mutant mice are shown to have seizures146. The most direct 
evidence for CaMKII playing a significant role in epilepsy comes from the mouse model 
for Angelman Syndrome (AS). Both AS mice and patients suffer from severe epilepsy.  In 
AS mice, CaMKII activity is found to be decreased, due to increased CaMKII TT305/6 
phosphorylation183. When these mice are crossed with mice that cannot be phosphorylated 
anymore on the TT305/6 residues (Camk2aTT305/6VA), thereby reducing the amount of 
inhibitory phosphorylated CaMKII molecules in AS mice, the epileptic phenotype is 
largely rescued, showing a direct involvement of CaMKII in epileptogenesis197.  
But what mechanism can explain the link between decreased CaMKII activity and 
enhanced excitability of neurons? It has been shown that during the initial phase of 
seizure activity, CaMKII translocates to the synapses, and the expression level of extra-
synaptic CaMKII decreases198. This is in correspondence with the finding that there is a 
large increase in intracellular calcium levels. After prolonged elevated levels of calcium, 
CaMKII is likely to prevent excessive activation, by TT305/6 phosphorylation199, thereby 
reducing its activity. αCaMKII is known to be able to positively regulate GABAA receptor 
function102. With both reduced expression and reduced activation of αCaMKII during 
epileptogenesis, this effect on GABAA receptors is gone; inhibition of neurons is reduced, 
which could lead to over-excitation and eventually epileptic activity. On the other hand, 
the same should also account for AMPA receptor insertion, which is also regulated by 
αCaMKII. In conclusion, more research is needed to fully understand the exact mechanism 
underlying epilepsy and the role of αCaMKII in enhanced neuronal excitability. 
  
6.3.  CaMKII and schizophrenia 
Schizophrenia is a chronic, severe mental disorder. The three main characteristics of 
the disorder are (1) positive symptoms, i.e. hallucinations and delusions; (2) negative 
symptoms, i.e. apathy and poverty of speech; (3) cognitive dysfunction, i.e. impaired 
working memory and conceptual disorganization. More and more evidence becomes 
available confirming the existence of both genetic and environmental factors in the 
etiology of schizophrenia (as reviewed by200). So far, different research groups identified 
several genes, which carry the title ‘schizophrenia genes’201. However, how these genes are 
involved in the disease and how they all contribute exactly to the characteristics of the 
disease is still hypothetical. 
Even though CaMKII has never been shown to be involved in the etiology of the 
disease, there is evidence that CaMKII does play a role in the disorder. Using postmortem 
frontal cerebral cortex tissues from schizophrenic patients, it was found that Camk2b 
mRNA levels are elevated compared to those in healthy subjects in this brain region202, 203. 
This was an interesting finding, since expression of βCaMKII in the brain starts already 
during development, indicating that it is likely to play a role in brain development18. 
Overactivation of CaMKII in young neurons has been shown to slow down dendritic 
growth31. Therefore it could be hypothesized that βCaMKII expression is already elevated 
during development, causing abnormal neurodevelopment and subsequent predisposition 
to schizophrenia. However, this remains to be investigated. 
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Since there are many genes involved in schizophrenia, it is difficult to make a good 
animal model to study the mechanisms underlying the disease. Nevertheless, withdrawal 
from repeated phencyclidine (PCP) treatment (a noncompetitive NMDA receptor 
antagonist) has been found to result in schizophrenia-like symptoms in humans204 and 
animals205. Using these animal models, it has been shown recently that the NMDA-
CaMKII signaling pathway in the prefrontal cortex is disturbed after PCP treatment206 (i.e. 
learning induced phosphorylation of CaMKII is absent in PCP treated mice), and that this 
is associated with dopaminergic hypofunction207. Whether it is the αCaMKII or the 
βCaMKII isoform that is affected is not specified in these studies. However, αCaMKII has 
also been suggested to play a role in schizophrenia, since Camk2a+/– mice show 
schizophrenia-like behavioral phenotypes, and show abnormal neurogenesis in the 
dentate gyrus, a brain region involved in working memory153. 
Taken together, even though CaMKII is not one of the ‘schizophrenia genes’, several 
studies now have provided evidence for a significant role for CaMKII in the disease. 
However, more research is needed to fully understand the exact involvement of CaMKII 
in schizophrenia.     
 
6.4.  CaMKII and Angelman Syndrome 
Angelman Syndrome (AS) is a severe genetic neurological disorder, first described by 
Harry Angelman in 1965208. He wrote a report on three children, which he called ‘Puppet 
Children’, with the same clinical features: severe mental retardation and epilepsy, ataxia, 
excessive laughter, absence of speech and dysmorphic facial features208.  
Angelman Syndrome is a classical example of genetic imprinting disorders. It is caused 
by loss of function of the maternal UBE3A gene located on chromosome 15q11-13, which 
encodes the ubiquitin ligase E6AP209, 210. It is shown that in the brain there is a specific 
imprinting pattern of the UBE3A gene211, 212, with only the maternal copy being expressed. 
The paternal allele shows expression of an antisense UBE3A transcript in the brain213(fig 
10).  
  
 
Figure 10. Detailed map of the SNURF-SNRPN/UBE3A region on chromosome 15q11-13. The 
paternally expressed SNURF-SNRPN/UBE3A antisense transcript with exons is indicated with the blue horizontal 
and vertical lines. The maternally expressed UBE3A sense transcript with exons is indicated with the red horizontal 
and vertical lines. (Adapted from Runte et al., Hum Mol Genet, 2001) 
 
Imprinting defects account for only 3-5% of the AS patients, so what genetic defects do 
the other AS patient show then? Most of the Angelman Syndrome patients have large de 
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novo deletions of the 15q11-13, which are always of maternal origin. Approximately 5-10% 
of the AS patients have maternally inherited point mutations in the UBE3A gene, and 1-2% 
of the patients have paternal uniparental disomy (UPD) of chromosome 15 (as reviewed 
by214). However, even though the UBE3A gene was identified as the ‘Angelman Syndrome 
gene’ already 16 years ago, little progress has been made providing insight in the role of 
E6AP in neuronal function. E6AP is an E3 ubiquitin ligase, involved in the degradation of 
certain proteins. Over the years several targets have been found for E6AP (as shown in 
table 5), but the critical target(s) explaining the characteristics of the disease is (are) still 
unknown. 
 
Table 5 
Targets of E6AP Function of the protein 
p53215 Tumor suppressor protein 
HHR23A216 DNA repair protein 
Mcm 7 substrate217 Involved in initiation of DNA replication 
E6AP218 Protein degradation 
Blk219 Tyrosine kinase 
PTPN3220 Tyrosine phosphatase 
PML221 Tumor suppressor protein 
Trihydrophobin 1222 Part of the negative transcription elongation factor complex 
Pbl/ECT2223 Rho guanine nucleotide exchange factor (Rho-GEF) 
AIB1224 Steroid receptor coactivator 
p27225 Cyclin-dependent kinase inhibitor 
TSC2226 Tumor suppressor protein 
Annexin A1227 Ca2+- and phospholipid-binding protein 
Targets of E6AP. 
 
When the UBE3A gene was discovered as the AS gene, a mouse model was generated 
to study the mechanisms underlying the syndrome181. These Ube3am-/p+ mice (in which the 
maternal copy of the gene is deleted), showed motor deficits, impaired learning and 
memory and epilepsy181, as seen in patients. Later studies found that CaMKII activity was 
reduced in these mice, and that this was due to increased phosphorylation at the TT305/6 
autophosphorylation sites on CaMKII183. Since CaMKII is known to play a pivotal role in 
neuronal function and since the phenotype of the CaMKIIT305D mice resembles the 
phenotype seen in the Ube3am–/p+ mice (AS mice)146, it was hypothesized that inhibition of 
CaMKII is responsible for the phenotypes seen in AS mice. In chapter V of this thesis we 
tested this hypothesis.  
 
7.  Scope of this thesis 
The general scope of this thesis is to further elucidate the role of αCaMKII and 
βCaMKII in neurological processes in different regions of the brain. Chapter II focuses on 
the role of αCaMKII in presynaptic hippocampal plasticity, showing that αCaMKII plays a 
structural, instead of an enzymatic role at the presynaptic site. Chapter III and IV focus on 
the function of βCaMKII in cerebellar plasticity (chapter III) and in hippocampal plasticity 
(chapter IV). There it is shown that in the cerebellum βCaMKII is responsible for the 
direction of plasticity at the parallel fiber – Purkinje cell synapse, both enzymatically and 
structurally, whereas in the hippocampus βCaMKII is more likely to play a structural role 
in plasticity. Finally, chapter V focuses on the role of αCaMKII in Angelman Syndrome, 
showing that reducing the amount of auto-inhibited CaMKII in AS mice rescues the 
neurological problems seen in AS mice. 
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Using targeted mouse mutants and pharmacologic inhibition of αCaMKII, we 
demonstrate that the αCaMKII protein, but not its activation, autophosphorylation or 
its ability to phosphorylate Synapsin I, is required for normal short-term presynaptic 
plasticity. Furthermore we show that αCaMKII regulates the number of docked vesicles 
independent of its ability to be activated. These results indicate that αCaMKII plays a 
non-enzymatic role in short-term presynaptic plasticity at hippocampal CA3-CA1 
synapses. 
 
The alpha isoform of Ca2+/calmodulin-dependent protein kinase II (αCaMKII) was 
originally identified as Synapsin I kinase1. Subsequent studies showed that αCaMKII is 
abundantly associated with presynaptic vesicles by binding to Synapsin I2. Together with 
the observation that αCaMKII is one of the most abundant proteins of the hippocampus3, 
these results may suggest that αCaMKII also has a non-enzymatic function, but such a 
function has not directly been demonstrated yet. Analysis of Camk2a knock-out (Camk2a–/–) 
mice confirmed a presynaptic role of αCaMKII in short-term presynaptic plasticity4, 5, but 
these experiments did not address whether this role is mediated by αCaMKII as a kinase, 
as a structural protein, or both. 
To study the enzymatic requirements of αCaMKII in presynaptic plasticity, we made 
use of four different lines of αCaMKII mutants. Autophosphorylation at the T286 and 
T305/T306 site was prevented by using Camk2aT286A mice, which lack αCaMKII 
autonomous (Ca2+/CaM independent) activity6 and by Camk2aT305/306VA mice, which lack 
αCaMKII inhibitory autophosphorylation7. Furthermore, we made use of Camk2aT305D 
mice, in which constitutive autophosphorylation at the T305 site in the Ca2+/CaM domain 
is mimicked. Hence, αCaMKII in these mice can not be activated7. The fourth line lacks the 
entire αCaMKII protein (Camk2a–/–)7 (for an overview of all phenotypes see 8).  
Since these mutants were backcrossed in C57BL6, we first tested whether the 
originally reported LTP deficits (in hybrid 129Sv/C57BL6 mice) were still present6, 7, 9. 
Indeed, we confirmed that αCaMKII activation and its subsequent autophosphorylation at 
T286 are absolute requirements for LTP, but that loss of αCaMKII can partially be 
compensated for (Supplementary Fig. 1). In contrast, loss of inhibitory phosphorylation in 
Camk2aTT305/6VA mice, reduced the threshold for LTP induction as reported previously7 
(Supplementary Fig. 1). Western blots on isolated synaptosomes of all the mutants did not 
reveal changes in the levels of the β, γ, δCaMKII isoforms, nor was the amount of 
calmodulin affected in these mutants (Supplementary Fig. 2).  
We looked at the ability of these mutants to phosphorylate Synapsin I at S603 (site 3), 
which is an exclusive CaMKII site. As shown in Fig.1, Camk2a–/– mice showed a marked 
decrease of Synapsin I phosphorylation as compared to wild-type mice (p<0.001; 
ANOVA), suggesting that none of the other CaMKII isoforms can efficiently compensate 
for the loss of αCaMKII phosphorylation of Synapsin I in vivo. Notably, steady-state levels 
of phosphorylated Synapsin I were not affected in Camk2aT286A (p=0.2) mice and in 
Camk2aTT305/306VA mice (p=0.3), indicating that loss of autonomous activity or self-inhibition 
is not important for Synapsin I phosphorylation in vivo. In contrast, activation of αCaMKII 
is an absolute requirement, since phosphorylation of Synapsin I in the Camk2aT305D mutant 
was not significantly above background level (p=0.2; Fig. 1a). The dominant negative 
nature of the Camk2aT305D mutation is further illustrated by the fact that this is also the only 
mutant in which autophosphorylation at both αCaMKII-T286 and βCaMKII-T287 is 
indistinguishable from background level (both p>0.8; Fig. 1b), further suggesting that 
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αCaMKII in this mutant is inactive. Taken together, these results show that these mutants 
provide an ideal tool to dissect the requirements for αCaMKII activation, αCaMKII 
autophosphorylation, and Synapsin I S603 phosphorylation in short-term presynaptic 
plasticity.  
 
Figure 1. Phosphorylation of 
Synapsin I and CaMKII-
T286/T287 in synaptosomes 
obtained from Camk2a mutants. 
(a) Phosphorylation of Synapsin I 
S603 is not affected by impaired 
αCaMKII autophosphorylation, 
but requires αCaMKII protein and 
its activation by Ca2+/Calmodulin. 
(b) Phosphorylation of αCaMKII-
T286 and βCaMKII-T287 is absent 
in Camk2aT305D mice. Graph 
represents data of βCaMKII-T287 
only. Error bars indicate SEM. 
Each sample contains pooled 
fractions from 4 independent 
isolations. 
 
Previous studies from multiple laboratories4, 5, 8, using independently generated 
targeted deletions of αCaMKII5, 9, have demonstrated that loss of αCaMKII results in 
enhanced augmentation and decreased synaptic fatigue, which are both measures of 
presynaptic plasticity. Augmentation is an increase in the evoked postsynaptic response 
observed several seconds after high-frequency afferent stimulation, caused by facilitated 
exocytosis10. We measured augmentation at hippocampal CA3-CA1 synapses using 
extracellular field recording (Supplementary methods). As shown in Fig. 2a,c Camk2a–/– 
mice showed a striking increase in synaptic augmentation (during 3-11s: F(4,92)=13, 
p<0.0001 repeated measures ANOVA), confirming that αCaMKII critically regulates this 
form of presynaptic plasticity4. Since transiently elevated presynaptic calcium is thought 
to be an important factor underlying synaptic augmentation, activation of presynaptic 
αCaMKII activity may play an important role. However, although αCaMKII activity is 
regulated by autophosphorylation, augmentation was not affected in the Camk2aT286A and 
Camk2aTT305/6VA autophosphorylation deficient mutants (Fig. 2c). The lack of a phenotype 
in these mutants could reflect the short-term nature of this kind of plasticity, and/or the 
fact that phosphorylation of Synapsin I-S603 is unaffected in these mutants (Fig. 1). 
Unexpectedly however, augmentation was also unaffected in Camk2aT305D mutants (p=0.5 
ANOVA; Fig. 2b,c) in which αCaMKII activation is blocked and Synapsin I 
phosphorylation is absent (Fig. 1). These results strongly suggest that synaptic 
augmentation does not depend on the ability to phosphorylate Synapsin I, nor on the 
activation of αCaMKII.  
Since activation of both αCaMKII and βCaMKII seem to be impaired in the 
Camk2aT305D mutant (Fig. 1b) a similar result should be obtained if the augmentation 
experiment is performed in the presence of the membrane-permeable CaMKII inhibitor 
KN-9311. This inhibitor competes with Ca2+/Calmodulin binding and therefore prevents 
activation of both αCaMKII and βCaMKII. LTP experiments in the presence of this 
inhibitor showed that KN-93 is indeed able to block LTP (Supplementary Fig. 1f). In 
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contrast, augmentation was similar in the presence of KN-93 as compared to its inactive 
analogue KN-92 (p=0.5 ANOVA; Fig. 2c), confirming that CaMKII activation is not 
required for normal augmentation.  
The biochemical experiments of Fig.1 indicate that CaMKII activity in the Camk2aT305D 
mutant is reduced to such extend, that phosphorylation of CaMKII substrates is 
undetectable. If CaMKII activity is indeed not required for augmentation, the potent 
CaMKII inhibitor AIP-II (autocamtide-2 related inhibitory peptide II) should not affect 
augmentation as well. This inhibitor is 500 times more potent than KN-93 and more 
importantly, it is non-competitive for Ca2+/Calmodulin and exogenous substrates, thus 
also blocking basal and autonomously active CaMKII12. Efficient penetration was achieved 
by making use of AIP fused to the Antennapedia transport peptide, and by preincubating 
the slices for 1 hour (see Supplementary Methods). Indeed, LTP was fully blocked, 
indicating that the drug is able to penetrate the slice (Supplementary Fig. 1g), and 
importantly, Ant-AIP-II showed no discernable effect on synaptic transmission 
(Supplementary Fig. 3), which makes it suitable to be used in these experiments.  
However, like KN-93, Ant-AIP-II did not affect augmentation (p=0.1 ANOVA; Fig. 2c). 
Taken together these results indicate that αCaMKII protein, but not αCaMKII activity, is 
required for normal augmentation. 
Previous whole-cell patch-clamp recordings in CA3-restricted Camk2a–/– mice, showed 
a significant enhancement of the EPSC amplitude during repetitive stimulation of CA3-
CA1 synapses5, suggesting that the fatigue rate of neurotransmitter release is regulated by 
αCaMKII. Likewise, extracellular field recordings from our global Camk2a–/– mice also 
demonstrated reduced synaptic fatigue (Fig. 2d). The responses to repetitive 10 Hz 
stimulation reveal the competing processes of facilitation, vesicle depletion, and vesicle 
mobilization10. Camk2a–/– mutants had a similarly-shaped curve as wild-type mice, 
however, there was a significant effect of genotype (F(1,45)=4.5, p<0.05) and a significant 
interaction between genotype and stimulus number (F(99,4455)=4,5, p<0.0001): Camk2a–/– 
mutants were only significantly different from wild-type mice after 20 stimuli (first 20: 
F(19,855)=1.2, p=0.3; last 80: F(79,3555)=2.6, p<0.001), suggesting a differential rate of vesicle 
depletion and/or mobilization, the cellular processes primarily responsible for the 
maintenance of EPSP amplitude during prolonged stimulation10.  
To test the αCaMKII autophosphorylation and Synapsin I phosphorylation 
requirements in this presynaptic measure, we repeated the experiment in the αCaMKII 
point mutants. No significant effect of genotype was observed in either Camk2aT286A or 
Camk2aTT305/6VA autophosphorylation defective mutants  (both p>0.3 ANOVA at stimulus 
number 100, Fig 2f). Notably, depletion rate was also not affected in Camk2aT305D mutants 
(p>0.7; Fig. 2e,f), in which activation of αCaMKII is prevented and phosphorylation of 
Synapsin I is absent. In addition, there was no discernable effect on depression in slices 
treated with KN-93 or Ant-AIP-II (p=0.9 and p=0.7 respectively; Fig. 2f). Taken together, 
this strongly suggests that the αCaMKII protein plays a structural role rather than an 
enzymatic role during this form of short-term presynaptic plasticity. 
 
 47 
 
Figure 2. Presynaptic short-term plasticity 
requires αCaMKII protein but not its 
autophosphorylation, activation or activity. (a-c) 
Increased synaptic augmentation in Camk2a–/– 
mutant mice is not caused by the lack of CaMKII 
kinase activity. (a,b) fEPSP responses 
(normalized to pre-tetanus baseline) were 
recorded at the indicated time after a 10 theta-
burst tetanus. Traces are from baseline response 
(grey) and the response 5s post tetanization 
(black). (c) Augmentation summary of responses 
obtained 5 seconds post-tetanus normalized to 
baseline. Black bars represent mutants or drug 
treated slices, white bars represent control slices 
as indicated. (d-f). Decreased synaptic fatigue 
during repetitive stimulation in Camk2a–/– mice 
is not caused by the lack of αCaMKII kinase 
activity. (d,e) fEPSP responses (normalized 
against baseline) were recorded during a 10Hz 
tetanus. Only the first and even numbered 
stimuli are shown for clarity. Traces are from 
wild-type (grey) and Camk2a–/– slices (black) 
recorded from stimulus number 21-30. (f) 
Depletion summary of the last (100th) stimulus of 
the 10Hz train. Black bars represent mutant or 
drug treated slices, normalized against the 
controls as indicated (white bars, set at 100%). 
Numbers between brackets indicate number of 
slices.  Error bars indicate SEM. 
 
Mechanistically, enhanced 
synaptic augmentation and reduced 
synaptic depression could reflect 
changes in the pool sizes of the 
synaptic vesicles, in particular the 
size of the readily releasable pool 
(RRP).  Therefore, we used electron-
microscopy to measure the number 
of docked vesicles, a morphological 
correlate of the RRP13, 14.  We 
obtained measurements at the active zone of excitatory synapses on CA1 spines of wild-
type, Camk2a–/–, and Camk2aT305D mice.  Indeed, there was a significant effect of genotype 
(F(2,41)=4.7, p<0.05), with synapses in Camk2–/– mice showing a 20% increase in the total 
number of docked vesicles compared to wild-type (Fisher's PLSD p<0.05) or Camk2aT305D 
mice (p<0.01) (Fig. 3a).  In contrast, no significant difference in the number of docked 
vesicles was observed between the Camk2aT305D mutant and wild-type mice (Fisher's PLSD 
p=0.24).  Additional measurements of the number of reserve pool vesicles, active zone 
length, and presynaptic terminal area were not different between the mutants and wild-
type mice (all measures p>0.2; Supplementary Fig. 4). Thus, the absence of αCaMKII 
protein results in an increased number of docked vesicles whereas the loss of αCaMKII 
activation and Synapsin I S603 phosphorylation does not affect vesicle docking. 
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Together, these results suggest a model in which αCaMKII functions non-
enzymatically to limit the size of the RRP, thereby modulating short-term presynaptic 
plasticity. If the observed increase in the size of EPSPs during repetitive stimulation in 
Camk2a–/– mice is indeed mediated by a larger RRP, then presynaptic function should be 
normal under conditions that minimize depletion of the RRP. Accordingly, we decreased 
the extracellular calcium concentration, which limits the rate of depletion from the RRP15. 
Indeed, decreasing the extracellular calcium concentration from 2.5 to 0.8 mM normalized 
the responses during 10 Hz stimulation in Camk2a–/– mice (F(1,31)< 0.0001, p= 1, Fig. 3b), 
supporting a model that αCaMKII limits the available pool of readily-releasable 
neurotransmitter vesicles. 
 
 
Figure 3: αCaMKII protein regulates the 
number of docked vesicles. (a) Quantitative 
electron microscopy of asymmetric synapses 
on dendritic spines of CA1 pyramidal 
neurons, show a 20% increase in the number 
of docked vesicles in Camk2a–/– mice. (b) 
Decreasing the depletion rate by lowering 
extracellular [Ca2+], reverses the phenotype of 
the Camk2a–/– mice during repetitive 
stimulation. Error bars indicate SEM. 
 
 
 
Taken together, our experiments suggest that Synapsin S603 phosphorylation and 
αCaMKII activity are not required for short-term presynaptic plasticity measures such as 
augmentation and synaptic fatigue during repetitive stimulation. Specifically, we have 
demonstrated that at hippocampal CA3-CA1 synapses, αCaMKII functions independent 
of its kinase activity to modulate short-term presynaptic plasticity by limiting the number 
of presynaptic docked neurotransmitter vesicles. Therefore, this is the first demonstration 
that αCaMKII also plays a non-enzymatic role in the synapse.  
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Supplementary Figures 
 
 
Supplementary Figure 1. 
Long-term potentiation at Schaffer 
Collateral CA1 synapses in Camk2a 
mutant mice after back-crossing in 
C57BL6 (a-e) and in 
pharmacologically treated wild-type 
slices (f,g).  LTP in all experiments 
was induced by four bursts of high 
frequency stimulation (four stimuli 
at 100 Hz), each burst separated by 
200 ms, except in (d) in which LTP 
was induced by 150 stimuli at 5 Hz. 
(a) LTP is reduced but not absent 
in Camk2a–/– mice, as observed 
previously1-3. 
(b,e) LTP is absent in Camk2aT286A 
and Camk2aT305D mice, as reported 
previously1, 4. 
(c,d) LTP in Camk2aTT305/6VA mice 
is normal upon strong stimulation 
(4 theta burst LTP) but increased 
upon weak stimulation (5Hz), 
consistent with previous findings1, 5. 
(f,g) LTP is blocked in wild-type 
slices in presence of CaMKII 
inhibitor KN93 (f) and Ant-AIP-II 
(g).  
Error bars represent SEM. 
Numbers between brackets refer to 
the number of slices used. See 
Supplementary methods for cited 
references. 
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Supplementary Figure 2. No changes in synaptic βCaMKII, 
γCaMKII, δCaMKII and Calmodulin in Camk2a mutants or point 
mutants. Synaptosomes were isolated as described (Supplementary 
methods), and analyzed by Western blotting. Each sample contains 
pooled fractions from 4 independent isolations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. Synaptic transmission is not 
affected by Ant-AIP-II. (a) Presynaptic excitability is not 
significantly affected by Ant-AIP-II (F1,55=1.4; p=0.24 Repeated 
Measures ANOVA). (b) Postsynaptic fEPSP responses are not 
affected by Ant-AIP-II (F1,60=0.9; p=0.34). (c) Overall synaptic 
transmission (fEPSP as function of the presynaptic fiber volley) 
is unaffected by Ant-AIP-II, in agreement with previous 
findings6. Error bars represent SEM. See Supplementary 
methods for cited references. 
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Measure   Wild-Type    αCaMKII-KO  αCaMKII-T305D  
 
Active zone (AZ) length (nm) 234±10   242±26 190±15 
Terminal area 138±15 158±18 112±19   
Reserve pool vesicles  40±4   47±5   37±5 
Reserve pool vesicles/area 309±21 306±15 365±40 
Docked vesicles/AZ 4.6±0.2 5.6±0.5 4.0±0.3 
Docked vesicles µm 20±0.7 24±1.3 21±1.2 
 
Supplementary Fig. 4. Quantitative electron microscopy of asymmetric synapses on dendritic spines of CA1 
pyramidal neurons. Camk2a–/– have more docked vesicles at the active zone than wild-type mice and Camk2aT305D mice. 
Arrowheads denote the lateral boundaries of the postsynaptic density, which was used to define the active zone across 
the synaptic cleft. Arrows show examples of vesicles counted as docked (see Methods for their definition). Statistical 
differences (p<0.05 compared to wild-type mice) are printed in bold. All values are mean ± SEM. 
 
Supplementary Materials and Methods 
 
Animals  
To study the role of presynaptic αCaMKII, we made use of a Camk2a mutant, in which 
Camk2a exon 2 is deleted1. Exon 2 encodes the catalytic site, and deletion of this exon 
results in a premature translation stop due to a frame shift, thus effectively resulting in a 
Camk2a knock-out (Camk2a–/–) line1. To study the role of autophosphorylation and activity 
of αCaMKII, we made use of three different mutants in which the endogenous Camk2a 
was mutated using ES cell-mediated gene targeting. In the first mutant (T286A), Camk2a 
Thr286 is substituted by alanine4. This mutation results in a kinase that is unable to switch 
to its Ca2+/CaM-independent state. In the Camk2aTT305/306VA mutant, Camk2a Thr305 and 
Thr306 are substituted by non-phosphorylatable amino acids (respectively, Valine and 
Alanine) to block inhibitory autophosphorylation1. In the Camk2aT305D mutant, Thr305 is 
substituted by negative charged Aspartate. This mimics persistent Thr305 phosphorylated 
αCaMKII, which interferes with Ca2+/CaM binding, thus blocking αCaMKII activation in 
this mutant1. For a review of previous reported phenotypes see3.  
All mice were obtained by breeding heterozygous parents. Littermate control animals 
were used for every experiment except for augmentation. For augmentation we combined 
the littermate wild-type animals of the various genotypes since they were 
indistinguishable. All mutants described in this paper were homozygous for the mutation 
unless specified otherwise. To allow for direct comparison with previously published 
experiments, we made use of hybrid F2, 129SvJ-C57BL/6 animals for augmentation 
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experiments and C57BL/6 (backcrossed at least 8 times) animals for all other experiments. 
For experiments using CaMKII inhibitors we used wild-type mice in the appropriate (see 
above) background. All experiments were approved by a Dutch ethical committee (DEC) 
for animal research. 
Slice preparation and electrophysiological recordings 
Electrophysiology experiments were performed on mice between the ages of 2 and 5 
months and all experiments and analysis were performed blind to genotype. After the 
animals had been sacrificed, hippocampi were removed in ice-cold artificial cerebrospinal 
fluid (ACSF), and saggital hippocampal slices (400 µm) were prepared using a vibratome. 
Normal hippocampal slices and hippocampal minislices (from which the CA3 area was 
removed) were maintained in artificial cerebrospinal fluid (ACSF) at room temperature for 
at least 1.5 hour to recover before experiments were initiated. Then they were transferred 
to a submerged chamber field recording set-up and perfused continuously at a rate of 
2mL/minute with ACSF equilibrated with 95% O2, 5% CO2 at 30oC. ACSF contained (in 
mM) 120 NaCl, 3.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1.25 NaH2PO4, 26 NaHCO3 and 10 D-
glucose. For the low-calcium experiment (Fig. 3), the calcium concentration was reduced 
to 0.8 mM. Extracellular recording of field excitatory postsynaptic potentials (fEPSPs) were 
started 20 minutes after transfer to the recording chamber (except for the CaMKII inhibitor 
studies, see below), and made in CA1 striatum radiatum area with a Pt/Ir recording 
electrode (FHC, Bowdoinham, ME). A bipolar Pt/Ir electrode was used to stimulate 
Schaffer collateral/commissural afferents with a stimulus duration of 100μs. Stimulus 
response curves were obtained at the beginning of each experiment and these were not 
different between mutants. Subsequent stimulation was performed at 1/3 of the 
maximum response. A stable baseline was recorded before the onset of each experiment. 
Similar to the previous study7, we used a 10 theta-burst  stimulation protocol in the 
presence of D-APV (2-amino-5-phosphonovalerate, 50 μM, Tocris) to measure synaptic 
augmentation. The 10 Hz experiments were done in the presence of D-APV and picrotoxin 
(100μM, Tocris), and on mini-slices in which CA3 area was removed to prevent epileptic 
discharges. The input/output curves of Supplementary fig. 3 were obtained in the 
presence of D-APV, prior to recording augmentation.  
KN92, KN93 (10 µM) and Ant-AIP-II (4 µM) were obtained from Calbiochem. 
Experiments using CaMKII inhibitors were performed at 32oC with a perfusion rate of 5–6 
mL/minute. These slices were pre-incubated with the drug under these conditions in the 
recording chamber for at least 1 hour before the experiment was started. Control slices 
were treated in the same way, except that either no drug or KN92 was present. The 
efficacy of KN93 and AIP was tested by their ability to impair LTP induction 
(Supplementary figure 1). All LTP experiments were performed at a stimulation strength 
2/3 of maximum. 
Analysis of presynaptic vesicle distribution 
The size of the readily releasable pool (RRP) was estimated by quantitative electron 
microscopy of asymmetric synapses on dendritic spines of CA1 pyramidal neurons. We 
quantified the number of clear, round synaptic vesicles in contact and within one vesicle 
diameter from the presynaptic active zone. This morphologically defined set of vesicles is 
thought to correlate with the readily-releasable pool of quanta8-10. We used a random 
sampling method from single thin sections as described11, since we previously showed 
that data obtained with this method correlates well with an unbiased serial sectioning 
approach12. Only complete profiles of nonperforated asymmetric synapses on dendritic 
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spines within striatum radiatum of area CA1 were photographed. The parameters 
measured in each synapse were: (1) the length of the active zone; (2) presynaptic terminal 
area, (3) total number of small (~50 nm) clear and round synaptic vesicles per terminal; 
and (4) the number of docked vesicles per active zone. The docked vesicles are defined as 
those up to one-vesicle-diameter (~50 nm) distance from the active zone, according to 
criteria developed by Reese and colleagues8, because these vesicles have been shown to be 
depleted during sustained, repetitive activity. For the synaptic sizes (active zone length, 
terminal bouton area) we quantified 70 wt, 53 Camk2a–/– and 54 Camk2aT305D synapses 
(from 2 mice of every genotype). For the vesicle distribution analysis we quantified 
21/13/10 synapses respectively. This method was previously validated by comparing it to 
serial sectioning12. 
Western blot analysis 
Synaptosomes were isolated as described previously1. The concentration of the 
synaptosomes was adjusted to 1 mg/ml. Western blots were probed with antibodies 
directed against Thr286/287-α/β-CaMKII (#06-881, 1:5000; Upstate Cell Signaling 
Solutions), Anti-Phospho-Ser603 Synapsin I (p1560-603, 1:1000; PhosphoSolutions), 
Synapsin I (AB1543P, 1:10.000; Chemicon), βCaMKII (CB-β1, 1:2000; Zymed), δCaMKII (sc-
5392, 1:200; Santa Cruz), γCaMKII (sc-1541, 1:1000; Santa Cruz) Calmodulin (#465, 1:500, 
Swant) and Actin (MAB1501R, 1:2000; Chemicon). Blots were first probed with the 
antibody of interest and after stripping (Restore western blot stripping buffer; Pierce) re-
probed with the loading control antibody. Western blots were quantified using NIH-
Image. 
Data analysis and statistics 
The experimenter was blind to the genotype until the experiment and analysis were 
completed. Error bars in graph indicate the standard error of mean. Sample size numbers 
in the graphs indicate the number of slices, and this number was also used for statistical 
comparisons. ANOVA’s were used for morphological studies and for determining the 
augmentation (5 seconds after the tetanus) and for determining the depletion (at the 100th 
stimulus). Repeated measures ANOVA were used for statistical analysis of the synaptic 
transmission curves, and for the entire augmentation and 10Hz curves, followed by a post-
hoc Fisher’s PLSD analysis if necessary. 
Compromise Power Analyses was performed to determine the statistical power of the 
morphologcal studies using G*Power (Erdfelder E, et al (1996) GPOWER: A general power 
analysis program. Behavior Research Methods, Instruments, and Computers 28:1-11). This 
analysis gave values of statistical power larger than 0.95 (i.e. 95% confidence of accepting 
the null hypothesis when it is true.  
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Here we show that βCaMKII, the predominant CaMKII isoform of the cerebellum, 
plays an essential role in controlling the direction of plasticity at the parallel fiber–
Purkinje cell synapse: a protocol that induces synaptic depression in wild–type mice, 
results in synaptic potentiation in Camk2b knock–out mice, and vice versa. These 
findings provide us with unique experimental insight into the mechanisms that 
transduce graded calcium signals into either synaptic depression or potentiation. 
 
The ability to strengthen and weaken synaptic connections is essential for memory 
formation. According to the Bienenstock, Cooper, and Munro model of synaptic plasticity, 
the magnitude and direction of synaptic weight changes is not only affected by the 
temporal pattern of calcium influx, but also by the ability of the synapse to change the 
modification threshold for synaptic depression and potentiation1. However, the precise 
mechanisms by which a synapse controls the direction of synaptic weight change are still 
poorly understood. 
Calcium–calmodulin dependent kinase type II (CaMKII) plays an essential role in 
transducing neuronal calcium signals. The CaMKII holoenzyme is a heteromeric protein 
complex, composed of a cell–type dependent ratio of αCaMKII to βCaMKII isoforms. In 
the adult hippocampus and neocortex, αCaMKII is the predominant isoform2, where its 
quantity and autophosphorylation status determine the amplitude and induction 
threshold of long–term potentiation (LTP)3-5. In contrast, αCaMKII is required for long–
term depression (LTD), but not LTP, at cerebellar parallel fiber–Purkinje cell synapses6. 
Notably, although βCaMKII is the most prominent cerebellar isoform2, the function of 
βCaMKII at this synapse is unknown. In addition, although in vitro studies show that 
changes in the α– to βCaMKII ratio have opposing effects on unitary synaptic strength7, it 
is unknown to what extent changes in the subunit ratio would affect synaptic plasticity in 
vivo. 
To elucidate the role of βCaMKII in synaptic plasticity, we generated a Camk2b knock–
out mouse by inserting the neomycin resistance gene in the βCaMKII regulatory domain 
at exon 11 (Supplementary Fig. 1). In situ hybridization and semi–quantitative RT–PCR 
analysis of these mice showed loss of full–length Camk2b mRNA (Fig. 1 and 
Supplementary Fig. 2). In addition, immunostaining and Western blot analysis revealed a 
total loss of βCaMKII immunoreactivity and no presence of a truncated βCaMKII protein 
in these mutants (Fig. 1c,e). The loss of βCaMKII did not cause up–regulation of Camk2a 
mRNA or protein (Fig. 1b and Supplementary Fig. 2). Consequently, total CaMKII 
activity was significantly reduced, particularly in the cerebellum (reduction of 51% 
(P<0.0001) for Ca2+/CaM–dependent activity and 41% (P<0.005) for Ca2+/CaM–
independent activity; Supplementary Fig. 1b), altogether suggesting a successful knock–
out of the Camk2b gene. 
Even though adult Camk2b–/– mice showed no differences in survival (measured from 
weaning till 8 months of age) or general health, they showed pronounced ataxia 
(Supplementary Movie 1), and severe deficits on the accelerating rotarod test and balance 
beam test (Fig. 1g, Supplementary Fig. 3). Ataxia commonly arises from cerebellar 
dysfunction, and is often observed in mutants with immature or degenerated Purkinje 
cells. However, Thionin staining of brain slices from adult mice revealed no gross 
differences in overall brain development between wild–type mice and Camk2b–/– mutants 
at the light microscopy level (Fig. 1a). Moreover, Purkinje cells of Camk2b–/– mutants did 
not show significant changes in the complexity of dendritic branching, and the density of 
spines, nor in Purkinje cell spine maturity (spine neck length and head width), indicating 
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that the loss of βCaMKII does not affect gross brain development or the maturation of 
Purkinje cells in vivo (Fig. 1f, Supplementary Fig. 4). 
 
 
Fig. 1. Basal characterization of the 
Camk2b–/– mutant. (a) Thionin staining 
shows no apparent morphological changes in 
Camk2b–/– brains. (b) In situ analysis shows 
decreased levels of 3’ UTR Camk2b mRNA in 
Camk2b–/– mutant mice, indicating a 
successful gene disruption. (c,d) 
Immunocytochemistry using α– and 
βCaMKII–isoform specific antibodies, shows 
complete loss of βCaMKII immunoreactivity 
in Camk2b–/– brains (c) which is not 
compensated by up–regulation of αCaMKII 
immunoreactivity (d). (e) Western blot 
analysis of wild–type and mutant cortex and 
cerebellum using a N–terminal pan–CaMKII 
antibody revels no truncated βCaMKII 
product in Camk2b–/– mutants. (f) Analysis of 
Purkinje cell morphology using Golgi–Cox 
staining and diOlistic labeling (inlay), 
showed no differences in arborization and 
spine density, neck length and head width 
(see for quantification Supplementary Fig. 
4). Scale bar: 10mM. (g) Motor performance 
assessed by an accelerating rotarod. Camk2b–
/– mice (n=16) stay on the rod significantly 
shorter than wild–type littermates (n=16) 
and do not increase their performance upon 
training (effect of genotype: P<0.005; 
interaction training x genotype P<0.05; Repeated measures ANOVA). Depicted is the latency until the mice fell from 
the rod. All animal procedures were approved by a Dutch ethical committee for animal experiments (DEC). 
 
Purkinje cells are the sole output of the cerebellar cortex, and plasticity at the parallel 
fiber–Purkinje cell synapse is generally believed to mediate cerebellar motor learning. To 
investigate the role of βCaMKII in parallel fiber–Purkinje cell plasticity, we performed in 
vitro whole–cell recordings of Purkinje cells from adult wild–type and Camk2b–/– mice. The 
ability to induce LTD was tested by paired parallel fiber and climbing fiber stimulation at 
1Hz for 5 minutes8,9. This stimulation protocol indeed resulted in significant LTD in wild–
type mice (83 ± 5%; P < 0.01), but failed to induce LTD in Camk2b–/– mice. In fact, it resulted 
in significant LTP (112 ± 3%; P< 0.01) in these mutants (Fig. 2a), similar to what has been 
reported previously for Camk2a–/– mice6. These results suggest that a critical amount of 
both αCaMKII and βCaMKII is required for the induction of cerebellar LTD. 
We next tested the role of βCaMKII in cerebellar LTP, by applying the same parallel 
fiber stimulus, but now in the absence of climbing fiber stimulation10. This postsynaptic 
form of LTP requires lower calcium transients than LTD induction9,10. Using this protocol, 
we indeed obtained significant LTP in wild–type Purkinje cells (120 ± 3%; P< 0.001), but 
surprisingly Camk2b–/– Purkinje cells now showed robust LTD (84 ± 4%; P< 0.01; Fig. 2b). 
To our knowledge, this is the first report of a genetic or pharmacological manipulation 
that bidirectionally inverts the polarity of changes in synaptic strength. 
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Fig. 2 Bidirectional inversion of plasticity at the parallel fiber–Purkinje cell synapse. (a) Paired 
parallel fiber and climbing fiber stimulation yields LTD in wild–type (n=12) Purkinje cells but LTP in Camk2b–/– 
(n=11) Purkinje cells. (b) Parallel fiber stimulation only, results in LTP in wild–type (n=11) Purkinje cells but yields 
LTD in Camk2b–/– (n=13) Purkinje cells. (c) Schematic model, visualizing how changes in the CaMKII driven 
depression pathway (top) can result in the different plasticity curves as observed in wild–type, Camk2a–/–and Camk2b–/– 
mice (bottom). The model illustrates that a reduced strength of the kinase driven depression pathway (‘down–shift’), 
combined with a reduced threshold for calcium activation (‘left–shift’) results in an inversion of the plasticity curve in 
Camk2b–/– mice. (d) LTD is rescued in Camk2b–/–slices in the presence of PP2B inhibitor Cyclosporin A (wild–type: 
n=6; Camk2b–/–: n=13). (e) LTP is rescued in Camk2b–/–slices using the CaMKII inhibitor KN93 (wild–type: n=12; 
Camk2b–/–: n=7). Insets show representative traces before (grey line) and after (black line) tetanization (scale bars 
100pA/10ms). Error bars represent SEM. Asterisks with brackets indicate statistical significance between wild–type 
and mutant slices (Student’s t–test over last 5 min). Asterisks without brackets indicate significant difference from 
baseline (paired t–test). *P<0.05; **P<0.01; ***P<0.005.  
 
Even though the plasticity induced by the protocols described above is known to be 
expressed postsynaptically9-12, the observed changes in synaptic plasticity could 
potentially result from additional presynaptic changes. However, Camk2b–/– mutants 
showed no difference in basal excitatory synaptic transmission and Purkinje cells were 
innervated by a single climbing fiber (Supplementary Fig. 5, 6), suggesting that the 
bidirectional inversion of parallel fiber–Purkinje cell plasticity is indeed caused by changes 
in postsynaptic plasticity.  
To better understand how the loss of βCaMKII can result in a bidirectional inversion 
of plasticity at the parallel fiber–Purkinje cell synapse, we propose the following plasticity 
rules that collectively provide a model which fully accounts for the observed data: First, 
the synaptic depression and potentiation pathways are independent competing processes 
driven by kinases and phosphatases, respectively9,10,12, each regulated by a distinct 
sensitivity for calcium. LTP is generated when phosphatase activity outweighs kinase 
activity, and LTD is generated when kinase activity outweighs phosphatase activity 
(schematically depicted in Fig. 2c, Supplementary Fig. 7). Second, since LTP induction is 
not affected by deleting the Camk2a gene6, nor by inhibition of CaMKII kinase activity11, 
we assume that αCaMKII and βCaMKII activity is contributing to the synaptic depression 
pathway only (Fig. 2c, Supplementary Fig. 7). Hence, loss of either αCaMKII or βCaMKII 
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selectively decreases the depression driving force, and patterns of stimulation that 
normally produce LTD, will therefore yield LTP in the Camk2a–/– mutant6 or Camk2b–/– 
mutant (Fig. 2a). Consequently, we predicted that blocking the opposing potentiation 
pathway, by inhibiting calcium sensitive phosphatase PP2B (calcineurin) activity12, should 
restore LTD induction in the Camk2b–/– mutant. Indeed, the presence of cyclosporin A 
during LTD induction, yielded a significant induction of LTD in the Camk2b–/– mutant (Fig. 
2d). This indicates that the PP2B–driven synaptic potentiation pathway is in direct 
competition with the CaMKII–driven synaptic depression pathway, and that loss of 
βCaMKII activity can be compensated by inactivating PP2B activity.  
Although the aforementioned plasticity rules readily explain the shift from LTD to 
LTP as seen in the Camk2a–/–6 and Camk2b–/– mutants, they are not sufficient to explain why 
an LTP inducing protocol results in LTD in Camk2b–/– mutants. An inversion of the 
plasticity curve as observed in the Camk2b–/– mutant, can be achieved only if the 
depression driving force in Camk2b–/– mutants is shifted to the left (indicated in Fig. 2c), 
reflecting a lower threshold for activation of this pathway. As αCaMKII is a major driver 
of the depression pathway6, this model would predict that activation of αCaMKII is 
facilitated in the Camk2b–/– mutant, leading to precocious induction of the LTD pathway 
under low calcium conditions. If this is true, the presence of a CaMKII inhibitor under LTP 
inducing conditions should rescue the LTP deficits in the Camk2b–/– mutant (Fig. 2c, 
Supplementary Fig. 7). This was indeed the case: addition of the CaMKII inhibitor KN93 
restored LTP in Camk2b–/–slices to wild–type levels (Fig. 2e). These results confirm that the 
induction of the LTD pathway under low calcium conditions in the Camk2b–/– mutant is 
indeed caused by the inadvertent activation of αCaMKII. 
 What could be the cause of the reduced threshold of αCaMKII activation in Camk2b–/– 
mutants? Notably, the reduced threshold for αCaMKII activation is not caused by 
increased expression of αCaMKII (Fig. 1, Supplementary Fig. 8). In addition, there is not a 
strong increase in basal levels of autonomously activated αCaMKII, as the reduction of 
calcium–dependent activity was not significantly different from the reduction of calcium–
independent activity (P=0.5), and no increase in T286P–αCaMKII was observed 
(Supplementary Fig. 1, 8). Moreover, the competitive CaMKII inhibitor KN93, which 
rescued the LTP deficit, can not inhibit αCaMKII if it is already in the autonomously active 
state, arguing strongly against high basal levels of autonomously active αCaMKII in 
Camk2b–/– mutants.  
A more likely explanation comes from the biochemical differences between αCaMKII 
and βCaMKII. βCaMKII contains an additional domain which enables βCaMKII to cluster 
the entire CaMKII holoenzyme to F–actin13-15. Since all cerebellar αCaMKII is associated 
with βCaMKII in wild–type mice (Supplementary Fig. 8), the loss of βCaMKII will cause a 
loss of αCaMKII clustering to F–actin, potentially increasing the availability of CaMKII 
holoenzymes13,15. In addition, elegant in vitro experiments showed that translocation to the 
PSD is 4 times shorter for αCaMKII homo–oligomers as compared to mixed 
αCaMKII/βCaMKII hetero–oligomers, and even 24 times shorter as compared to βCaMKII 
homo–oligomers15. Such a substantial reduction in the translocation rate of CaMKII 
holoenzymes could well explain the reduced threshold for CaMKII activation in the 
Camk2b–/– mutants. 
Taken together, we show that Camk2b is not an essential gene for overall brain 
development or Purkinje cell maturation, but rather plays an essential role in motor 
coordination and cerebellar plasticity. Although we cannot rule out that these defects are 
potentially caused by developmental changes, the observation that we can rescue both the 
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LTD and LTP deficits by pharmacology suggests a direct role of βCaMKII in regulating 
bidirectional synaptic plasticity at the parallel fiber–Purkinje cell synapse. Specifically, we 
show that parallel fiber–Purkinje cell plasticity is regulated by a balanced and integrated 
coordination of kinase and phosphatase activity, and that βCaMKII modulates the polarity 
of synaptic plasticity in two functionally distinct ways: Like αCaMKII6, βCaMKII activity 
is required for driving the synaptic depression pathway under high calcium conditions. 
However under low calcium conditions, βCaMKII prevents activation of this pathway. 
Overall, these findings provide us with a unique insight in the molecular mechanisms 
governing the rules for bidirectional synaptic plasticity. 
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Supplementary figures and legends  
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig 1. Generation of the Camk2b–/– mutant mice. (a) Strategy to generate the Camk2b–/– 
mutant mice. (Top) Wild-type Camk2b locus with the location of exons 6-12 depicted as black boxes. (Middle) 
Targeting construct used for generation of Camk2b–/– mutant mice with the gene encoding the Diphteria Toxin A chain 
(DTA) outside the homologous recombination sites and the Neomycin resistance gene (NEO) inserted in exon 11. 
Shown are the restriction sites used for insertion of the NEO gene and the NsiI site used to linearize the targeting 
construct. (Bottom) Mutant Camk2b locus after homologous recombination. (b) Ca2+-dependent and Ca2+-independent 
CaMKII activity are significantly (P<0.0001;P<0.005 respectively) reduced in the cerebellum of Camk2b–/– mutant 
mice (n=5) as compared to wild-type mice (n=5).  
 
 
Supplementary Fig. 2. In 
situ hybridization and 
RT-PCR analysis of 
Camk2b and Camk2a 
mRNA in mutant and 
wild-type mice. (a-i) In 
situ hybridization of Camk2a 
and Camk2b mRNA in wild-
type (left panels), Camkb–/– 
(middle panels), and 
Camk2a–/– mice (right 
panels). Thionin staining 
(blue stained slices) was 
performed after the in situ 
hybridization to investigate 
brain morphology. (a-f) In 
situ hybridization shows that 
Camk2b mRNA is highly abundant in cerebellum, cortex, hippocampus and striatum of wild-type mice. Camk2b–/– 
mutant mice show decreased levels of 3’ UTR Camk2b mRNA (b) but normal levels of 5’ UTR Camk2b mRNA in 
Camk2b–/– mice (e), suggesting a successful truncation of the gene. (g-i) Camk2a mRNA level is not affected in 
Camk2b–/– mutant mice. (j-l) semi-quantitative RT-PCR analysis shows normal Camk2a mRNA levels but strongly 
reduced 3’ (exon 14-17) Camk2b mRNA levels in the cerebellum of Camk2b–/– mutant mice. PCR primers were directed 
against exon 2-4 (j) and exon 14-17 (k) of the Camk2b (which are up- or downstream of the inserted NEO gene, 
respectively) and directed against exon 2-5 for the Camk2a gene (i). As a quantitative control, primers against 
Synapsin I mRNA were included. The ‘Cx’ lane is a RT-PCR on the same amount of mRNA (0.3 µg) derived from 
wild-type cortical tissue. To assure that the PCR conditions were in the linear range, a serial dilution was performed on 
all samples (not shown). 
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Supplementary Fig. 3. Assessment of general locomotion deficits of Camk2b–/– mutant mice. (a) 
Camk2b–/– mutants (front) are viable and healthy. The mouse in the back is a littermate wild-type mouse (age 4 
months). But despite their healthy appearance, Camk2b–/– mutants show signs of cerebellar ataxia. (b) Balance beam 
test. Indicated is the number of mice that were able to stay on a 1.5 cm thick square beam. All wild-type mice (n=16) 
were able to stay on the beam for 60 sec, whereas only 9/16 of the Camk2b–/– mutant mice could stay on the beam for one 
minute (P<0.01, paired t-test). Error bars are standard errors of mean taken from binomial distribution. (c,d) The 
balance beam and rotarod deficits are not caused by a lack of desire to move, as Camk2b–/– mice move a similar distance 
as wild-type mice in the open-field (b) (n= 5/5; P=0.6) and in an home cage-like environment (Phenotyper, Noldus 
Information Technology, The Netherlands) (c) (n=12/12; P=0.7 during dark phase, P=0.6 during light phase). Error 
bars represent standard error of the mean. 
 
 
 
 
 
 
 
Supplementary Fig. 4. Assessment of cerebellar Purkinje cell morphology in Camk2b–/– mutant 
mice. Quantification of the arborization (a) and number of spines (b) of Golgi-Cox stained Purkinje cells showed no 
significant differences between wild-type mice and mutants (P=0.4 and P=0.2, respectively). Arborization was 
determined by counting the number of tips per Purkinje cell and the number of spines per 10 mm dendrite. 
Quantification of the neck length (c) and head width (d) of Purkinje cell spines using diOlistic labeling also showed no 
significant differences (P=0.5 and P=0.3, respectively). Number of mice used: WT (3); Camk2b–/– (3). Error bars 
represent standard error of the mean. 
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Supplementary Fig. 5. Parallel fiber-Purkinje cell transmission and basal properties of Purkinje 
cells are not significantly different in Camk2b–/– mutant mice. (a) Camk2b–/– Purkinje cells show a normal 
EPSC amplitude (P=0.9; n=11 WT, n=9 Camk2b–/– mutants). (b), Camk2b–/– Purkinje cells show normal paired pulse 
facilitation (50 ms inter-stimulus interval) (P=0.3; n=13 WT, n=13 Camk2b–/– mutants). (c) Camk2b–/– Purkinje cells 
show normal tdecay (single-exponential fit) of the EPSC (P=0.3; n=13 WT, n=10 Camk2b–/– mutants). (d) Camk2b–/– 
Purkinje cells show normal average input resistance (calculated by a 10mV hyperpolarizing voltage step; see 
supplementary methods) (P=0.4; n=9 WT, n=7 Camk2b–/– mutants). Error bars represent standard error of the mean. 
 
 
 
Supplementary Fig. 6. Climbing fiber-
Purkinje cell synaptic transmission is 
normal in Camk2b–/– mutant mice. (a) 
Average trace of six double CF-EPSCs for wild-
type (upper) and Camk2b–/– (lower) cells. 
Horizontal scale bar indicates 20 ms; vertical 
indicates 1 nA. (b) All recorded Purkinje cells of 
both wild type (n=10) and Camk2b–/– (n=13) 
mice showed absence of multiple climbing fiber 
innervation. Shown is the percentage of Purkinje 
cells with mono-climbing fiber innervation. (c) 
Camk2b–/– Purkinje cells show normal CF-EPSC 
amplitudes (P=0.6; n=10 WT, n=13 Camk2b–/–). 
(d) Camk2b–/– Purkinje cells show normal paired-
pulse depression of the CF-EPSCs at an inter-
stimulus interval of 50 ms (P=0.2; n=10 WT, 
n=13 Camk2b–/–). (e) Camk2b–/– Purkinje cells 
show normal 10-90% rise times of the first CF-
EPSC (P=1.0; n=10 WT, n=13 Camk2b–/–). (f) 
Camk2b–/– Purkinje cells show normal tdecay 
(single-exponential fit) of the first CF-EPSC 
(P=0.2; n=10 WT, n=13 Camk2b–/–). (g) Average 
trace of 20 CF-EPSPs for wild type (upper) and 
Camk2b–/– (lower). Horizontal scale bar indicates 
20 ms; vertical indicates 20 mV. (h) Camk2b–/– 
Purkinje cells show normal amplitudes of Na+-
spikes in CF-EPSPs (P=0.7; n=7/7). (i) Camk2b–/– Purkinje cells show normal amplitudes of the first Ca2+-spikelet in 
CF-EPSPs (P=0.3; n= 7/7). Error bars represent standard error of the mean. 
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Supplementary Fig. 7. Role of CaMKII and PP2B in parallel fiber-Purkinje cell plasticity. Simplified 
model depicting the role of αCaMKII, βCaMKII and phosphatase PP2B in LTP and LTD at the parallel fiber-Purkinje 
cell synapse. In wild-type Purkinje cells high calcium influx (top) activates the phosphatase PP2B driven synaptic 
potentiation pathway but also results in maximal induction of the CaMKII driven synaptic depression pathway, which 
effectively out-competes PP2B, leading to a net LTD. In contrast, in the absence of βCaMKII the synaptic depression 
pathway (which requires αCaMKII and βCaMKII activity) is no longer able to out-compete PP2B, resulting in net 
LTP. Low calcium influx (bottom) only moderately activates PP2B, but as there is no or insignificant activation of 
CaMKII, the net result is LTP. In Camk2b–/– Purkinje cells, low calcium influx results in precocious activation of 
αCaMKII, which is sufficient to out-compete PP2B, resulting in net LTD. 
 
 
 
Supplementary Fig. 8. Neither αCaMKII protein level nor its autophosphoryation is increased in 
Camk2b–/– mutants. (a) Expression of αCaMKII protein is not increased in the cerebellum. If anything, there is a 
slight reduction at the protein level. Shown are Western blots of cerebellar lysates of 2 wild-type mice and 2 mutants; 
with 5mg and 10 mg loaded of each sample. Blots were probed with a specific αCaMKII (Chemicon; clone 6G9) or 
βCaMKII (Zymed; clone CB-b1) antibody. (b) The amount of Ph-T286-αCaMKII is not changed in the hippocampus of 
Camk2b–/– mutants. Ph-T286-αCaMKII could not be detected in the cerebellum, which is likely due to the 60-fold lower 
concentration of αCaMKII in cerebellar lysates (not shown). (c) Immunoprecipitation using a βCaMKII-specific 
antibody, reveals that all αCaMKII is asscoiated with βCaMKII in the cerebellum of wild-type mice. IP: 
immunoprecipitated fraction; Sup: supernatant fraction after immunoprecipitation.  
 
 
 
 67 
Supplementary Materials and Methods  
 
Generation of Camk2b mutant mice 
The Camk2b knock-out targeting construct was generated as follows. The Camk2b genomic 
sequence (ENSMUSG00000057897) was obtained from a public database (Ensembl) and 
used to design the primers for the targeting constructs. PCR fragments encompassing exon 
6-11 (5.3 Kb; exon denotation according to ENSMUST00000019133) using:  
5’ primer: 5’-GGTACCTGAGGAAGGTGCCAGCTCTGTCCC-3’ and  
3’ primer: 5’–TTATCGATTCTCCTGTCTGTGCATCATAGAGG-3’  
and exon 11-13 (6 Kb) using:  
5’ primer: 5’-GCGGCCGCCTGTTAAAGGAATGGTTCTC-3’ and  
3’ primer: 5’-ATGCATCTAAAAGGCAGGCAGGATGATCTGC-3’ were amplified using 
High Fidelity Taq Polymerase (Roche) on ES cell genomic DNA and cloned on either site 
of a PGK-Neomycin selection cassette. All exons were sequenced to verify that no 
mutations were introduced accidentally. For counter selection, a gene encoding Diphtheria 
toxin chain A (DTA) was inserted at the 5’ of the targeting construct. The targeting 
construct was linearized and electroporated into E14 ES cells (derived from 129P2 mice). 
Cells were cultured in BRL cell conditioned medium in the presence of Leukemia 
inhibitory factor (LIF). After selection with G418 (200 µg/ml), targeted clones were 
identified by PCR (long-range PCR from Neomycin resistance gene to the region flanking 
the targeted sequence). A clone with normal karyotype was injected into blastocysts of 
C57Bl/6 mice. Male chimeras were crossed with female C57Bl/6 mice (Harlan). The 
resulting F1 heterozygous mice (in the 129P2-C57Bl/6 background) were used to generate 
F2 homozygous mutants and wild-type littermate controls. These mice were used for all 
the behavioral and electrophysiological experiments. The experimenter was blind for the 
genotype, but homozygous mice were easily recognizable by the ataxic gait. Therefore, 
data was also analyzed by a second person blind to the genotype. Mice were housed on a 
12 hours light/dark cycle with food and water available ad libitum and used between 2 
and 6 months of age for all experiments described (including electrophysiology). All 
animal procedures were approved by a Dutch Ethical Committee (DEC) for animal 
experiments.  
 
Molecular analysis of mutants 
In situ hybridization. Whole brains were quickly isolated and frozen on dry ice. Sagittal 
slices (14µm) were cut using Cryostat (Jung CM 300, Leica. Instruments, Nussloch, 
Germany) and thaw-mounted on slides (Superfrost®Plus, Menzel-Glaser, Germany). In 
situ hybridization was performed as described previously 1. Probes used were antisense to 
the 5’ UTR of Camk2b: 
5’-GGCCATGGCGGTGGCGATCGGGCTCGGCGTGCGCTCGGC-3’,  
antisense to the 3’UTR of Camk2b: 
5’-GGTACCTACAGACTAACACGGTCGGCATGGGCACATTCACG-3’ and antisense to 
exon 2 of Camk2a: 
5’-GCTGCATACTCATGGCCGGTACAGAGCTTGACACAGCGTCGGAC-3’. Afterwards 
slices were stained with thionin.  
RT-PCR. RNA was isolated from cerebellum and cortex, by homogenization in TRIzol® 
Reagent (Invitrogen). A semi-quantitative RT-PCR (verified by serial dilutions) was 
performed using SuperscriptTMIII Reverse transcriptase (Invitrogen) and RNAsin 
(Promega). Expression of the Camk2b mRNA in the heterozygous and homozygous 
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Camk2b mutant mice, was analyzed separately up- and downstream of the Neomycin 
cassette by detection of exon 2-4 of Camk2b, using 5’ primer 5’-
CGACGCTGTGTCAAGCTCTGTAC-3’ and 3’ primer: 5’-GAAGCCCTCTTCAGAGATGC-
3’ and detection of exon 14-17 of Camk2b, using 5’ primer: 5’-
GAAAGCAGATGGAGTCAAG-3’ and 3’ primer: 5’-GTTGTGTTGGTGCTGTCG-3’. The 
expression of Camk2a mRNA was analyzed by detection of exon 2-5 of Camk2a, using 5’ 
primer: 5’-GCGCAGGTGTGTGAAGGTGC-3’ and 3’ primer: 5’-
CACAATGTCTTCAAACAGTTCC-3’. A control PCR was performed with pimers against 
exon 5-8 of Synapsin I using 5’ primer: 5’-TGCCCAGATGGTTCGACTAC-3’ and 3’ 
primer: 5’-TGTCAGACATGGCAATCTGC-3’. 
Western blot and immunoprecipitations. Lysates for westernblot were prepared by quick 
dissection of the brain and by homogenization of the brain tissue in lysis buffer (10mM 
TRIS-HCl 6.8, 2.5% SDS, 2mM EDTA) and protease and phosphatase inhibitor cocktails 
(Sigma). The concentration of the lysates was adjusted to 1 mg/ml. 10 µg was used for 
Western blot analysis, unless otherwise specified. Western blots in Fig. 1 were probed with 
antibodies directed against the N-terminal CaMKII (H-300, 1:500; Santa-Cruz). 
Westernblots shown in Supplementary Fig. 8 were probed with αCaMKII (clone 6G9; 
1:1000; Chemicon), βCaMKII (clone CB-b1; 1:10000; Zymed), Ph-T286/T87 CaMKII 
antibody (1:5000; #06-881, Upstate Cell Signaling Solutions) or actin (clone C4; 1:10.000; 
Chemicon). Bands were visualized using Enhanced Chemo Luminescence (Pierce). For 
immunoprecipitations P2 synaptosomes were solubilized in a final buffer containing 
25mM Hepes, 150mM NaCl, 1%. Triton and diluted to a final concentration to 2.5 mg/ml 
protein. For the immunoprecipitation we used 1 ml of homogenate (2.5 mg) and added 10 
mg βCaMKII antibody (Zymed, clone CB-b1). 
Kinase activity. Ca2+-dependent and Ca2+-independent activity were determined in fresh 
cerebellar lysates, using Autocamtide 2 as a substrate (CaMKII assay kit from Upstate cell 
signaling solutions, Boiling Springs, USA). Each assay was tested for linearity (serial 
dilution of lysates), and data was normalized to a wild-type (Ca2+-dependent) control, 
which was present at each run. 
Immunocytochemistry. Brains from adult mice were fixed with 4% paraformaldehyde by 
transcardial perfusion. Immunocytochemistry was performed on free-floating 40µm thick 
frozen sections employing a standard avidin-biotin-immunoperoxidase complex method 
(ABC, Vector Laboratories, USA) with βCaMKII (Zymed), αCaMKII (Chemicon) or 
Calbindin (Sigma) as the primary antibody and diaminobenzidine (0.05%) as the 
chromogen 2. 
 
Morphological analysis: For dendritic arborization measurements we used Golgi-Cox 
staining on unfixed cerebelli using the FD Rapid GolgiStain Kit (FD NeuroTechnologies 
Inc., USA), according to the manufacturers’ instructions. Sagittal sections, 100 µm thick, 
were cut on a microtome with cryostat adaptations. Purkinje cell counting and selection 
for further detailed analysis was done by an observer who was blind to the genotype. The 
tips of the outer branches were manually counted using a 40X objective and were used as 
a measure for dendritic branching. A calibration grid was used to count the number of 
spines per 10 µm, using a 100X objective. For the spine analysis, brains from adult mice 
were fixed with 4% paraformaldehyde by transcardial perfusion. To examine dendritic 
spine number and morphology, 200 micrometer cerebellar sections were subjected to 
‘diOlistic’ labeling 3. Tungsten particles (1.7 micrometer; Bio-Rad, Hercules, CA) coated 
with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate crystals (DiI; 
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Invitrogen, Eugene, OR) were propelled into fixed tissue with biolistic Helios gene gun 
(Bio-Rad) through a membrane filter with a 3 µm pore size (Falcon 3092; BD Biosciences, 
Franklin Lakes, NJ). Sections were postfixed in 4% paraformaldehyde overnight and then 
mounted for confocal microscopy. A Zeis LSM510 confocal microscope, with a Zeiss 63x 
objective was used to obtain an image series of sections at 0.5 µm intervals. All imaging 
and analysis was performed in blinded manner. For quantification n=6 cells per genotype 
were identified (number of mice: WT (3); Camk2b–/– (3)), and protrusions were measured as 
described previously 4. Morphometric analysis and quantification were performed using 
MetaMorph software (Universal Imaging Corporation, West Chester, PA) by investigators 
who were blind to genotype and experimental manipulation. 
 
Behavioral analysis 
Balance beam. Mice were placed on a 1.5 cm wide square beam, which was elevated 30 cm, 
and were allowed to stay on the beam for a maximum of 60 seconds.  
Accelerating Rotarod. Motor coordination on the accelerating (4–40 rpm, in 5 minutes) 
rotarod (model 7650, Ugo Basile Biological Research Apparatus, Varese, Italy) was 
measured in 5 trials with 1 hour inter trial interval. The indicated time is the time spent on 
the rotarod, or time until the mouse made 3 consecutive rotations on the rotarod. 
Open field. Mice we placed in a dimly–lit open field (120 cm diameter), and the total 
distance moved was recorded for 5 minutes (SMART software, Panlab, Barcelona, Spain). 
Phenotyper. Mice were placed in the Phenotyper (Noldus Information Technology, 
Wageningen, The Netherlands) for 24 hours, and the total distance moved was 
determined. The phenotyper is a home-cage like environment, with a camera in the top-
lid. 
 
Electrophysiology 
Sagittal slices of the cerebellar vermis (200-250 µm) of 16-22 week old mice, were made 
using a Vibratome (Leica VT1000S, Leica, Nussloch, Germany) and afterwards kept for >2 
hours in ACSF (containing (in mM): 124 NaCl, 5 KCl, 1.25 Na2HPO4, 2 MgSO4, 2 CaCl2, 26 
NaHCO3, and 10 D-glucose aerated with 95% O2 and 5% CO2) before the recordings 
started. All drugs were purchased from Sigma. Experiments were performed at room 
temperature and in the presence of bath-applied 100 mM picrotoxin (Sigma) to block 
GABAA-receptors. KN-93 (1 µM) and Cyclosporin A (5 µM dissolved in 0.5% EtOH) were 
added where indicated to block kinase and phosphatase activity respectively5. Purkinje 
cells were visualized using an upright microscope (Axioskop 2 FS plus, Carl Zeiss, Jena, 
Germany) equipped with a 40X water immersed objective. Whole-cell patch-clamp 
recordings were performed using an EPC-10 amplifier (HEKA Electronics, Lambrecht, 
Germany). For long-term plasticity recordings, electrodes were filled with a solution 
containing (in mM): 9 KCl, 10 KOH, 120 K-gluconate, 3.48 MgCl2, 10 HEPES, 4 NaCl, 4 
Na2ATP, 0.4 Na3GTP and 17.5 sucrose (pH 7.25, osmolarity ~290 osm). Currents were 
filtered at 3 kHz and digitized at 8 kHz. For extracellular stimulation, glass pipettes were 
filled with external saline. Long-term plasticity at the parallel fiber – Purkinje cell synapse 
was assessed by either pairing parallel fiber and climbing fiber stimulation at 1 Hz for 5 
minutes (PF-LTD protocol) or by parallel fiber stimulation alone at 1 Hz for 5 minutes (PF-
LTP protocol). Test responses were evoked at a frequency of 0.05 Hz (2 stimuli; 50 ms inter 
stimulus interval) with ~0.5-6 µA pulses that were applied for 500 (LTP) or 700 µs (LTD). 
Holding potentials in the range of -60 to -75 mV were chosen to prevent spontaneous spike 
activity. In all experiments, cells were switched to current-clamp mode for tetanization. 
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Recordings were excluded if RS or RI varied by >15% over the course of the experiment. 
Paired-pulse facilitation was tested using double test pulses with 50 ms inter stimulus 
interval. EPSC kinetics were recorded using Cs2+-based intracellular recordings 
(containing (in mM) 115 CsMeSO4, 20 TEA-Cl, 10 HEPES, 2.5 MgCl2, 4 Na2ATP, 0.4 
Na3GTP, 10 Na2-Phosphocreatine, 0.6 EGTA, pH 7.25-7.30, osmolarity ~290 osm) while 50-
80% online RS-compensation (residual RS < 10 MΩ) was applied. For climbing fiber-
mediated EPSC recordings Purkinje cells were held at -10mV and 5 mM QX-314 were 
added to the internal medium to prevent spiking activity. During these recordings we 
checked for multiple climbing fiber innervation by gradually increasing the stimulus 
intensity7.  
 
Statistical analysis 
Statistical analysis was performed using StatView (SAS institute, USA). For behavioral 
analysis (more than one measurement per group) we used a repeated measurements 
ANOVA, followed by a post hoc Fisher’s PLSD analysis whenever it was appropriate. For 
comparison of two groups (one measurement each) we used a Student’s t-test. Differences 
in LTD/LTP between wild-type mice and mutants were assessed by running a two-
sample Student’s t-test on the average values of the 5 last minutes of the recording (as 
indicated in the graphs). To assess whether significant LTP/LTD was obtained within a 
group, we used a paired t-test, in which we compared for each animal the average 
baseline value with the average value of the last 5 minutes of the recording (as indicated in 
the graphs). For climbing fiber-mediated EPSC analysis we averaged 6 responses per cell 
and used a single-exponential fit to calculate the decay time constant, 10-90% rise time and 
amplitude. Twenty climbing fiber-mediated EPSCs were averaged to calculate the 
absolute amplitude of the Na+-spike and the first Ca2+-spikelet.  
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CaMKII plays an essential role in hippocampal synaptic plasticity, learning and 
memory. However, most research has focused on αCaMKII and little is known about 
the role of βCaMKII. Using two different Camk2b mouse mutants we assessed the role 
of βCaMKII in learning and hippocampal plasticity. We found that a Camk2bA303R 
mutant, in which the Ca2+/calmodulin binding domain of βCaMKII was mutated to 
prevent its activation, showed no deficits in hippocampal long-term potentiation (LTP) 
or contextual fear conditioning. In contrast, the absence of βCaMKII caused marked 
impairments in both hippocampal plasticity and learning.  Taken together these results 
strongly suggest that βCaMKII plays an essential role in hippocampal learning and 
LTP, but that this role is independent of its ability to be activated. Hence, our data 
provides compelling support for a model in which βCaMKII plays a non-enzymatic, 
structural role in hippocampal function.  
 
Introduction 
Calcium/calmodulin-dependent kinase type II (CaMKII) is one of the most abundant 
proteins of the hippocampus, and its role in hippocampal plasticity and learning has been 
thoroughly investigated by pharmacological and genetic approaches. The hippocampus 
expresses two major isoforms of CaMKII: (alpha (α) and beta (β) CaMKII) which are 
encoded by two distinct genes (CaMK2a and CaMK2b, respectively)1. Because αCaMKII 
and βCaMKII are highly homologous they cannot be distinguished using a 
pharmacological approach. Since almost all genetic approaches have focused on αCaMKII 
(see reviews2-5), little is known about the role of βCaMKII. However, recent studies 
showed that βCaMKII is essential for cerebellar plasticity and learning, and inducible up-
regulation of βCaMKII activity in the dentate gyrus interferes with memory 
consolidation6, 7.  
Interestingly, there are several indications that the role of βCaMKII may to some 
extent be independent of its activity. For instance, whereas βCaMKII activity is required 
for parallel fiber-Purkinje cell LTD induction after high-calcium influx, βCaMKII plays a 
non-enzymatic role under low-calcium conditions, where it functions to prevent 
precocious activation of αCaMKII6.  
It is likely that such a non-enzymatic function relies on the extra domain that is 
present in the variable region of βCaMKII only8-11. In vitro studies showed that this 
domain enables the βCaMKII subunits to cluster the entire CaMKII holoenzyme to F-actin 
in an activity-controlled manner10, 11 12, 13. In addition, these studies showed that βCaMKII 
requires this F-actin binding domain to control dendritic arborization in vitro, and that a 
βCaMKII-A303R mutant which cannot be activated by Ca2+/Calmodulin and therefore can 
not be released from the F-actin can still exert this effect. Mainly due to these different 
actin-binding properties, αCaMKII and βCaMKII have opposing effects on synaptic 
strength in cultured neurons14. Additional evidence that the actin binding domain in the 
variable region of βCaMKII probably plays a critical role in synaptic function comes from 
the observation that exons in this domain are controlled at the transcriptional level by 
alternative splicing1, 15. Indeed, the presence of just one single exon in the variable region 
determines the interaction with F-actin15.  
 To investigate the role of βCaMKII in hippocampal plasticity and learning, and to test 
to what extend its function relies on its enzymatic or non-enzymatic (F-actin binding) 
properties, we generated a Camk2b–/– (knockout) mouse and a Camk2bA303R mutant in 
which the Ca2+/calmodulin binding site (Ala303) is mutated. This mutated βCaMKII 
protein is still able to bind to F-actin, but it cannot be activated by Ca2+/calmodulin12, 16. 
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We show that these Camk2bA303R mice show normal hippocampal plasticity and learning. 
In contrast, Camk2b–/– mice show impaired hippocampal plasticity and learning. Together 
these results indeed show that βCaMKII plays a non-enzymatic role in hippocampal 
plasticity and learning.  
 
Results 
Generation and molecular characterization of the Camk2bA303R and Camk2b–/– mice 
To dissect the precise mechanism by which βCaMKII regulates hippocampal synaptic 
plasticity, we used the Camk2b–/– mutant6 and we created a knock-in mutant of the Camk2b 
gene, in which we substituted Alanine303 for an Arginine (A303R) (Fig. 1). This amino acid 
is located in the Ca2+/calmodulin binding domain and mutating it into an Arginine has 
been shown to block binding of Ca2+/calmodulin, thereby preventing kinase activation of 
βCaMKII11, 12, 15. Importantly, this mutation does not affect its binding to F-actin11, 12, 15.  
 
Figure 1. Generation of Camk2bA303R mice. (a) 
Schematic diagram for the generation of the Camk2bA303R 
mutants. (Genome) wild-type Camk2b locus with the 
exons around Ala303 depicted as black boxes. 
(Construct) Targeting construct used for introducing the 
mutation in Ala303. The asterisk in exon 12 indicates 
the mutation at Ala303. The LoxP sites flanking the 
neomycin gene are depicted as triangles. The Diphtheria 
Toxin cassette (DTA) was cloned in the construct for 
positive selection. (Recombined) Mutant Camk2bA303R 
locus after homologous recombination in ES cells. 
(Floxed) Mutant Camk2bA303R locus after Cre 
recombination. (b) Camk2b sequence of the exon 
encoding Ala303. (Upper) Wild-type DNA indicating 
the location of Ala303 in bold. (Bottom) DNA of the 
A303R mutant. The basepares and aminoacids which are 
mutated are shown in bold-italics. Note the presence of 
the EcoRI restriction site after introducing the mutation. 
 
Immunostaining and Western blot analysis 
of brains of Camk2b–/– mutants confirmed 
the absence of βCaMKII in the 
hippocampus of the Camk2b-/- mouse (Fig. 
2a,b). Since in vitro experiments showed 
that up-regulation of βCaMKII causes 
down-regulation of αCaMKII14, we tested whether the absence of βCaMKII caused up-
regulation of αCaMKII in vivo. However we did not observe up-regulation of αCaMKII 
protein levels (Fig. 2b) although there is a slight reduction in Thr286 phosphorylation of 
αCaMKII (Fig. 2b). 
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Figure 2. Molecular analysis of the Camk2b–/– 
mice. (a) Immunocytochemistry using an antibody specific 
for βCaMKII showed complete absence of βCaMKII in the 
hippocampus. (b) Western blot analysis using antibodies 
specific for αCaMKII and βCaMKII showed complete 
absence of βCaMKII in the hippocampus, without any 
change in the levels of αCaMKII. Furthermore, western blot 
analysis using an antibody specific for detecting the 
phosphorylation levels of αCaMKII-T286 and βCaMKII-
T287 revealed a slight reduction of T286 phosphorylation, 
whereas the T287 phosphorylation is completely absent.  
 
Immunostaining and Western blot analysis of brains of homozygous pointmutants 
(designated Camk2bA303R mice) revealed no change in expression of βCaMKII and αCaMKII 
(Fig. 3a,b) in the Camk2bA303R mouse indicating that the mutation does not affect 
expression levels of βCaMKII and αCaMKII. Since binding of Ca2+/calmodulin is a 
prerequisite for auto-phosphorylation of CaMKII at Thr286/287 as reviewed by5, 17, 18 we 
used the Phospho-Thr286/287 antibody to confirm that this mutation renders the 
βCaMKIIA303R protein insensitive to Ca2+/calmodulin activation. Indeed Western blot 
analysis showed that βCaMKII- Thr287 was entirely absent in the Camk2bA303R mouse (Fig. 
3b), confirming in vitro studies that the A303R mutation blocks activation of βCaMKII12, 15. 
We also observed a slight reduction of αCaMKII Thr286 autophosphorylation in this 
mutant (Fig. 3b), which is not unexpected given that most of the αCaMKII subunits are 
associated with βCaMKII subunits, and that it takes two adjacent activated CaMKII 
subunits to get intersubunit autophosphorylation at Thr286/2875, 17, 18. These data show 
that in Camk2b-/- mice βCaMKII is absent and protein expression of αCaMKII is unaltered, 
whereas in Camk2bA303R mice, we show that the A303R mutation was successful, 
preventing activation of βCaMKII without affecting the levels of expression of both 
βCaMKII and αCaMKII.  
 
Figure 3. Molecular analysis of the Camk2bA303R 
mice. (a) Immunocytochemistry staining using an antibody 
specific for βCaMKII showed no difference in βCaMKII 
staining in the hippocampus of Camk2bA303R mice compared 
to wild-type mice. (b) Western blot analysis using antibodies 
specific for αCaMKII and βCaMKII showed no difference in 
the levels of αCaMKII and βCaMKII in the hippocampus of 
the Camk2bA303R mice. Antibodies specific for detecting the 
phosphorylation levels of αCaMKII-Thr286 and βCaMKII-
Thr287 revealed a slight reduction of Thr286 
phosphorylation, whereas the Thr287 phosphorylation is 
completely absent in the hippocampus of the Camk2bA303R mice. 
 
Previous studies showed that down- or upregulation of βCaMKII in vitro, caused 
respectively decreased or increased dendritic arborization12. Since this phenomenon was 
only observed in transfected premature cultures, and not in mature cultures, βCaMKII 
appears to be critical for normal dendritic development. However, we did not find any 
gross changes in overall brain development nor in the development of the Purkinje cells of 
the Camk2b-/- mouse in our earlier study6. Thionin staining of brain sections of the 
Camk2bA303R mice also did not reveal gross changes in overall brain morphology (Fig. 4a). 
In addition, more detailed examination of the hippocampus using the thionin staining did 
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not reveal any changes in hippocampal structure at the light microscope level (Fig. 4b) of 
Camk2b–/– mice. Furthermore we investigated the morphology of the CA1 pyramidal cells 
of Camk2b–/– using Golgi-Cox staining. We found no significant change in the density of 
spines (6.35 ± 0.36 n=15 cells from 3 mice; 7.07 ± 0.61 n=15 from 3 mice for wild-type and 
Camk2b-/- mice respectively; one-way ANOVA F1,28=1.34; p>0.28; Fig. 4c,d). Together these 
data show that neuronal development in Camk2b-/- mice is normal. 
  
Figure 4. Morphological analysis of Camk2bA303R 
and Camk2b–/– mice. (a) Thionin staining showed no gross 
morphological difference in the brain of Camk2bA303R mice. (b) 
Thionin staining showed no apparent morphological changes in 
the hippocampus of Camk2b–/– mice compared to wild-type 
mice. (c,d) Golgi analysis of the hippocampal pyramidal cells 
did not reveal any difference in spine density (p=0.3; wild-type, 
n=5; Camk2b–/–, n=5). Error bars indicate SEM 
 
Behavioral characterization of the Camk2bA303R 
and Camk2b–/– mice 
Like the Camk2b–/– mice6, Camk2bA303R mice 
showed clear ataxia. In addition, when tested on 
the accelerating rotarod, a motor performance 
test, the Camk2bA303R mice had significantly 
shorter latency times than their wild-type 
littermates (repeated measures ANOVA 
F1,18=39.05; p<0.001; Fig. 5a). These results are 
consistent with our previous findings that 
suggested that cerebellar function relies critically on both the enzymatic and non-
enzymatic mechanisms of βCaMKII.  
To investigate the requirement of βCaMKII activation in hippocampus-dependent 
learning, we tested the Camk2bA303R mice in the contextual fear conditioning task. In this 
test mice are conditioned to associate a certain context with a mild aversive foot shock. 
Learning is assessed by measuring freezing behavior, i.e. the cessation of all movement 
except respiration, which is a natural expression of fear in mice.  Camk2bA303R mice showed 
indistinguishable freezing behavior from their wild-type littermates when tested on the 
contextual fear conditioning task (one-way ANOVA F1,18=0.06; p>0.80; Fig. 5b) without 
any change in baseline freezing behavior (one-way ANOVA F1,18=0.86; p>0.36). These 
results suggest that normal context conditioning does not require βCaMKII activation by 
Ca2+/calmodulin nor its autonomous activity by Thr287 phosphorylation. 
To see if the presence of βCaMKII protein is necessary for fear learning, we also tested 
the Camk2b–/– mice. In contrast to the intact fear conditioning of Camk2bA303R mice, we 
found significantly less freezing in the Camk2b-/- mutants compared to their wild-type 
littermates (one-way ANOVA F1,39=22.9; p<0.001; Fig. 5c) without any change in baseline 
freezing behavior (one-way ANOVA F1,19=0.91; p>0.35; Fig. 5c) indicating an impairment 
of fear learning. Importantly, the motor coordination deficits of Camk2b–/– mice cannot 
explain the deficits in fear conditioning, since Camk2b–/– mice have similar motor 
dysfunction as Camk2bA303R mice6, which showed normal fear conditioning.  These data 
show that presence of βCaMKII protein, independent of its kinase activation, is necessary 
for contextual fear learning. 
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Figure 5. Behavioral analysis of Camk2bA303R and 
Camk2b–/– mice. (a) Motor performance assessed by the 
accelerating rotarod. Camk2bA303R mice (n=6) stayed on the 
rotarod for a significantly shorter period compared to wild-type 
mice (n=14) (p<0.001). The latency until the mice fell off the 
rod is shown. Error bars indicate SEM. (b) Camk2bA303R mice 
(n=6) show normal fear conditioning learning, and normal 
baseline freezing compared to wild-type mice (n=14) (p=0.8 
and p=0.4 respectively). (c) Camk2b–/– mice (n=16) show 
reduced fear conditioning learning (p<0.001), whereas baseline 
freezing is normal compared to wild-type mice (n=25) (p=0.4). 
Error bars indicate SEM. 
 
Hippocampal synaptic plasticity in the 
Camk2bA303R and Camk2b–/– mice  
The behavioral data presented above strongly 
suggests that hippocampal dependent learning 
requires the presence of βCaMKII, but not its 
enzymatic activity. To investigate if the same 
applies to hippocampal plasticity, we 
investigated the properties of the Schaffer-
collateral pathway synapses of the Camk2bA303R mouse in acute hippocampal slices using 
fEPSP measurements. No significant differences were found in basal synaptic transmission 
or PPF ((Basal synaptic transmission: repeated measures ANOVA fiber volley F1,124=0.96; 
p>0.30 (Suppl. Fig. 1a); and fEPSP F1,124=0.10; p>0.70 (Suppl. Fig. 1b); n=68 and 58 for 
wild-type and Camk2bA303R mice respectively; Fig. 6a), and (PPF repeated measures 
ANOVA: F1,151=0.004; p>0.95; n=82 and 71 for wild-type and Camk2bA303R mice 
respectively; Fig. 6b)). We then investigated the ability to induce long-term potentiation 
(LTP) at the Schaffer-collateral pathway. We tested LTP using the commonly used 100 Hz 
for one second protocol and found no difference between Camk2bA303R and wildtypes 
(132.9 ± 5.5 n=28; 132.9 ± 7.8 n=19 for wild-type and Camk2bA303R mice respectively; one-
way ANOVA F1,45=0.28; p<0.60; Fig. 6c). Additionally, when applying the 10 Hz for 10 sec 
protocol, which is closer to the LTP induction threshold and is within the natural 
occurring Theta rhythm frequency, no difference was found between the Camk2bA303R and 
wildtypes (148.2 ± 7.3 n=12; 145.3 ± 5.9 n=9 for wild-type and Camk2bA303R mice 
respectively; one-way ANOVA F1,19=0.77; p<0.77; Fig. 6d). These results show that for 
these forms of hippocampal synaptic plasticity, the activation of βCaMKII is not required.  
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Figure 6. Normal hippocampal synaptic plasticity in Camk2bA303R mice. (a) Camk2bA303R mice show 
normal synaptic transmission (fiber volley, p=0.3; fEPSP slope, p=0.7; wild-type, n=68; camk2bA303R, n=58). (b) 
Camk2bA303R mice show normal PPF (p=0.9; wild-type, n=82; camk2bA303R, n=71). (c) Camk2bA303R mice show normal 
100 Hz LTP (p=0.6; wild-type, n=28; camk2bA303R, n=19). (d) Camk2bA303R mice show normal 10 Hz LTP (p=0.8; 
wild-type, n=12; camk2bA303R, n=9). 
 
To test if hippocampal plasticity requires βCaMKII protein at all, we applied the same 
electrophysiological analysis for Camk2b–/– mice. No significant impairment in basal 
synaptic transmission was observed in the Camk2b-/- mice (Fig. 7a), since they do not show 
a significant change in fiber volley (repeated measures ANOVA F1,135=0.22; p>0.50; Suppl. 
Fig. 2a) nor in fEPSP slope (repeated measures ANOVA F1,135=1.4; p>0.23; Suppl. Fig. 2b). 
However, Paired Pulse Facilitation (PPF), a form of short-term pre-synaptic plasticity, was 
slightly but significantly enhanced across a broad range of intervals in Camk2b-/- mice 
(repeated measures ANOVA F1,168=10.66; p<0.002; Fig. 7b), which could be due to a small 
reduction in vesicle release probability. When we tested LTP, we found a significant 
impairment in Camk2b-/- mutants compared to wild-type littermates for both 100 Hz as 
well as 10 Hz (100 Hz, 152.6 ± 7.7 n=27; 119.3 ± 4.4 n=21 for wild-type and Camk2b-/- mice 
respectively; one-way ANOVA F1,46=13.14; p<0.001; Fig. 7c; 10 Hz, 135.7 ± 4.6 n=12; 119.8 ± 
6.0 n=9 for wild-type and Camk2b-/- mice respectively; one-way ANOVA F1,19=6.89; p<0.05; 
Fig. 7d). Taken together, these experiments show that βCaMKII plays an essential role in 
hippocampal plasticity and learning, but that the activation of βCaMKII is not required for 
this function.   
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Figure 7. Enhanced PPF and impaired 10 and 100 Hz LTP in Camk2b–/– mice. (a) Camk2b–/– mice show 
normal synaptic transmission (fiber volley, p=0.5; fEPSP slope, p=0.2; wild-type, n=74; camk2b–/–, n=63). (b) 
Camk2b–/– mice show enhanced PPF (p<0.01; wild-type, n=82; camk2b–/–, n=88). (c) Camk2b–/– mice show impaired 
100 Hz LTP (p<0.001; wild-type, n=27; camk2b–/–, n=21). (d) Camk2b–/– mice show impaired 10 Hz LTP (p<0.05; 
wild-type, n=12; camk2b–/–, n=9). 
 
Discussion 
Here we describe the role of βCaMKII in hippocampal synaptic plasticity and fear 
learning, using two different βCaMKII mutants; a null-mutant (Camk2b-/-) and an inactive 
mutant (Camk2bA303R). We have shown that neither the absence nor the inactivation of 
βCaMKII affects brain development at the light microscopic level, contrary to what would 
be expected based on in vitro studies from literature. Furthermore, we have shown that the 
absence of βCaMKII impairs fear learning and hippocampal synaptic plasticity while 
inactivating βCaMKII does not. Thereby strongly suggesting that βCaMKII has a non-
enzymatic, structural role in fear learning and hippocampal synaptic plasticity.  
 
Development and homeostasis 
Considering the earlier expression of βCaMKII compared to αCaMKII19, 20 and the effects 
of βCaMKII overexpression on cultured hippocampal neurons12 or neuroblastoma cells21, 
an important role in neuronal development could be expected. In contrast, we have found 
no perturbations of neuronal development in neither the Camk2b-/- nor the Camk2bA303R 
mice. An explanation for this discrepancy could lie in the different experimental systems 
used, which results in two important differences. First, our mouse mutants have changed 
βCaMKII throughout development. In contrast, neurons used for cultures, developed in 
the presence of βCaMKII protein but are suddenly confronted with decreased βCaMKII 
expression and assessed only 24 hours later. This may not allow them sufficient time to 
compensate for this change.  Second, given the low neuronal density, neurons in culture 
are mostly dependent on intrinsic signaling mechanisms to develop, whereas neurons in a 
brain also rely on cues from neighboring cells and synaptic inputs. It would be interesting 
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to see how neurons derived from Camk2b–/– mice develop in culture, to clarify the 
differences between the in vivo and in vitro experiments. 
 
Synaptic plasticity 
Our data clearly show that NMDA receptor dependent LTP (10 and 100 Hz) is impaired 
when βCaMKII is absent (Camk2b-/-) but not when βCaMKII is inactive (Camk2bA303R), 
suggesting an exclusive non-enzymatic role of βCaMKII in hipocampal plasticity. This 
finding is at odds with the notion that the increased affinity for Ca2+/calmodulin is also 
important for the role of βCaMKII in neuronal function. For instance, it has been shown 
that in cultured neurons the α/β ratio is regulated by neuronal activity14 which was 
suggested to be an homeostasis mechanism, where reduced activity would increase Ca2+ 
sensitivity of the CaMKII holoenzymes by decreasing the α/β ratio and vice versa because 
βCaMKII has higher affinity for Ca2+/calmodulin. Although we do find an increased LTP 
threshold in the Camk2b-/- mice ((LTP deficit with 10 and 100 Hz but not with a stronger 
200 Hz tetanus (data not shown)), this does not appear to be the result of a reduced 
Ca2+/calmodulin sensitivity caused by the lack of the more sensitive βCaMKII sub-unit for 
two reasons. First, the Camk2bA303R mutant shows normal LTP, despite the loss of 
Ca2+/calmodulin binding. Second, loss of the αCaMKII protein did not result in a lower 
threshold for LTP induction in the heterozygous or homozygous Camk2a knockout mouse, 
in which the subunit compensation has been shifted towards βCaMKII. 
Given that Ca2+/calmodulin binding is required to release the α- and βCaMKII 
containing holoenzyme from the actin skeleton and to allow subsequent translocation to 
the PSD11, one would expect an LTP and learning impairment in the Camk2bA303R mouse. 
So why does the Camk2bA303R mouse not show a deficit in hippocampal plasticity? One 
possible explanation is that binding to F-actin is an absolute requirement for normal LTP, 
and that the remaining unbound αCaMKII in the Camk2bA303R synapses are sufficient to 
target to the PSD and exert their (enzymatic) function. Hence, this would imply that 
synaptic plasticity requires binding of CaMKII to F-actin, but not necessarily its activity 
induced release from F-actin. This notion is in agreement with in vitro studies that showed 
that the βCaMKIIA303R protein is still able to regulate dendritic arborization. Importantly, a 
similar, but not identical, mutation in the Ca2+/calmodulin binding domain of αCaMKII 
(T305D) abolishes learning and LTP in homozygous mice, and even has a dominant 
negative effect in LTP22, in sharp contrast to lack of effect of the A303R mutation. The 
T305D mutation in αCaMKII mimics natural inhibitory autophosphorylation of αCaMKII 
and not only prevents Ca2+/calmodulin binding and Thr286 autophosphorylation, it also 
strongly reduces the levels of post-synaptic density (PSD) associated CaMKII22. Taken 
together these findings strongly suggest that CaMKII binding to F-actin and CaMKII 
targeting to the PSD are critical steps in synaptic plasticity. However, these steps do not 
have to occur successively, but can operate independent of each other. 
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 Material and Methods 
 
Generation of the Camk2bA303R mutants.  
The Camk2bA303R targeting construct was generated as follows. The Camk2b genomic 
sequence (ENSMUSG00000057897) was obtained from a public database (Ensembl) and 
used to design the primers for the targeting constructs. PCR fragments encompassing exon 
6-11 using  
5’ primer: 5’-GGTACCTGAGGAAGGTGCCAGCTCTGTCCC-3’ and  
3’ primer: 5’–GTCGACCAGGGTAGTCACGGTTGTCC-3’ (5.3 Kb; exon denotation 
according to ENSMUST00000019133) and exon 11-12 using  
5’ primer: 5’-GCGGCCGCCTGTTAAAGGAATGGTTCTC-3’ and  
3’ primer: 5’-ATGCATCTAAAAGGCAGGCAGGATGATCTGC-3’ (6 Kb)  
were amplified using High Fidelity Taq Polymerase23 on ES cell genomic DNA and cloned 
on either site of a PGK-Neomycin selection cassette. All exons were sequenced to verify 
that no mutations were introduced accidentally. Site directed mutagenesis was used to 
introduce the pointmutation Ala303Arg. For counter selection, a gene encoding Diphteria 
toxin chain A (DTA) was inserted at the 5’ of the targeting construct. The targeting 
construct was linearized and electroporated into E14 ES cells (derived from 129P2 mice). 
Cells were cultured in BRL cell conditioned medium in the presence of Leukemia 
inhibitory factor (LIF). After selection with G418 (200 µg/ml), targeted clones were 
identified by PCR (long-range PCR from Neomycin resistance gene to the region flanking 
the targeted sequence). A clone with normal karyotype was injected into blastocysts of 
C57Bl/6 mice. Male chimeras were crossed with female C57Bl/6 mice (Harlan). The 
resulting F1 heterozygous mice (in the 129P2-C57Bl/6 background) were used to generate 
F2 homozygous mutants and wild-type littermate controls. These mice were used for all 
the behavioral and electrophysiological experiments. The experimenter was blind for the 
genotype, but homozygous mice were easily recognizable by the ataxic gait. Therefore, a 
second person blind to the genotype also analyzed data. Mice were housed on a 12 hours 
light/dark cycle with food and water available ad libitum and used between 2 and 6 
months of age for all experiments described (including electrophysiology). All animal 
procedures were approved by a Dutch Ethical Committee (DEC) for animal experiments.  
 
Molecular analysis  
Western blot. Lysates were prepared by quick dissection of the brain and by 
homogenization of the brain tissue in lysis buffer (10mM TRIS-HCl 6.8, 2.5% SDS, 2mM 
EDTA and protease and phosphatase inhibitor cocktails (Sigma). The concentration of the 
lysates was adjusted to 1 mg/ml. 10 µg was used for Western blot analysis. Western blots 
were probed with antibodies directed against αCaMKII (MAB3119, 1:10,000; Chemicon), 
βCaMKII (CB-β1, 1:10,000; Zymed), Ph-T286/T87 CaMKII antibody (1:5000; #06-881, 
Upstate Cell Signaling Solutions) and Actin (MAB1501R, 1:2000; Chemicon). Blots were 
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stained using Enhanced ChemoLuminescence (#32106, Pierce) Western blot quantification 
was performed using NIH-Image. 
Immunocytochemistry. Immunocytochemistry was performed on free-floating 40µm thick 
frozen sections employing a standard avidin-biotin-immunoperoxidase complex method 
(ABC, Vector Laboratories, USA) with, βCaMKII (CB-β1, 1:2000; Zymed) as the primary 
antibody and diaminobenzidine (0.05%) as the chromogen24. For gross brain morphology 
sections were stained with thionin. 
Dendritic arborization. Golgi-Cox staining on unfixed hippocampi of 3 Camk2b–/– mutants 
and 3 wild-type mice was performed using the FD Rapid GolgiStain Kit (FD 
NeuroTechnologies Inc., USA), according to the manufacturers’ instructions. Saggital 
sections, 100µm thick, were cut on a microtome with cryostat adaptations. Pyramidal cell 
counting and selection for further detailed analysis was done by two independent 
observers who were both blind for genotype. A calibration grid was used to count the 
number of spines per 10µm, using a 40X objective. 
 
Behavioral analysis 
Accelerating Rotarod. Motor coordination on the accelerating (4–40 rpm, in 5 minutes) 
rotarod (model 7650, Ugo Basile Biological Research Apparatus, Varese, Italy) was 
measured in 5 trials with 1 hour inter trial interval. The indicated time is the time spent on 
the rotarod, or time until the mouse made 3 consecutive rotations on the rotarod. 
Fear conditioning was performed in a conditioning chamber (Med. Associates) equipped 
with a grid floor via which the foot shock could be administered. Each mouse was placed 
inside the conditioning chamber for 180 seconds. A foot shock (2 s, 0.4 mA) was delivered 
148 s after placement in the chamber. Twenty-four hours later, context-dependent freezing 
was measured during 3 minutes. 
 
Electrophysiology 
After the animals had been sacrificed sagittal slices (400 µm) were made submerged in ice-
cold artificial CSF (ACSF) using a vibratome and hippocampi were dissected out. These 
sagittal hippocampal slices were maintained at room temperature for at least 1.5 hours to 
recover before experiments were initiated. Then they were placed in a submerged 
recording chamber and perfused continuously at a rate of 2 ml/min with ACSF 
equilibrated with 95% O2, 5% CO2 at 31°C. ACSF contained the following (in mM): 120 
NaCl, 3.5 KCl, 2.5 CaCl2, 1.3 MgSO4, 1.25 NaH2PO4, 26 NaHCO3, and 10 D-glucose. 
Extracellular recording of field EPSP (fEPSPs) were made in CA1 stratum radiatum with 
platinum/iridium electrodes (Frederick Haer Companu, Bowdoinham, ME). A bipolar 
Pt/Ir was used to stimulate Schaffer-collateral/commissural afferents with a stimulus 
duration of 100 μs. Stimulus response curves were obtained at the beginning of each 
experiment, 20 minutes after placing the electrodes. LTP was evoked using two different 
tetani: (i) 10 Hz (1 train of 10 seconds at 10 Hz) and (ii) 100 Hz (1 train of 1 second 100 Hz). 
The 10 Hz protocols were performed at two-thirds and the 100 Hz protocol at one-third of 
the maximum fEPSP. fEPSP measurements were done once per minute. Potentiation was 
measured as the normalized increase of the mean fEPSP slope for the duration of the 
baseline. Only stable recordings were included and this judgment was made blind to 
genotype. Average LTP was defined as the mean last 10 minutes of each protocol.  
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Statistical analysis 
All results are presented as means ± SEM and all statistical analysis were done using SPSS 
15 software. A one-way ANOVA was used for was used to analyze differences between 
genotypes for spine density, freezing time and LTP induction (based on the average of the 
last 10 min.). A repeated-measures ANOVA was used to analyze differences between 
genotypes for rotarod, fiber volley, fEPSP slope, and PPF.  
 
Supplementary figures 
 
Supplementary Figure 1. Normal basal synaptic 
transmission in Camk2bA303R mice. (a,b) Camk2bA303R mice 
show normal synaptic transmission ((a) fiber volley, p=0.3; (b) 
fEPSP slope, p=0.7; wild-type, n=68; camk2bA303R, n=58).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2. Normal basal synaptic 
transmission in Camk2b–/– mice. (a,b) Camk2b–/– mice 
show normal basal synaptic transmission ((a) fiber volley, 
p=0.5; (b) fEPSP slope, p=0.2; wild-type, n=74; camk2b–/–, 
n=63) 
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Angelman Syndrome (AS) is a severe neurological disorder characterized by mental 
retardation, motor dysfunction and epilepsy. We now show that the molecular and 
cellular deficits of an AS mouse model can be rescued by introducing an 
additional mutation at the inhibitory phosphorylation site of αCaMKII. Moreover, 
these double mutants do no longer show the behavioral deficits seen in AS mice, 
suggesting that these deficits are the direct result of increased αCaMKII inhibitory 
phosphorylation. 
  
Angelman Syndrome (AS) is caused by loss of function of imprinted genes on human 
chromosome 15q11-13 or by mutations in the UBE3A gene which resides in this region1-4. 
Imprinting of this gene results in exclusive maternal expression in hippocampal neurons 
and cerebellar Purkinje cells5. The UBE3A gene encodes E6-AP, a ubiquitin protein ligase, 
but its role remains elusive. Heterozygous mice with a maternally inherited Ube3a 
mutation (from here on designated as AS mice) exhibit seizures, motor and cognitive 
abnormalities similar to the symptoms seen in AS patients6. Biochemical analysis of these 
mice indicates a reduction of calcium/calmodulin-dependent kinase type 2 (CaMKII) 
activity, and increased phosphorylation of the inhibitory Thr305 and Thr306 site7. Because 
increased CaMKII inhibitory phosphorylation has a severe impact on neuronal function8-
10, we now investigated whether the increased inhibitory CaMKII phosphorylation is 
directly responsible for the major deficits seen in AS. Female AS mice were crossed with 
heterozygous males that carry the targeted αCaMKII-T305V/T306A mutation, which 
prevents αCaMKII inhibitory phosphorylation (designated as CaMKII-305/6+/– mice) 
(Supplementary methods). This resulted in offspring with four different genotypes: wild-
type (WT) mice, mutants carrying the AS mutation or αCaMKII-305/6+/– mutation, and 
mice carrying the double AS/CaMKII-305/6+/– mutation. As shown previously7,  Western 
blot analysis of hippocampal lysates, showed a significant increase of Thr305 
phosphorylation in AS mice (130%; P<0.05 Fisher’s PLSD). In contrast, inhibitory 
phosphorylation was significantly reduced in CaMKII-305/6+/– mutants (40%, P<0.001), 
and remained at this low level in AS/CaMKII-305/6+/– double mutants (Fig. 1a and 
Supplementary Fig.1). Moreover, the decreased kinase activity of the AS mutants was 
restored to near wild-type levels in the AS/CaMKII-305/6+/– double mutants (Fig. 1b). 
Thus, these mutants are suitable to test to what extend increased CaMKII inhibitory 
phosphorylation is underlying the neurological phenotype of AS mice.  
All mutants appeared healthy, but adult (> 2 months) AS mice showed a small (20%) 
but significant increase in bodyweight (P<0.005 Fisher’s PLSD; Supplementary Fig. 2). 
Although obesity is not a characteristic feature of the disease, it has been reported in 15% 
of all AS children11 and in the majority of AS children carrying the Ube3a mutation12. 
Moreover, obesity is common feature of children with a previously unrecognized form of 
AS13. Notably, increased bodyweight was absent in AS/CaMKII-305/6+/– double mutants 
(P>0.3). Since αCaMKII expression is restricted to neurons, these results suggest that the 
increased bodyweight of AS mice has a neurological basis, and is caused by increased 
αCaMKII Thr305/306 phosphorylation.  
Epilepsy is a common feature of AS11, 14. However, since epilepsy is absent in some AS 
patients and background-dependent in AS mice8, several genes seem to be involved in the 
development of this phenotype. Nevertheless, since reduced αCaMKII activity can result 
in epilepsy8, it could potentially contribute to the increased seizure propensity of AS mice. 
Using audiogenic stimulation, we observed seizures in 50% of the AS mice, whereas no 
seizures were observed in WT mice or CaMKII-305/6+/– mutants. Notably, there was a 3 
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fold reduction of seizure propensity in AS/CaMKII-305/6+/– double mutants as compared 
to the AS mutants (P<0.05 Pearson’s test, Fig. 1c). This suggests that the increased CaMKII 
inhibitory phosphorylation strongly contributes to the increased seizure susceptibility of 
the AS mutants.  
Motor coordination deficits are common in all AS patients and AS mice6, 14. The 
UBE3A gene is imprinted in cerebellar Purkinje cells5 and we have previously shown that 
αCaMKII is essential for cerebellar motor learning and Purkinje cell plasticity15. Therefore, 
these deficits could well be caused by deregulation of cerebellar CaMKII. Motor 
performance of the mutants was assessed using an accelerating rotarod. Indeed there was 
a significant effect of genotype (F3,31=6.9, P<0.005 repeated measures ANOVA): AS mice 
stayed significantly shorter on the rotarod compared to their wild-type littermates 
(P<0.0001 Fisher’s PLSD; Fig.1d). In contrast, CaMKII-305/6+/– mutants performed better 
than wild-type mice (P<0.005) whereas AS/CaMKII-305/6+/– mice were normal (WT 
versus AS/CaMKII-305/6+/–: P=0.5). These results suggest that regulation of CaMKII 
inhibitory phosphorylation plays a critical role in motor coordination performance and 
that the increased CaMKII inhibitory phosphorylation directly underlies the motor 
performance deficits of AS mice. 
 
Figure 1. Reduction of αCaMKII inhibitory 
phosphorylation rescues CaMKII activity, seizure 
propensity and motor performance deficits associated 
with AS. (a) CaMKII Thr305 phosphorylation is 
reduced in hippocampal lysates of AS/CaMKII-305/6+/– 
double mutants (b) Restoration of CaMKII activity in 
hippocampal synaptosomes of AS/CaMKII-305/6+/– 
double mutants. (c) Propensity to audiogenic seizures of 
AS mutants is reduced in AS /CaMKII-305/6+/– double 
mutants. (d) Opposing effects of the AS mutation and 
CaMKII-305/6+/– mutation on performance on the 
accelerating rotarod. Asterisks indicate significant 
differences from wild-type mice. Error bars represent 
s.e.m. All animal experiments were approved by the 
Dutch Ethical Committee, or in accordance with 
Institutional Animal Care and Use Committee 
guidelines. See text and Supplementary methods for 
statistics, experimental details and number of subjects 
used. 
 
The UBE3A gene is also imprinted in 
the hippocampus5. The critical role of αCaMKII in hippocampus-dependent learning8 
makes it likely that the increased inhibitory phosphorylation of αCaMKII underlies the 
cognitive deficits in AS patients and AS mice6. Hippocampal-dependent learning was first 
assessed using the Morris watermaze task. A probe trial given after 6 days of training 
revealed a significant effect of genotype when the number of target platform crossings was 
compared between mutants (F3,66=3.7, P<0.05 ANOVA). Indeed, whereas WT and 
CaMKII-305/6+/– mutants showed significant more crossings of the target platform 
position as compared to the other positions, AS mice did not (WT P<0.0001; CaMKII-
305/6+/– P<0.0001; AS P=0.16, Paired t-test between target and average of other 
positions)(Fig 2a,b). The learning deficit of AS mutants was not due to impaired motor 
performance or decreased motivation to escape, since all mutants showed similar escape 
latencies in the hidden platform task (F3,31=0.8, P=0.5 repeated measures ANOVA, Fig 2c) 
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as well as in the visible platform task (Supplementary Fig. 3). Moreover, swim speed of 
AS mice was similar as wild-type mice, and the spatial learning deficits were overcome by 
additional training (Supplementary Fig. 3). Importantly, the spatial learning deficits of AS 
mice at day 6, were again completely rescued by the CaMKII-305/6+/– mutation, since the 
AS/CaMKII-305/6+/– double mutants showed a highly selective search strategy (target 
crossing versus average of other positions P<0.0001, Paired t-test). 
Hippocampal-dependent learning was also assessed using contextual fear 
conditioning. Context-dependent memory was tested 24 hours or 7 days following 
training (Fig 2d). A significant effect of genotype was observed at both time points with 
AS mice freezing significantly less than any other group (24 hours: F3,25= 9, P<0.0005 
ANOVA all P<0.01 Fisher’s PLSD; 7 days: F3,25= 26, P<0.0001 ANOVA; all P<0.0001 
Fisher’s PLSD). In contrast, CaMKII-305/6+/– mutants showed significantly more freezing 
in the 7 days memory test (all P<0.05 Fisher’s PLSD) but not in the 24 hours memory test. 
Once more, the phenotype was rescued by the AS/CaMKII-305/6+/– double mutation (WT 
versus AS/CaMKII-305/6+/– 24 hours: P=0.6; 7 days: P=0.4 Fisher’s PLSD). Since cued 
conditioning was normal in the AS mice (Supplementary Fig. 4), we conclude that AS 
mice have a hippocampal learning deficit, and that this deficit can be rescued by 
decreasing αCaMKII inhibitory phosphorylation. 
αCaMKII inhibitory phosphorylation plays an important role in setting the threshold 
for the induction of long-term potentiation (LTP): homozygous CaMKII-305/6 mice show 
increased LTP at sub-threshold stimulation, and normal LTP when a strong stimulation 
protocol is applied9. Conversely, AS mice show a striking LTP deficit, which is rescued by 
a strong stimulation protocol6, 7. To directly test whether the LTP deficit of AS mice is due 
to excessive Thr305/306 phosphorylation, we measured LTP in hippocampal slices of the 
mutants. Consistent with previous findings, AS mice showed a severe LTP deficit 
compared to wild-type mice (F3,87=0.3, P<0.0001 ANOVA; all P<0.001 Fishers PLSD)(Fig. 
2e). However, LTP was normal in the CaMKII-305/6+/– mice (P=0.5 Fishers PLSD) as well 
as in the AS/CaMKII-305/6+/– double mutants (P=0.4 Fishers PLSD), suggesting that the 
plasticity deficits of AS mice are the result of increased CaMKII inhibitory 
phosphorylation. 
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Figure 2. Hippocampal learning and plasticity of 
AS mice is rescued by the CaMKII-305/6+/– 
mutation. (a-c) Learning in the Morris 
watermaze. (a) A probe trial shows that AS mice 
search less focussed for the platform as compared 
to WT and CaMKII-305/6+/– mice. The plots are a 
visual representation of all search tracks 
combined, in which the colour indicates the mean 
time spent at a certain position. The black circle 
indicates the target platform position used during 
training. The other (virtual) positions are 
indicated in white. (b) Quantification of the 
platform positions as indicated in (a). Bars 
represent target position, adjacent right, opposite, 
adjacent left position respectively. Asterisks 
indicate that target position crossing is 
significantly more than crossing of the other 
positions. (c) Escape latency to reach the platform 
shows no difference between the mutants. (d) AS 
mutants show impaired contextual conditioning. 
Freezing was assessed either 24 hours, or 7 days 
after conditioning. (e) LTP deficits of AS mice are 
rescued by the CaMKII-305/6+/– mutation. Error 
bars represent s.e.m. See text and 
Supplementary methods for statistics, 
experimental details and number of subjects used. 
 
Although further research is 
needed to link E6-AP to CaMKII 
inhibitory phosphorylation, this is the 
first study to report a functional 
connection between CaMKII and a human learning and memory disorder. It also 
represents a fundamental breakthrough in our basic understanding of the molecular basis 
of the motor, seizure and cognitive facets observed in Angelman syndrome.  
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Supplementary figures  
 
Supplementary Figure 1. Decreased inhibitory 
phosphorylation in hippocampal lysates of AS/CaMKII-
305/6+/– double mutants. AS mice show a significantly 
increased CaMKII-T305 phosphorylation, as compared 
to their WT littermates, which is decreased when crossed 
with CaMKII-305/6+/– mice. Western blots were first 
probed with antibodies directed against Thr305-
αCaMKII and after stripping re-probed with αCaMKII 
and Actin. To ensure that the staining was within the 
linear range, the wild-type samples were also loaded at a 
two fold higher concentration.  
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Supplementary Figure 2. The increased 
bodyweight in AS mice returns to WT level 
in AS/CaMKII-305/6+/– mice. AS mice show 
a small but significant (P<0.005) increase in 
bodyweight (females (2.5 months old): 
F3,48=5.6, P<0.005, males (4 months old): 
F3,13 =9.6, P<0.005 ANOVA; Post hoc 
analysis: all P< 0.005 Fisher’s PLSD), which 
was absent in AS/CaMKII-305/6+/– double 
mutants (P>0.3 for males and females). 
Error bars represent SEM. 
 
 
Supplementary Figure 3. Learning of the 
hidden platform (a-e) and visible (f) platform 
watermaze. AS mice show impaired 
hippocampal learning at the probe trial given 
at day 6 compared to their wild type 
littermates, which is improved after two 
additional training days. (a) During the probe 
trial at day 6 AS mice do not spent 
significantly more time in the target quadrant 
as compared to all the other quadrants, 
whereas the AS/CaMKII-305/6+/– mice show 
high preference for the target quadrant. (b) 
The learning impairment of the AS mice 
cannot be ascribed to motor impairments or 
motivational problems, as they swim as fast as 
their wild type littermates. Only the CaMKII-
305/6+/– mice tend to swim faster. (c,d,e) At 
the probe trial given at day 8, the AS mice 
caught up with their littermate controls and 
showed selective searching as judged from the 
time spend in target quadrant (d) and from 
the number of platform crosses (e). To exclude 
that AS mice have visual or motivational 
problems that could account for the impaired 
learning, a visible watermaze was performed 
and the escape latency was determined. This 
task shows no effect of genotype (F3,14=1.4, 
P=0.3 repeated measures ANOVA). Error bars represent SEM. 
 
 
Supplementary Figure 4. AS mice show no deficits in 
cued conditioning. Cued conditioning test was used to assess 
whether the contextual conditioning phenotype of the AS 
mice was hippocampus-dependent. Cued conditioning did 
not reveal any difference between the different mutants, 
indicating that the contextual phenotype found in AS mice is 
indeed hippocampus-dependent (F3,34 =0.6, P=0.6 repeated 
measures ANOVA). Error bars represent SEM. 
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Material and Methods  
Breeding of mutants. 
Mutants with the Ube3a null mutation (designated as AS mice) and mutants carrying the 
targeted αCaMKII-T305V/T306A mutation which prevents phosphorylation at these 
residues (designated as CaMKII-305/6+/– mice) were developed as described previously6, 9. 
All experiments described in this paper were carried out using hybrid mice in the mixed 
129/Sv-C57BL/6 background. To that end, male αCaMKII-305/6+/– mutants in the 
C57BL/6 background were crossed with female AS mutants in the 129/Sv background 
(weight, rotarod, watermaze) or with female AS mutants in the 129/Sv-C57BL/6 
background (epilepsy, fear conditioning, LTP).  
Mice were genotyped when they were 7-10 days, but the experimenter remained blind 
for the genotype during data collection and the initial analysis. Genotypes were again 
established after all experiments were done and the code was then broken to perform the 
final statistical analysis. All experiments were done with 2-4 month old littermates that 
were housed in groups of 2-3 per homecage. Genotype groups were approximately sex 
and age matched. Single-housed mice were excluded for the behavioral studies. The mice 
were kept on a 12h light/dark cycle, with food and water available ad libitum. The 
behavioral experiments were performed during the light period of the cycle. All animal 
experiments were approved by the Dutch Ethical Committee, or in accordance with 
guidelines of Institutional Animal Care and Use Committee of Vanderbilt University. 
Western blot analysis of the phosphorylation state of CaMKII.  
Lysates were prepared by quickly dissecting the hippocampus followed by 
homogenization in lysis buffer (10mM TRIS-HCl 6.8, 2.5% SDS, 2mM EDTA and protease 
and phosphatase inhibitor cocktails (Sigma)). Lysates were then adjusted to 1 mg/ml, and 
10 µg was used for SDS-PAGE analysis and Western blotting. Western blots were first 
probed with antibodies directed against Thr305-αCaMKII (pB609, 1:5000) and after 
stripping re-probed with αCaMKII (MAB3119, 1:10000; Chemicon), and Actin 
(MAB1501R, 1:2000; Chemicon). Blots were quantified using NIH-Image using the 
αCaMKII signal as loading control, and normalized against wild-type. The number of 
mice used: WT (4); AS (4); CaMKII-306/5+/– (4); AS/CaMKII-305/6+/– (4).  
CaMKII Activity Measurement 
Mice were sacrificed by cervical dislocation and hippocampi were quickly isolated in ice-
cold cutting solution and sonicated in cold homogenization buffer containing 4 mM 
HEPES, 320 mM sucrose and protease inhibitor cocktail (Sigma, Saint Louis, MO). The 
homogenates were centrifuged at 1500 g for 10 min. The supernatant was then centrifuged 
at 16000 g for 20 min to yield a pellet containing the crude synaptosome fraction. This 
fraction was resuspended in 200µl homogenization buffer to measure the Ca2+/calmodulin 
dependent CaMKII activity using the assay kit from Millipore Inc. (14-217). The number of 
mice used: WT (6); AS (6); CaMKII-306/5+/– (6); AS/CaMKII-305/6+/– (6).  
Weight and seizure susceptibility 
Female AS mice started to show increased bodyweight after 2 months, whereas male AS 
mice started to become significantly heavier after 4 months.  Number of mice used: 
females (8-9 weeks): WT (13); AS (7); CaMKII-305/6+/– (10); AS/CAMKII-305/6+/–, (13). 
Males (16-18 weeks): WT (4); AS (3); CaMKII-305/6+/– (6); AS/CaMKII-305/6+/– (4). To 
assess seizure susceptibility we induced audiogenic seizures by vigorously scratching 
scissors across the metal grating of the mouse cage lid for 20 seconds, or shorter if a 
seizure developed before that time. The number of mice used in this paradigm: WT (11); 
AS (10); CaMKII-305/6+/– (12); AS/CaMKII-305/6+/– (15). 
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Motor performance.  
We tested motor function in F1 mice using the accelerating rotarod (4-40 rpm, in 5 
minutes; model 7650, Ugo Basile Biological Research Apparatus, Varese, Italy). Mice were 
given two trials per day with a 45-60 min inter trial interval for 4 consecutive days.  For 
each day we calculated the average of the time spent on the rotarod, or of the time until 
the mouse made 3 consecutive rotations on the rotarod. Maximum duration of a trial was 
5 min. The number of mice used: WT (10); AS (7); CaMKII-305/6+/–  (10); AS/CaMKII-
305/6+/– (8). 
Water Maze.  
To test spatial memory we used the Water Maze. Prior to the test mice were handled 
extensively (2 min/day; 5 days). Our pool is 1.2 m in diameter and has an 11 cm diameter 
platform submerged 1 cm below the water surface. The water is painted milk-white with 
non-toxic paint and water temperature is kept constant at 26°C. We use dimmed lighting, 
and mouse-tracking is performed using SMART version 2.0 (Panlab, Barcelona, Spain). 
Mice were given 2 trials per day, with 30 sec inter trial interval for 8 consecutive days. At a 
training session, the mouse was first placed on the platform for 30 sec.  Then it was placed 
in the water at a pseudo-random start position and it was given a maximum of 60 seconds 
to find the platform. If the mouse did not find the platform within 60 seconds, it was 
placed back on the platform. After 30 seconds on the platform, this training procedure was 
repeated once more. The platform position remained at the same position during all trials. 
One hour after the training on day 6 and day 8, a probe trial was given to test spatial 
learning. Mice were placed on the platform for 30 seconds, after which the platform was 
removed from the pool and the mice were placed in the pool at the opposite side of the 
previous platform position. The mice were then allowed to search for the platform for 60 
seconds. The number of mice used for this paradigm: WT (18); AS (11); CaMKII-306/5+/– 
(18); AS/CaMKII-305/6+/– (14).  
The visible water maze was performed done in the same way as the hidden platform 
water maze, except that this time the platform was flagged with a small cue on top the 
platform. The number of (naïve) mice used for this paradigm: WT (6); AS (5); CaMKII-
306/5+/– (4); AS/CaMKII-305/6+/– (3).  
Fear Conditioning.   
Fear conditioning was performed in a testing chamber (26 × 22 × 18 cm; San Diego 
Instruments, San Diego, CA) made of Plexiglas equipped with a grid floor via which the 
foot shock could be administered and a CCD camera to monitor activity. The conditioning 
chamber was placed inside a soundproof isolation cubicle. Training and testing occurred 
in the presence of white light and white noise. Each mouse was placed inside the 
conditioning chamber for 150 seconds before the onset of a 2 s foot shock (0.5 mA). After 
150 seconds, a second foot shock was delivered, and the mouse was returned to its home 
cage after another 2.5 min. Testing of context-dependent fear was performed either 24 
hours or 1 week after the conditioning in the same context. 
For cued conditioning, each mouse was placed inside the conditioning chamber for 2 
min before the onset of a conditioned stimulus (CS; an 85 dB tone), which lasted for 30 s. 
training occurred in the presence of white light and white noise. A 2 s US foot shock (0.5 
mA) was delivered immediately after the termination of the CS. Each mouse remained in 
the chamber for an additional 120 s, followed by another CS–US pairing. Each mouse was 
returned to its home cage after another 2.5 min. Cued fear conditioning was tested in the 
presence of a masked context consisting of a small Plexiglas cube attached to an opaque 
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Plexiglas floor insert, different lighting conditions, and a vanilla odor. Each mouse was 
placed in this novel context for 3 min at approximately 24 h after training, and they were 
exposed to the CS for another 3 min. 
Freezing behavior was recorded and processed by SDI Photobeam Activity System 
software throughout each testing session. The mouse was considered to be freezing after a 
lack of movement for 2 s.  Number of animals used: 24 hours context: WT (6); AS (6); 
CaMKII-305/6+/– (8); AS/CaMKII-305/6+/– (9) ; 1 week context: (WT (7); AS (8); CaMKII-
305/6+/– (7); AS/CaMKII-305/6+/– (8).  24 hours cued: WT (11); AS (11); CaMKII-305/6+/– 
(7); AS/CaMKII-305/6+/– (9) ; 
Shock threshold was assessed by placing the animal in the conditioning chamber and 
by delivering foot shocks starting at 0.075 mA and increasing by 0.05 mA every 30 s. The 
experiment was terminated at the shock intensity sufficient to induce vocalization. There 
was no difference in shock sensitivity between the groups (F3,75=0.53, P=0.9 ANOVA). 
Hippocampal slice preparation and electrophysiology 
The brain was quickly removed and placed in ice-cold high sucrose cutting solution 
containing (in mM): 110 sucrose, 60 NaCl, 3 KCl, 28 NaHCO3, 1.25 NaH2PO4, 7 MgCl2, 0.5 
CaCl2, 0.6 sodium ascorbate, and 5 D- glucose, pH 7.3–7.4. Horizontal 400 μm sections 
were cut in sucrose cutting solution using a Vibratome. The slices were stored in 95% 
O2/5% CO2-equilibrated artificial CSF containing (in mM): 125 NaCl, 2.5 KCl, 1.25 
NaH2PO4, 28 NaHCO3, 1.0 MgCl2, 2.0 CaCl2, and 10 D- glucose, (pH 7.3-7.4) and kept at 
room temperature for at least 1 hour before switching to the interface chamber supported 
by a nylon mesh and allowed to recover for a minimum of 1 hour prior to recording. The 
chamber was kept at 32 ± 0.5 °C with a laminar ACSF flow rate of 2–3 ml/min. 
Extracellular field recordings were obtained from area CA1 of the stratum radiatum. 
Stimulations were supplied with a bipolar Teflon-coated platinum electrode and 
recordings were obtained with the use of a glass microelectrode field with ACSF with tip 
diameter about 1 μm (1–4 MΩ electrical resistance). Tetani used to evoke CA1 LTP 
consisted of two trains of 100 Hz stimulation for 1s with each train separated by a 20s 
interval. Stimulus intensities were adjusted to give pEPSPs (population excitatory 
postsynaptic potentials) with slopes that were <50% of the maximum determined from an 
input/output curve. Potentiation was measured as the normalized increase of the mean 
pEPSP for the duration of the baseline recording. Experimental results were obtained from 
those slices that exhibited stable baseline synaptic transmission for a minimum of 30 min 
prior to the delivery of the LTP- inducing stimulus. For recording we used an Axon 1320 
Digidata data acquisition hardware operated by Axon pClamp 9.2 software. We used 
maximally two slices per mouse. The number of slices used for the experiment are: WT 
(11); AS (6); CaMKII-305/6+/– (6); AS/CaMKII-305/6+/– (6). 
 
Statistical analysis.  
StatView data analysis software was used for statistical analysis. An ANOVA or repeated 
measures ANOVA was used for multiple group data, to test for the effect of genotype. If 
this was significant, the data was further analyzed using the Fisher PLSD Post Hoc test. 
All figure data represents mean ±SEM. An analysis with a value of p<0.05 was considered 
to be statistically significant (indicated by an asterisk in the figures).  
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Chapter VI 
 
 
 
 
 
 
 
 
 
 
 
General Discussion: 
What can still be learned about CaMKII 
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The overall aim of the studies described in this thesis was to further elucidate the role 
of CaMKII in plasticity, learning and disease. To obtain more knowledge on CaMKII we 
made use of different α- and βCaMKII mutants. 
 
To clarify the role of αCaMKII in presynaptic plasticity we analyzed different 
αCaMKII mutants (chapter II)1. By looking at Synapsin I phosphorylation in the different 
mutants, it was first determined which mutants still exert enzymatic functions. Only in the 
αCaMKII knockout and the dominant negative αCaMKIIT305D mutant showed no 
phosphorylation of Synapsin I. However, when analyzing presynaptic plasticity, the 
αCaMKIIT305D showed no difference compared to wildtypes, whereas the αCaMKII 
knockout showed enhanced synaptic augmentation and decreased synaptic fatigue. 
Together with the data obtained using competitive inhibitors blocking Ca2+/CaM binding, 
we showed unambiguously that kinase activity of αCaMKII, and phosphorylation of 
Synapsin I by αCaMKII, is not required for presynaptic plasticity. The decreased synaptic 
fatigue could be the result of an increase in the number of docked vesicles in the αCaMKII 
knockout mice, which indeed appeared to be the case. Hence, it can be concluded that 
αCaMKII plays a structural role at the presynaptic site, limiting the number of docked 
vesicles, and thereby modulating short-term presynaptic plasticity. Recently, a kinase 
dead αCaMKII mutant (αCaMKIIK42R) was generated and further supporting our findings, 
this mutant showed no difference in short-term presynaptic plasticity2. There is however 
still some discrepancy on the role of CaMKII in presynaptic plasticity. αCaMKII has been 
shown to either enhance or inhibit presynaptic plasticity, depending on the experimental 
setup or physiological circumstances. Therefore, it is hypothesized that presynaptic 
CaMKII is a bidirectional modulator of neurotransmitter release, depending on the sort of 
presynaptic activity3. It would be very interesting to see what the binding partners for 
αCaMKII at the presynaptic site are, and how they play a role in regulating the direction 
of plasticity. 
Can we conclude now that presynaptic αCaMKII activity is not important at all? 
Presynaptic CaMKII activity has been shown to be required for CA3-CA3 LTP in 
organotypic slices4, indicating that presynaptic αCaMKII activity is required for other 
presynaptic measures, for example those that involve a longer time scale. The best way to 
test this hypothesis would be to generate CA3-specific αCaMKII knockouts and measure 
the effect on long-term plasticity and learning.   
 
In chapter III and IV we started to unravel the role of βCaMKII in plasticity and 
learning. Since βCaMKII is the predominant CaMKII isozyme in the cerebellum5, and 
αCaMKII was already shown to play an important role in cerebellar motor learning and 
plasticity6, it is very likely that this isozyme is of even greater importance for cerebellar 
functioning. In chapter III of this thesis we started with assessing the role of βCaMKII in 
cerebellar plasticity using βCaMKII–/– mouse7. Surprisingly, even though most in vitro 
studies revealed an important role for βCaMKII in neuronal development and dendritic 
arborization8, 9, the βCaMKII–/– mice did not show deficits in overall brain development or 
Purkinje cell maturation7. However, the mice did show severe problems at the parallel 
fiber-Purkinje cell synapse, in that plasticity at this synapse appeared to be completely 
reversed: LTP inducing stimulus protocols induces LTD in βCaMKII–/– and vice versa, 
indicating that this isozyme is of crucial importance for the direction of plasticity at this 
synapse.  
 97 
 
 
 
Figure 1. Role of CaMKII and PP2B in parallel fiber-Purkinje cell plasticity. Simplified model 
depicting the role of αCaMKII, βCaMKII and phosphatase PP2B in LTP and LTD at the parallel fiber-Purkinje cell 
synapse. In wild-type Purkinje cells high calcium influx (top) activates the phosphatase PP2B driven synaptic 
potentiation pathway but also results in maximal induction of the CaMKII driven synaptic depression pathway, which 
effectively out-competes PP2B, leading to a net LTD. In contrast, in the absence of βCaMKII the synaptic depression 
pathway (which requires αCaMKII and βCaMKII activity) is no longer able to out-compete PP2B, resulting in net 
LTP. 
Low calcium influx (bottom) only moderately activates PP2B, but as there is no or insignificant activation of 
CaMKII, the net result is LTP. In βCaMKII–/– Purkinje cells low calcium influx results in precocious activation of 
αCaMKII, which is sufficient to out-compete PP2B, resulting in net LTD. 
 
What could explain the inversed plasticity in the βCaMKII–/– mutants? It is widely 
accepted that in the Purkinje cell there is a balance between phosphatase and kinase 
activity, with the kinases being more activated during LTD induction (high Ca2+ influx) 
and the phosphatases being more activated during LTP induction (low Ca2+ influx) (as 
reviewed by10). According to the impact of αCaMKII deletion on cerebellar function in 
adult mice6, it is reasonable to assume that the CaMKIIs are one of the most important 
kinases in the Purkinje cells of adult mice. Therefore, we propose the following model (fig 
1): When one of CaMKII isozymes (αCaMKII or βCaMKII) is absent, the balance during 
high calcium influx is shifted towards the phosphatase PP2B and LTP instead of LTD will 
be induced. Using phosphatase blockers we showed that this is indeed the case. However, 
this phosphatase/kinase balance does not explain the shift from LTP to LTD, during low 
calcium levels. βCaMKII tethers αCaMKII to the actin cytoskeleton limiting the number of 
αCaMKII subunits that can get activated during low calcium stimulation. This makes it 
reasonable to assume, that when βCaMKII is absent, more αCaMKII homomers are 
available to become activated under low calcium conditions, thereby outweighing PP2B, 
resulting in LTD instead of LTP, which was confirmed using the CaMKII inhibitor KN93. 
Hence, we hypothesized that βCaMKII activity is required for LTD expression, whereas 
under LTP inducing conditions, βCaMKII prevents activation of the LTD pathway. 
However, we cannot exclude a possible role for other neurons, since βCaMKII–/– is 
expressed in most of the cell types in the cerebellum6, 11. It would be very interesting to 
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assess the role of βCaMKII in the other cell types as well. Cell-specific βCaMKII knockouts 
could be a useful tool to study the specific roles of βCaMKII in all these different cell types 
in the cerebellum.  
 
In chapter IV of this thesis we describe the role of βCaMKII in the hippocampus, using 
the βCaMKII–/– and the βCaMKIIA303R mice. Interestingly, we found that absence of 
βCaMKII results in impaired LTP and impaired fear conditioning memory in mice, 
whereas the presence of βCaMKII, even though it cannot be activated (βCaMKIIA303R) 
results in normal LTP and fear conditioning memory in mice. These results indicate that in 
the hippocampus, the presence of βCaMKII is sufficient for plasticity and learning, hence 
that the role of βCaMKII in the hippocampus is more likely to be structural instead of 
enzymatic.  
It is still puzzling that the βCaMKIIA303R mice do not show a phenotype, even though 
theoretically, the αCaMKII containing holoenzymes cannot be released from actin and 
therefore cannot be translocated. It can be hypothesized that the βCaMKII containing 
holoenzymes attached to actin are close enough to the PSD, so that αCaMKII, even though 
it cannot be released from the actin cytoskeleton, is still able to phosphorylate some of its 
substrates, enough to induce LTP. It has been shown that in hippocampal cultures, actin-
bound βCaMKII is located mostly in the dendritic spines, and therefore that αCaMKII is 
already close to the PSD12. It can also be hypothesized that in the βCaMKIIA303R mice there 
are more αCaMKII homomers present as to compensate for the αCaMKII subunits that 
cannot be released from the actin cytoskeleton, and that the actin cytoskeleton now 
functions as a ‘gate’, keeping the spine closed to prevent αCaMKII to disperse out of the 
synapse. Pulldown assays using the βCaMKII antibody, and investigating how much 
αCaMKII comes down with βCaMKII can answer the question which of these hypotheses 
is more likely to be true.  
What mechanism can explain the phenotype in the βCaMKII–/– mice? When βCaMKII 
is absent, αCaMKII cannot bind to actin anymore and could therefore be dispersed 
throughout the neuron, leaving not enough αCaMKII molecules located at the proper 
position to be able to induce LTP upon stimulation. Indeed, in vitro studies showed that 
reducing the amount of βCaMKII12, or treating cells with actin depolymerisation drugs13, 
results in dispersion of αCaMKII away from the PSD. If it is true that there is not enough 
αCaMKII at the proper location, it is likely that when the intracellular [Ca2+] increases not 
only in the spine, but also in the dendrite, more αCaMKII is activated, which then could 
induce LTP. This could be tested using a 200 Hz protocol, which also activates the voltage-
gated calcium channels (VGCCs)14, inducing a large Ca2+ influx at different locations. This 
could then rescue the LTP deficit in the βCaMKII–/– mice. However, the only way to 
directly prove the dislocalization of αCaMKII is by using fluorescent microscopy or 
immunogold labeling and look directly at the localization of αCaMKII in neurons of 
βCaMKII–/– mice.  
Taken together, βCaMKII plays a non-enzymatic role in the hippocampus, and it is 
hypothesized that it regulates the subcellular localization of αCaMKII. A simplified model 
of αCaMKII localization in the different βCaMKII mutants is shown in figure 2.  
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Figure 2: Model for αCaMKII localisation in βCaMKII mutants. a) WT synapse. The actin cytoskeleton is 
highly organized and most of the αCaMKII subunits are tethered to the actin cytoskeleton by βCaMKII, b) βCaMKII–/– 
synapse. The actin cytoskeleton is not organized anymore and the αCaMKII homomers are dispersed throughout the 
neuron, c) βCaMKIIA303R synapse. The actin cytoskeleton is highly organized and prevents αCaMKII homomers to 
disperse from the spine. Depicted are postsynaptic CA1 synapses at rest stage. Red dots: αCaMKII; blue dots: 
βCaMKII; black stripes: actin; Yellow ovals: NMDA receptor; Blue ovals: AMPA receptor.  
 
When considering the results in chapter III and IV it becomes clear that the function of 
βCaMKII depends on the brain region. Deletion of βCaMKII in the cerebellum has more 
impact than deletion of βCaMKII in the hippocampus. What causes this difference? It is 
known that there is a difference in the α:β ratio in the two brain regions. In the 
hippocampus, the α:β ratio is 3:115, whereas in the cerebellum the α:β ratio is 1:416. 
However, these ratios are an average for the complete hippocampus and cerebellum, 
when looking at specific cell types, these ratios change. In the hippocampus, αCaMKII is 
solely expressed in excitatory neurons17, 18, whereas βCaMKII is expressed also in 
inhibitory interneurons. In the cerebellum, again αCaMKII is limited to one cell type, 
namely Purkinje cells19, whereas βCaMKII is expressed throughout the cerebellum in most 
of the cell types11. Thus, when looking at the cell types where both isoforms are present, 
i.e. excitatory neurons in the hippcampus and Purkinje cells in the cerebellum, the ratio 
between αCaMKII and βCaMKII changes to approximately 4:1 and 1:1 respectively. It can 
be assumed that this has direct implications for the importance of βCaMKII in these cell 
types. Absence of βCaMKII in Purkinje cells is likely to result in a more severe phenotype 
than absence of βCaMKII in excitatory neurons in the hippocampus, which is exactly what 
we see. Apart from that, we have shown that βCaMKII fulfills different functions in the 
different cell types. In Purkinje cells, βCaMKII has both an enzymatic and a structural role, 
whereas in the hippocampus, βCaMKII is more likely to play only a structural role. 
Therefore, it is of great interest to look at the different targets of βCaMKII in both cell 
types to see what the differences are to finally get an idea of the mechanisms underlying 
plasticity in both the cerebellum and the hippocampus. 
 
It has previously been shown that AS mice have increased inhibitory 
autophosphorylation at the TT305/6 residues of αCaMKII20. In Chapter V we assessed 
whether the phenotype seen in AS mice is the result of this increased inhibition of 
αCaMKII. To test this hypothesis, we crossed CaMKIITT305/6VA mice, in which the 
inhibitory phosphorylation sites are blocked, with AS mice21. Surprisingly, introducing 
this counter mutation in AS mice completely rescued the motor deficits, the learning 
problems and the impaired plasticity. The epilepsy was largely, although not completely, 
rescued, indicating that other genes are involved in this phenotype. Taken together, these 
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results prove that CaMKII plays a major role in the pathophysiology of Angelman 
Syndrome.  
What could be the link between the loss of E6AP and the increase in inhibitory 
phosphorylation of CaMKII? Three models can be proposed (fig 3).  
 
 
Figure 3. Three models showing how the absence of UBE3A can cause an increase in self-inhibited CaMKII. See text 
for a detailed description of these models. 
 
In the first model (fig 3a) (‘indirect model’), it is assumed that UBE3A has many 
different targets, and that one (or several) of these targets is essential for normal neuronal 
function and plasticity. The misregulation of this critical target (designated ‘C’) could 
cause plasticity defects, which in turn results in self-inhibition of CaMKII. This so called 
‘basal’ self-inhibition occurs in the prolonged absence of calcium, and has been shown to 
occur in vitro22. However, the finding that we can rescue the neurological and plasticity 
deficits seen in AS mice by decreasing the amount of CaMKII that can undergo self-
inhibition21, cannot be explained by this model, making this the least attractive model to 
pursue.  
In the second model (fig 3b) (‘phosphatase model’) a critical protein controlling 
phosphatase function is misregulated in the absence of UBE3A. This results in reduced 
phosphatase function, which leaves CaMKII in the inhibited (T305/T306 phosphorylated) 
form. This increased self-inhibition leads to plasticity deficits. This model takes into 
account the finding that PP1/2a activity is reduced in AS mice20. Very recently a new 
target for UBE3A was discovered, the promyelocytic leukemia tumor suppressor (PML)23. 
Intriguingly, another study showed that PML regulates cell fate in the developing 
neocortex, indicating it plays a role in neuronal function24. The exact role of PML in 
neuronal function is still unknown, but it is shown that PML regulates PP1 and PP2a 
localization in the cell24. This could result in reduced dephosphorylation of CaMKII: 
overexpression of PML due to absence of UBE3A, results in delocalization of PP1 and 
PP2a, away from CaMKII, hence less dephosphorylation of CaMKII. This model can 
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explain how the neurological and plasticity deficits seen in AS mice are rescued by 
reducing the amount of self-inhibited CaMKII21. 
In the third model (fig 3c) (‘direct model’) it is hypothesized that CaMKII itself is a 
direct target for UBE3A. It could be that the self-inhibited form of CaMKII undergoes a 
conformational shift, which makes it a target for UBE3A.  In the absence of UBE3A this 
self-inhibited form starts to accumulate, which affects the dendritic local synthesis of new 
CaMKII.  The net effect would be that the total amount of CaMKII is unaffected, however 
most of it is in the self-inhibited form. The accumulation of the self-inhibited form reduces 
neuronal plasticity. The neuron attempts to counteract the reduced plasticity by 
decreasing phosphate activity which under normal conditions would favour induction of 
long-term plasticity (LTP)25. This model is compatible with all our current knowledge of 
the molecular mechanisms underlying synaptic plasticity, and it also explains why all the 
neurological and plasticity deficits of AS mice can be rescued so well by decreasing the 
amount of self-inhibited CaMKII21. 
Even though we propose three different models, it could also be that the function of 
PP1 and PP2a are indeed the cause of the decreased dephosphorylation of CaMKII and 
that CaMKII is a target for UBE3A, thus a combination of model 2 and 3. To test model 2 it 
would be interesting to cross PML–/– mice with AS mice and test whether we can rescue 
the phenotypes again. To test if CaMKII is a target for UBE3A, pull down assays and yeast 
two hybrid screens could be done.  
But knowing the exact pathway or mechanisms underlying Angelman Syndrome, 
does not necessarily mean that we can go and find a cure for these patients. One question 
that needs to be addressed first is whether synaptic function becomes normal again upon 
for example re-expression of the UBE3A protein. This is important, because there is a 
chance that absence of the protein changes synaptic networks already during 
development, which cannot be reversed at a later age. If that is the case, then there is less 
chance of finding a cure for the patients. Therefore it is of high importance to first test in 
AS mice whether the phenotype can be rescued in adulthood. One of the methods to do 
that is to use inducible knockouts.  
Hopefully, by knowing the exact pathway or mechanisms underlying Angelman 
Syndrome, we will be able to find a treatment for these patients in the future.  
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Summary 
 
CaMKII is one of the most abundant proteins and probably also one of the most 
extensively studied kinases of the brain. To date, already more than 2000 articles have 
been published on CaMKII, however, there is still no full understanding on the exact 
functions of the protein in the different parts of the brain. The two most abundant CaMKII 
isozymes present in the brain are αCaMKII and βCaMKII. In this thesis we attempt to 
further elucidate the role of these two isozymes in learning, synaptic plasticity and 
disease.  
Chapter II focuses on the role of αCaMKII in presynaptic plasticity. Using targeted 
mouse mutants and pharmacologic inhibition of αCaMKII, we demonstrate that the 
presence of αCaMKII protein is required for normal short-term presynaptic plasticity, but 
not its activation, autophosphorylation nor its ability to phosphorylate Synapsin I. 
Furthermore we show that αCaMKII regulates the number of docked vesicles independent 
of its ability to be activated. These results indicate that αCaMKII plays a non-enzymatic 
role in short-term presynaptic plasticity at hippocampal CA3-CA1 synapses. 
βCaMKII is the second most abundant CaMKII in the brain, however, so far not much 
is known about the role of βCaMKII in plasticity and learning. One of the reasons for the 
lack of knowledge is the fact that for a long time no mouse model was available. Our lab is 
the first lab to generate a βCaMKII null-mutant. Since βCaMKII is the predominant 
CaMKII isoform of the cerebellum, we first assessed the function of βCaMKII in the 
cerebellum using this mouse model (chapter III). We showed that βCaMKII plays an 
essential role in controlling the direction of plasticity at the parallel fiber–Purkinje cell 
synapse: a protocol that induces synaptic depression in wild–type mice, results in synaptic 
potentiation in βCaMKII knock–out mice, and vice versa. We propose a model in which 
βCaMKII plays a structural role at the parallel fiber-Purkinje cell synapse during the 
induction of LTP, and in which the enzymatic function of βCaMKII is necessary for the 
induction of LTD. These findings provide us with unique experimental insight into the 
mechanisms that transduce graded calcium signals into either synaptic depression or 
potentiation. 
In chapter IV we looked at the role of βCaMKII in hippocampal plasticity and 
learning, using two different βCaMKII mutants. Here we show that the absence of 
βCaMKII severely impairs fear conditioning and hippocampal long-term potentiation 
(LTP). Remarkably, preventing βCaMKII activation by mutating the Ca2+/Calmodulin 
binding domain (A303R) has effect on neither plasticity nor learning. Taken together, these 
results strongly suggest a non-enzymatic, structural role in hippocampal learning and LTP 
for βCaMKII. 
CaMKII is known to be involved in several neurological and psychiatrical disorders, 
one of which is Angelman Syndrome. In this neurological disorder, CaMKII shows 
increased phosphorylation at the inhibitory phosphorylation sites (TT305/6). In chapter V 
we show that the molecular and cellular deficits of an AS mouse model can be rescued by 
introducing a mutation at the inhibitory phosphorylation site of αCaMKII. Moreover, 
these double mutants do no longer show the behavioral deficits seen in AS mice, 
suggesting that these deficits are the direct result of increased αCaMKII inhibitory 
phosphorylation. 
Taken together, our research has helped to further elucidate the role of CaMKII in 
learning, plasticity and disease. 
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Samenvatting 
 
CaMKII is een van de meest voorkomende eiwitten en waarschijnlijk een van de meest 
bestudeerde kinases in het brein. Tot op heden zijn er al meer dan 2000 artikelen 
gepubliceerd over CaMKII, maar desondanks is er nog steeds geen volledige duidelijkheid 
over de exacte functies van het eiwit in de verschillende gebieden in het brein. De twee 
meest voorkomende CaMKII isozymen aanwezig in het brein zijn αCaMKII en βCaMKII. 
In dit proefschrift doen we een poging om de rol van deze twee isozymen in de processen 
van leren, synaptische plasticiteit en ziekten verder te ontrafelen.  
Hoofdstuk II concentreert zich op de rol van αCaMKII in presynaptische plasticiteit. 
Door gebruik te maken van muismutanten en farmacologische inhibitie van αCaMKII, 
laten we zien dat de aanwezigheid van het αCaMKII eiwit nodig is voor normale 
presynaptische plasticiteit, maar dat activatie, autofosforylatie, noch zijn mogelijkheid om 
Synapsin I te fosforyleren daarvoor nodig zijn. Verder laten we zien dat αCaMKII het 
aantal membraan gebonden neurotransmitter blaasjes reguleert zonder dat het daarvoor 
geactiveerd hoeft te worden. Deze resultaten impliceren dat αCaMKII een niet-
enzymatische rol speelt in korte-termijn presynaptische plasticiteit in hippocampale CA3-
CA1 synapsen.  
βCaMKII is de tweede meest voorkomende CaMKII in het brein, maar desondanks is 
er tot op heden weinig bekend over de rol van βCaMKII in plasticiteit en leren. Een van de 
redenen daarvoor is het feit dat er lange tijd geen enkel muismodel voorhanden was. Ons 
lab is het eerste lab dat een βCaMKII knock-out muis heeft gegenereerd. Omdat βCaMKII 
de overheersende CaMKII isoform is in het cerebellum, hebben we eerst gekeken naar de 
functie van βCaMKII in het cerebellum (Hoofdstuk III). We laten zien dat βCaMKII een 
essentiële rol speelt in het controleren van de richting van plasticiteit in de parallel vezel-
Purkinje cel synaps: een protocol om synaptische depressie te induceren in wild–type 
muizen, resulteert in synaptische potentiatie in βCaMKII knock-out muizen, en vice versa. 
We stellen een model voor waar βCaMKII in de parallel vezel-Purkinje cel synaps een 
structurele rol speelt gedurende de inductie van LTP en waar enzymatische rol van 
βCaMKII noodzakelijk is om LTD te krijgen. Door deze bevindingen hebben we nu een 
uniek experimenteel inzicht in de mechanismen die graduele calcium signalen omzet in 
synaptische depressie of juist potentiatie. 
In hoofdstuk IV hebben we gekeken naar de rol van βCaMKII in hippocampale 
plasticiteit en leren, door gebruik te maken van twee verschillende βCaMKII mutanten. 
We laten hier zien dat afwezigheid van βCaMKII de context conditionering en 
hippocampale lange-termijn potentiatie ernstig verstoort. Opmerkelijk is dat het 
verhinderen van activatie van βCaMKII door het muteren van het Ca2+/Calmodulin 
bindend domein (A303R), geen effect heeft op plasticiteit of leren. Samengenomen 
suggereren deze resultaten een niet-enzymatische, structurele rol voor βCaMKII in 
hippocampaal leren en LTP. 
Het is bekend dat CaMKII betrokken is bij verschillende neurologische en 
psychiatrische stoornissen, waaronder Angelman Syndroom (AS). In deze neurologische 
ziekte is meer CaMKII gefosforyleerd op de inhibitoire fosforylatie plaatsen (TT305/6). In 
hoofdstuk V laten we zien dat de moleculaire en cellulaire deficiënties in een AS 
muismodel verholpen kunnen worden door een mutatie in de inhibitoire fosforylatie 
plaatsen van αCaMKII. Bovendien laten deze dubbelmutanten geen gedragsproblemen 
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meer zien, die wel te zien waren in AS muizen, wat suggereert dat deze problemen het 
directe resultaat zijn van de verhoogde inhibitoire fosforylatie van αCaMKII. 
Samen genomen hebben onze studies een bijdrage geleverd aan het verder ontrafelen 
van de rol van CaMKII in leren, plasticiteit en ziekten. 
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